|
|
||||||||||||||||||||
1. DeGruttola V, Dix L, D'Aquila R, Holder D, Phillips A, Ait-Khaled M, et al.. The relation between baseline HIV drug resistance and response to antiretroviral therapy: re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther. 2000;5:41-8. Cerrar [Medline] [Descargar cita] |
2. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et al.. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-94. Cerrar [Medline] [Descargar cita] |
3. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al.. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000;14:F83-F93. Cerrar [Medline] [Descargar cita] |
4. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, et al.. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002; 16:209-18. Cerrar [Medline] [Descargar cita] |
5. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, et al.. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS. 2002;16:369-79. Cerrar [Medline] [Descargar cita] |
6. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al.. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet. 1999;353:2195-9. Cerrar [Medline] [Descargar cita] |
7. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, et al.. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS. 2002;16:727-36. Cerrar [Medline] [Descargar cita] |
8. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, et al.. Update of the Drug Resistance Mutations in HIV-1: Fall 2005. Top HIV Med. 2005;13:125-31. Cerrar [Medline] [Descargar cita] |
9. www.iasusa.org.. Cerrar |
10. http://hivatis.org/trtgdlns.html.. Cerrar |
11. Clinical and laboratory guidelines for the use of HIV-1 drug resistance testing as part of treatment management: recommendations for the European setting.. The EuroGuidelines Group for HIV resistance. AIDS. 2001;15: 309-20. Cerrar [Medline] [Descargar cita] |
12. Gatell JM, Blanco JL, Alcami J, Antela A, Arrizabalaga J, Casado JL, et al.. GESIDA Consensus document on the use of resistance studies in clinical practice. Enferm Infecc Microbiol Clin. 2001;19(Monogr�fico):53-60. Cerrar [Art�culo] |
13. Riera-Jaume M, Pe�aranda-Vera M, Ribas-Blanco MA, Murillas-Angoiti J, Campins A, Salas-Aparicio A, et al.. Utilizaci�n en la pr�ctica cl�nica de los tests de resistencia genot�pica al VIH-1. Factores predictivos de mala evoluci�n virol�gica en tratamientos de rescate. Enferm Infecc Microbiol Clin. 2005. Cerrar |
14. Ena J, Ruiz de Apodaca RF, Amador C, Benito C, Pasquau F.. Net benefits of resistance-testing-directed-therapy compared with standard-of-care in HIV-infected patients with virological failure: A meta-analysis. Enferm Infecc Microbiol Clin. 2005. Cerrar |
4. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, et al.. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002; 16:209-18. Cerrar [Medline] [Descargar cita] |
8. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, et al.. Update of the Drug Resistance Mutations in HIV-1: Fall 2005. Top HIV Med. 2005;13:125-31. Cerrar [Medline] [Descargar cita] |
15. http://hivdb.stanford.edu/.. Cerrar |
16. http://www.geno2pheno.org/.. Cerrar |
17. Zazzi M, Romano L, Venturi G, Shafer RW, Reid C, Dal Bello F, et al.. Comparative evaluation of three computerized algorithms for prediction of antiretroviral susceptibility from HIV type 1 genotype. J Antimicrob Chemother. 2004;53:356-60. Cerrar [Medline] [Descargar cita] |
18. Cabrera C, Cozzi-Lepri A, Phillips AN, Loveday C, Kirk O, Ait-Khaled M, et al.. Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study. Antivir Ther. 2004;9:787-800. Cerrar [Medline] [Descargar cita] |
19. Kempf DJ, Isaacson JD, King MS, Brun SC, Sylte J, Richards B, et al.. Analysis of the virological response with respect to baseline viral phenotype and genotype in protease inhibitor-experienced HIV-1-infected patients receiving lopinavir/ritonavir therapy. Antivir Ther. 2002;7:165-74. Cerrar [Medline] [Descargar cita] |
20. Ross L, Boulme R, Fusco G, Scarsella A, Florance A.. Comparison of HIV type 1 protease inhibitor susceptibility results in viral samples analyzed by phenotypic drug resistance assays and by six resistance algorithms: an analysis of a subpopulation of the CHORUS cohort. AIDS Res Hum Retroviruses. 2005;21:696-701. Cerrar [Medline] [Descargar cita] |
21. Vergne L, Snoeck J, Aghokeng A, Maes B, Valea D, Delaporte E, et al.. Genotypic drug resistance interpretation algorithms display high levels of discordance when applied to non-B strains from HIV-1 naive and treated patients. FEMS Immunol Med Microbiol. 2006;46:53-62. Cerrar [Medline] [Descargar cita] |
22. Fletcher CV, Anderson PL, Kakuda TN, Schacker TW, Henry K, Gross CR, et al.. Concentration-controlled compared with conventional antiretroviral therapy for HIV infection. AIDS. 2002;16:551-60. Cerrar [Medline] [Descargar cita] |
1. Pilcher CD, Tien HC, Eron JJ, Vernazza PL, Leu Sy, Stewart PW, et al.. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis. 2004;189:1785-92. Cerrar [Medline] [Descargar cita] |
2. Weintrob AC, Giner J, Menezes P, Patrick E, Benjamin DK, Lennox J, et al.. Infrequent Diagnosis of Primary HIV Immunodeficiency Infection. Arch Int Med. 2003;163:2097-100. Cerrar |
3. Pilcher CD, Fiscus SA, Nguyen TQ, Foust E, Wolf L, Williams D, et al.. Detection of acute infections during HIV testing in North Carolina. N Engl J Med. 2005;352:1873-83. Cerrar [Medline] [Descargar cita] |
4. Rosenberg E, Altfeld M, Poon S, Phillips MN, Wilkes BM, Eldridge RL, et al.. Immune control of HIV-1 after early treatment of acute infection. Nature. 2000;407:523-6. Cerrar [Medline] [Descargar cita] |
5. Oxenius A, Price D, Easterbrook P, O'Callaghan CA, Kelleher AD, Whelan JA, et al.. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD4 and CD8 T lymphocytes. PNAS. 2000;97: 3382-7. Cerrar [Medline] [Descargar cita] |
6. Hightow LB, MacDonald P, Pilcher CD, Leone PA.. The Unexpected Movement of the HIV Epidemic in the Southeastern United States: Transmission Among College Students. JAIDS. 2005;38:531-7. Cerrar [Medline] [Descargar cita] |
7. Yerly S, Vora S, Rizzardi P, Chave JP, Vernazza PL, Flepp M, et al.. Acute HIV infection: impact on the spread of HIV and transmission of drug resistance. AIDS. 2001;15:2287-92. Cerrar [Medline] [Descargar cita] |
8. Little SJ, Holte S, Routy JP, Daar ES, Markowitz M, Collier AC, et.. al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-94. Cerrar [Medline] [Descargar cita] |
9. Cates W, Chesney MA, Cohen MS.. Primary HIV Infection � A Public Health Opportunity. AJPH. 1997;87:1928-30. Cerrar |
10. Pilcher CD, Eron JJ, Galvin S, Gay C, Cohen MS.. Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest. 2004;113:937-45. Cerrar [Medline] [Descargar cita] |
11. Pao D, Fisher M, Hue S, Dean G, Murphy G, Cane PA, et al.. Transmission of HIV-1 during primary infection: relationship to sexual risk and sexually transmitted infections. AIDS. 2005;19:85-90. Cerrar [Medline] [Descargar cita] |
12. Centers for Disease Control and Prevention.. HIV transmission among black college student and non-student men who have sex with men�North Carolina, 2003. MMWR Morb Mortal Wkly Rep. 2004;53:731-4. Cerrar [Medline] [Descargar cita] |
13. Kassutto S, Rosenberg ES.. Primary HIV type 1 infection. Clin Infect Dis. 2004;38:1447-53. Cerrar [Medline] [Descargar cita] |
14. Pope M, Haase AT.. Transmission, acute HIV-1 infection and the quest for strategies to prevent infection. Nat Med. 2003;9:847-52. Cerrar [Medline] [Descargar cita] |
15. Galvin SR, Cohen MS.. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol. 2004;2:33-42. Cerrar [Medline] [Descargar cita] |
1. Pilcher CD, Tien HC, Eron JJ, Vernazza PL, Leu Sy, Stewart PW, et al.. Brief but efficient: acute HIV infection and the sexual transmission of HIV. J Infect Dis. 2004;189:1785-92. Cerrar [Medline] [Descargar cita] |
16. Saville RD, Constantine NT, Cleghorn FR, Jack N, Bartholomew C, Edwards J, et al.. Fourth-generation enzyme-linked immunosorbent assay for the simultaneous detection of human immunodeficiency virus antigen and antibody. J Clin Microbiol. 2001;39:2518-24. Cerrar [Medline] [Descargar cita] |
17. Leynaert B, Downs AM, De Vincenzi I.. Heterosexual transmission of human immunodeficiency virus: variability of infectivity throughout the course of infection. European Study Group on Heterosexual Transmission of HIV. Am J Epidemiol. 1998;148:88-96. Cerrar [Medline] [Descargar cita] |
18. Pilcher CD, Eron JJ Jr, Vemazza PL, Battegay M, Harr T, Yerly S, et al.. Sexual transmission during the incubation period of primary HIV infection. JAMA. 2001;286:1713-4. Cerrar [Medline] [Descargar cita] |
19. Wawer MJ, Gray RH, Sewankambo NK, Serwadda D, Xianbin L, Laeyewdecker O, et al.. Rates of HIV-1 transmission per coital act, by stage of HIV-1 infection, in Rakai, Uganda. JID. 2005;191:1403-9. Cerrar [Medline] [Descargar cita] |
20. Koopman JS, Jacquez JA, Welch GW, Simon CP, Foxman B, Pollock SM, et al.. The role of early HIV infection in the spread of HIV through populations. J Acquir Immune Defic Syndr. 1997;14:249-58. Cerrar |
21. Colfax GN, Buchbinder SP, Cornelisse PG, Vittinghoff E, Mayer K, Celum C.. Sexual risk behaviors and implications for secondary HIV transmission during and after HIV seroconversion. AIDS. 2002;16:1529-35. Cerrar [Medline] [Descargar cita] |
22. Ellish NJ, Weisman CS, Celentano D, Zenilman JM.. Reliability of partner reports of sexual history in a heterosexual population at a sexually transmitted diseases clinic. Sex Transm Dis. 1996;23:446-52. Cerrar [Medline] [Descargar cita] |
23. Sued O, Miro, JM, Alquezar A, Claramonte X, Garc�a F, Plana M, et al.. Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003). Enferm Infecc Microbiol Clin. 2006;24:238-44. Cerrar [Art�culo] |
13. Kassutto S, Rosenberg ES.. Primary HIV type 1 infection. Clin Infect Dis. 2004;38:1447-53. Cerrar [Medline] [Descargar cita] |
13. Kassutto S, Rosenberg ES.. Primary HIV type 1 infection. Clin Infect Dis. 2004;38:1447-53. Cerrar [Medline] [Descargar cita] |
23. Sued O, Miro, JM, Alquezar A, Claramonte X, Garc�a F, Plana M, et al.. Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003). Enferm Infecc Microbiol Clin. 2006;24:238-44. Cerrar [Art�culo] |
16. Saville RD, Constantine NT, Cleghorn FR, Jack N, Bartholomew C, Edwards J, et al.. Fourth-generation enzyme-linked immunosorbent assay for the simultaneous detection of human immunodeficiency virus antigen and antibody. J Clin Microbiol. 2001;39:2518-24. Cerrar [Medline] [Descargar cita] |
3. Pilcher CD, Fiscus SA, Nguyen TQ, Foust E, Wolf L, Williams D, et al.. Detection of acute infections during HIV testing in North Carolina. N Engl J Med. 2005;352:1873-83. Cerrar [Medline] [Descargar cita] |
23. Sued O, Miro, JM, Alquezar A, Claramonte X, Garc�a F, Plana M, et al.. Primary human immunodeficiency virus type 1 infection: clinical, virological and immunological characteristics of 75 patients (1997-2003). Enferm Infecc Microbiol Clin. 2006;24:238-44. Cerrar [Art�culo] |
3. Pilcher CD, Fiscus SA, Nguyen TQ, Foust E, Wolf L, Williams D, et al.. Detection of acute infections during HIV testing in North Carolina. N Engl J Med. 2005;352:1873-83. Cerrar [Medline] [Descargar cita] |
1. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al.. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 Recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2004;37:113-28. Cerrar |
2. Gatell J, Blanco JL, Alcam� J, Antela A, Arrizabalaga J, Casado JL.. Documento de consenso de GESIDA sobre la utilizaci�n de los estudios de reistencias en la practica cl�nica. Enferm Infecc Microbiol Clin. 2002;19: 53-60. Cerrar [Art�culo] |
3. Baxter J, Mayers D, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al.. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing antiretroviral. AIDS. 2000;14:F83-F93. [Medline] [Descargar cita] 4. Cohen CJ, Hunt S, Sension MG, Farthing C, Conant MA, Jacobson S, et al.. A randomized trial assesing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16:579-88. [Medline] [Descargar cita] 5. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin Geal, et al.. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS. 2002; 16:727-36. [Medline] [Descargar cita] 6. Tural C, Ruiz L, Doltzer C, Schapiro JM, Viciana P, Gonz�lez J, et al.. Clinical utility of HIV genotyping and expert advise: The Havana trial. AIDS. 2002;16:209-18. [Medline] [Descargar cita] 7. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammasari A, Baldini F.. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy. A randomized study (ARGENTA). AIDS. 2002;16:369-79. [Medline] [Descargar cita] 8. Durant J, Clevenbergh J, Hafton P, Delgiudice P, Porsin S, Simonet P, et al.. Drug resistance genotyping in HIV therapy: the VIRADAPT randomized controlled trial. Lancet. 1999;353:2195-9. [Medline] [Descargar cita] Cerrar |
9. Riera M, Ribas MA, P�rez-El�as MJ, Mallolas J, Portilla J, Viciana P.. Aproximaci�n al tratamiento del paciente en situaci�n de multifracaso. Enferm Infecc Microbiol Clin. 2002;20 Supl 2:58-67. Cerrar |
2. Gatell J, Blanco JL, Alcam� J, Antela A, Arrizabalaga J, Casado JL.. Documento de consenso de GESIDA sobre la utilizaci�n de los estudios de reistencias en la practica cl�nica. Enferm Infecc Microbiol Clin. 2002;19: 53-60. Cerrar [Art�culo] |
1. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al.. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 Recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2004;37:113-28. Cerrar |
2. Gatell J, Blanco JL, Alcam� J, Antela A, Arrizabalaga J, Casado JL.. Documento de consenso de GESIDA sobre la utilizaci�n de los estudios de reistencias en la practica cl�nica. Enferm Infecc Microbiol Clin. 2002;19: 53-60. [Art�culo] 3. Baxter J, Mayers D, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al.. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing antiretroviral. AIDS. 2000;14:F83-F93. [Medline] [Descargar cita] 4. Cohen CJ, Hunt S, Sension MG, Farthing C, Conant MA, Jacobson S, et al.. A randomized trial assesing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16:579-88. [Medline] [Descargar cita] 5. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin Geal, et al.. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS. 2002; 16:727-36. [Medline] [Descargar cita] Cerrar |
1. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al.. Antiretroviral drug resistance testing in adults infected with human immunodeficiency virus type 1: 2003 Recommendations of an International AIDS Society-USA Panel. Clin Infect Dis. 2004;37:113-28. Cerrar |
3. Baxter J, Mayers D, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al.. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing antiretroviral. AIDS. 2000;14:F83-F93. [Medline] [Descargar cita] 4. Cohen CJ, Hunt S, Sension MG, Farthing C, Conant MA, Jacobson S, et al.. A randomized trial assesing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16:579-88. [Medline] [Descargar cita] 5. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin Geal, et al.. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS. 2002; 16:727-36. [Medline] [Descargar cita] 6. Tural C, Ruiz L, Doltzer C, Schapiro JM, Viciana P, Gonz�lez J, et al.. Clinical utility of HIV genotyping and expert advise: The Havana trial. AIDS. 2002;16:209-18. [Medline] [Descargar cita] 7. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammasari A, Baldini F.. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy. A randomized study (ARGENTA). AIDS. 2002;16:369-79. [Medline] [Descargar cita] 8. Durant J, Clevenbergh J, Hafton P, Delgiudice P, Porsin S, Simonet P, et al.. Drug resistance genotyping in HIV therapy: the VIRADAPT randomized controlled trial. Lancet. 1999;353:2195-9. [Medline] [Descargar cita] 9. Riera M, Ribas MA, P�rez-El�as MJ, Mallolas J, Portilla J, Viciana P.. Aproximaci�n al tratamiento del paciente en situaci�n de multifracaso. Enferm Infecc Microbiol Clin. 2002;20 Supl 2:58-67. 10. Gallego O, Ruiz L, Vallejo A, Ferrer I, Rubio A, Clotet B, et al.. Change in the rate of genotypic resistance to antiretroviral drugs in Spain. AIDS. 2001;15: 1894-6. [Medline] [Descargar cita] 11. Rodes B, Garc�a F, Guti�rrez C, Mart�nez-Picado J, Aguilera A, Saumoy M, et al.. High Rate of Multidrug resistance Genotypes in Heavily Treatment-Experience Patients. 2nd European HIV Drug Resistance Worshop; 2004. 12. Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich RH, Cheng H, et al.. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in Human Immunodeficiency virus-infected adults with virologic failure on Indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis. 2000;182:1375-84. [Medline] [Descargar cita] 13. Squires K, Hammer S, Degruttola V, et al.. Randomized trial of abacavir (ABC) in combination with indinavir and efavirenz (EFZ) in HIV-infected patients with nucleoside anlog experience. 7 th Conference on Retroviruses and Opportunistic Infections, Abstract 529. 2000. 14. Albrecht M, Bosch R, Hammer S, Liou SH, Kessler H, Para MF, et al.. ACTG364. Nelfinavir, Efavirenz, or both after the failure of nucleoside. Treatment of HIV infection. N Engl J Med. 2001;345:398-407. [Medline] [Descargar cita] 15. Miller V, Sabin CA, Hertogs K, Blloer S, Mart�nez Picado J, D'Aquila RT, et al.. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS. 2000;14:2857-67. [Medline] [Descargar cita] Cerrar |
10. Gallego O, Ruiz L, Vallejo A, Ferrer I, Rubio A, Clotet B, et al.. Change in the rate of genotypic resistance to antiretroviral drugs in Spain. AIDS. 2001;15: 1894-6. Cerrar [Medline] [Descargar cita] |
11. Rodes B, Garc�a F, Guti�rrez C, Mart�nez-Picado J, Aguilera A, Saumoy M, et al.. High Rate of Multidrug resistance Genotypes in Heavily Treatment-Experience Patients. 2nd European HIV Drug Resistance Worshop; 2004. Cerrar |
3. Baxter J, Mayers D, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al.. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing antiretroviral. AIDS. 2000;14:F83-F93. Cerrar [Medline] [Descargar cita] |
5. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin Geal, et al.. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trial. AIDS. 2002; 16:727-36. Cerrar [Medline] [Descargar cita] |
6. Tural C, Ruiz L, Doltzer C, Schapiro JM, Viciana P, Gonz�lez J, et al.. Clinical utility of HIV genotyping and expert advise: The Havana trial. AIDS. 2002;16:209-18. Cerrar [Medline] [Descargar cita] |
8. Durant J, Clevenbergh J, Hafton P, Delgiudice P, Porsin S, Simonet P, et al.. Drug resistance genotyping in HIV therapy: the VIRADAPT randomized controlled trial. Lancet. 1999;353:2195-9. Cerrar [Medline] [Descargar cita] |
12. Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich RH, Cheng H, et al.. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in Human Immunodeficiency virus-infected adults with virologic failure on Indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis. 2000;182:1375-84. [Medline] [Descargar cita] 13. Squires K, Hammer S, Degruttola V, et al.. Randomized trial of abacavir (ABC) in combination with indinavir and efavirenz (EFZ) in HIV-infected patients with nucleoside anlog experience. 7 th Conference on Retroviruses and Opportunistic Infections, Abstract 529. 2000. 14. Albrecht M, Bosch R, Hammer S, Liou SH, Kessler H, Para MF, et al.. ACTG364. Nelfinavir, Efavirenz, or both after the failure of nucleoside. Treatment of HIV infection. N Engl J Med. 2001;345:398-407. [Medline] [Descargar cita] Cerrar |
15. Miller V, Sabin CA, Hertogs K, Blloer S, Mart�nez Picado J, D'Aquila RT, et al.. Virological and immunological effects of treatment interruptions in HIV-1 infected patients with treatment failure. AIDS. 2000;14:2857-67. [Medline] [Descargar cita] 16. Phillips AN, Youle M, Johnson M, Loveday N.. Use of stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use resistance development. AIDS. 2001;15:2211-20. [Medline] [Descargar cita] 17. Ruiz L, Ribera E, Bonjoch A, Romeu J, Mart�nez-Picado J, Paredes R, et al.. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: The Retrogene Study. J Infect Dis. 2003;188:977-85. [Medline] [Descargar cita] Cerrar |
18. Deeks SG, Barbour JD, Martin JN, Swansson M, Grant RM.. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with human immunodeficiency virus infection. J Infect Dis. 2000;181:946-53. Cerrar [Medline] [Descargar cita] |
19. Zaccarelli M, Tozzi V, Lorenzini F, Forbici M, Trotta MP, Visco-Comandini C, et al.. Drug class multi-resistance as main marker of disease progression and poor survival after genotype guided antiretroviral salvage therapy. 2nd European HIV Drug Resistance Workshop. 2004. Cerrar |
20. Lee N, Hogg RS, Yip B, Harrigan PR, Harris M, O'Shaughnessy MV, et al.. Rates of disease progression among human immunodeficiency virus-infected persons initiating multiple-drug rescue therapy. J Infect Dis. 2003;188:137-41. Cerrar [Medline] [Descargar cita] |
19. Zaccarelli M, Tozzi V, Lorenzini F, Forbici M, Trotta MP, Visco-Comandini C, et al.. Drug class multi-resistance as main marker of disease progression and poor survival after genotype guided antiretroviral salvage therapy. 2nd European HIV Drug Resistance Workshop. 2004. Cerrar |
21. The PLATO Collaboration.. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1 infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364:51-9. Cerrar [Medline] [Descargar cita] |
22. Katzenstein D, Bosch R, Hellmann N, Wang N, Bacheler L, Albrecht M.. Phenotypic susceptibility and virologic outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. ACTG 364. AIDS. 2003;17:821-30. Cerrar [Medline] [Descargar cita] |
23. Haubrich RH, Kemper CA, Hellman N, Keiser PH, Witt M, Forthal DH, et al.. The clinical relevance of non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates. AIDS. 2002;16:F41-F7. Cerrar [Medline] [Descargar cita] |
24. Fessel WJ, Rhee SY, Hurley L, Nguyen DP, Slome S, Smith S, et al.. High level dual and triple class multidrug resistance in a large health maintenance organization: prevalence, risk factors and response to salvage therapy. 11th Conference on Retrovirus and Opportunistic Infections. San Francisco, abstract 690. 2004. Cerrar |
25. D'Aquila RT, Hughes MD, Johnson V, Fischl MA, Somadossi JP, Lime SH, et al.. Nevirapine, zidovudine and didanosine compared with zidovudine and didanosine in patients with HIV-1 infection: a randomized, double blind, placebo controlled trial. Ann Intern Med. 1996;124:1019-30. Cerrar [Medline] [Descargar cita] |
11. Rodes B, Garc�a F, Guti�rrez C, Mart�nez-Picado J, Aguilera A, Saumoy M, et al.. High Rate of Multidrug resistance Genotypes in Heavily Treatment-Experience Patients. 2nd European HIV Drug Resistance Worshop; 2004. Cerrar |
26. Condra JH, Petropoulos CJ, Ziermann R, Schleif WA, Shivaprakash M, Emini EA.. Drug resistance and predicted virologic responses to human immunodeficiency virus type 1 protease inhibitor therapy. J Infect Dis. 2000;182: 758-65. Cerrar [Medline] [Descargar cita] |
27. Kempf DJ, Isaacson J, King M, Brun S, Xu Y, Real K.. Identification of genotypic changes in human immunodeficiency virus protease that correlate with reduced susceptibility to the protease inhibitor lopinavir among isolates from protease inhibitor-experienced patients. J Virol. 2001;75:7462-9. Cerrar [Medline] [Descargar cita] |
12. Gulick RM, Hu XJ, Fiscus SA, Fletcher CV, Haubrich RH, Cheng H, et al.. Randomized study of saquinavir with ritonavir or nelfinavir together with delavirdine, adefovir, or both in Human Immunodeficiency virus-infected adults with virologic failure on Indinavir: AIDS Clinical Trials Group Study 359. J Infect Dis. 2000;182:1375-84. Cerrar [Medline] [Descargar cita] |
28. Mocroft A, Phillips AN, Miller V, Gatell J, Van Lunzen J, Parkin JM, et al.. The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study. AIDS. 2001;15:201-9. Cerrar [Medline] [Descargar cita] |
17. Ruiz L, Ribera E, Bonjoch A, Romeu J, Mart�nez-Picado J, Paredes R, et al.. Role of structured treatment interruption before a 5-drug salvage antiretroviral regimen: The Retrogene Study. J Infect Dis. 2003;188:977-85. Cerrar [Medline] [Descargar cita] |
29. Lawrence J, Huppler K, Mayers D, Abrams D, Baxter J, and the CPCRA 064.. Baseline resistance predictors of virological response in the CPCRA 064 study: a randomized trial of structured treatment interruption for patients with multidrug resistant. XII International HIV Drug Resistance Workshop, Los Cabos. M�xico. Antiviral Therapy 8, Issue 3. 2003. Cerrar |
1. Hirsch MS, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, D'Aquila RT, et al.. Antiretroviral drug resistance testing in adults infected with Human Immunodeficiency Virus Type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infec Dis. 2003;37:113-28. 2. US Department of Health and Human Services, Henry J.. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/guidelines/adult/AA 040705.pdf 3. The EuroGuidelines Group for HIV resistance.. Clinical and laboratory guidelines for the use of HIV-1 resistance testing as part of treatment management: recommendations from the European setting. AIDS. 2001;15:309-20. [Medline] [Descargar cita] Cerrar |
4. Youree BE, D'Aquila RT.. Antiretroviral resistance testing for clinical management. AIDS Rev. 2002;4:3-12. Cerrar [Medline] [Descargar cita] |
5. Hanna GJ, D'Aquila RT.. Clinical use of genotypic and phenotypic drug resistance testing to monitor antiretroviral chemotherapy. Clin Infect Dis. 2001;32:774-82. Cerrar [Medline] [Descargar cita] |
6. Torre D, Tambini R.. Antiretroviral drug resistance testing in patients with HIV-1 infection: a meta-analysis study. HIV Clin Trials. 2002;3:1-8. Cerrar [Medline] [Descargar cita] |
7. Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al.. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials. 1996;17:1-12. Cerrar |
2. US Department of Health and Human Services, Henry J.. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/guidelines/adult/AA 040705.pdf Cerrar |
8. DerSimonian R, Laird N.. Meta-analysis in clinical trials. Control Clin Trials. 1986;7:177-88. Cerrar [Medline] [Descargar cita] |
9. Altman DG, Bland JM.. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219. Cerrar [Medline] [Descargar cita] |
10. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al.. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet. 1999;353:2195-9. [Medline] [Descargar cita] 11. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al.. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000;14:F83-F93. [Medline] [Descargar cita] 12. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, et al.. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trail. AIDS. 2002;16:727-36. [Medline] [Descargar cita] 13. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, et al.. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002; 16:209-18. [Medline] [Descargar cita] 14. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, et al.. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS. 2002;16:369-79. [Medline] [Descargar cita] 15. Haubrich R, Keiser P, Kemper C, Witt M, Leedom I, Forthol D, et al.. CCTG 575: a randomized prospective study of phenotype testing (PHENO) versus standard of care (SOC) for patients failing antiretroviral therapy. Abstract 127. In program and Abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires (Argentina); 2001. p. 123. 16. Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, et al.. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16:579-88. [Medline] [Descargar cita] 17. Rubini NPM, Brindeiro PA, Brindeiro RM, Llerena CA, Hertogs K, Tanuri A, et al.. Clinical value of HIV-1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. [Abstract TuPeB4642]. XIV International AIDS Conference. Barcelona, 2002. Cerrar |
15. Haubrich R, Keiser P, Kemper C, Witt M, Leedom I, Forthol D, et al.. CCTG 575: a randomized prospective study of phenotype testing (PHENO) versus standard of care (SOC) for patients failing antiretroviral therapy. Abstract 127. In program and Abstracts of the 1st International AIDS Society Conference on HIV Pathogenesis and Treatment. Buenos Aires (Argentina); 2001. p. 123. Cerrar |
17. Rubini NPM, Brindeiro PA, Brindeiro RM, Llerena CA, Hertogs K, Tanuri A, et al.. Clinical value of HIV-1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. [Abstract TuPeB4642]. XIV International AIDS Conference. Barcelona, 2002. Cerrar |
11. Baxter JD, Mayers DL, Wentworth DN, Neaton JD, Hoover ML, Winters MA, et al.. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy. CPCRA 046 Study Team for the Terry Beirn Community Programs for Clinical Research on AIDS. AIDS. 2000;14:F83-F93. Cerrar [Medline] [Descargar cita] |
12. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, et al.. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trail. AIDS. 2002;16:727-36. Cerrar [Medline] [Descargar cita] |
16. Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, et al.. A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS. 2002;16:579-88. Cerrar [Medline] [Descargar cita] |
10. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al.. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet. 1999;353:2195-9. Cerrar [Medline] [Descargar cita] |
13. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, et al.. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002; 16:209-18. Cerrar [Medline] [Descargar cita] |
14. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, et al.. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS. 2002;16:369-79. Cerrar [Medline] [Descargar cita] |
9. Altman DG, Bland JM.. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219. Cerrar [Medline] [Descargar cita] |
2. US Department of Health and Human Services, Henry J.. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/guidelines/adult/AA 040705.pdf Cerrar |
10. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al.. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet. 1999;353:2195-9. Cerrar [Medline] [Descargar cita] |
12. Meynard JL, Vray M, Morand-Joubert L, Race E, Descamps D, Peytavin G, et al.. Phenotypic or genotypic resistance testing for choosing antiretroviral therapy after treatment failure: a randomized trail. AIDS. 2002;16:727-36. [Medline] [Descargar cita] 13. Tural C, Ruiz L, Holtzer C, Schapiro J, Viciana P, Gonzalez J, et al.. Clinical utility of HIV-1 genotyping and expert advice: the Havana trial. AIDS. 2002; 16:209-18. [Medline] [Descargar cita] 14. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, et al.. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS. 2002;16:369-79. [Medline] [Descargar cita] Cerrar |
17. Rubini NPM, Brindeiro PA, Brindeiro RM, Llerena CA, Hertogs K, Tanuri A, et al.. Clinical value of HIV-1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. [Abstract TuPeB4642]. XIV International AIDS Conference. Barcelona, 2002. Cerrar |
2. US Department of Health and Human Services, Henry J.. Kaiser Family Foundation. Guidelines for the use of antiretroviral agents in HIV infected adults and adolescents. Available at: http://www.aidsinfo.nih.gov/guidelines/adult/AA 040705.pdf Cerrar |
10. Durant J, Clevenbergh P, Halfon P, Delgiudice P, Porsin S, Simonet P, et al.. Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomized controlled trial. Lancet. 1999;353:2195-9. Cerrar [Medline] [Descargar cita] |
14. Cingolani A, Antinori A, Rizzo MG, Murri R, Ammassari A, Baldini F, et al.. Usefulness of monitoring HIV drug resistance and adherence in individuals failing highly active antiretroviral therapy: a randomized study (ARGENTA). AIDS. 2002;16:369-79. Cerrar [Medline] [Descargar cita] |
17. Rubini NPM, Brindeiro PA, Brindeiro RM, Llerena CA, Hertogs K, Tanuri A, et al.. Clinical value of HIV-1 genotyping in children and adolescents heavily experiences in antiretroviral therapy. [Abstract TuPeB4642]. XIV International AIDS Conference. Barcelona, 2002. Cerrar |
9. Altman DG, Bland JM.. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219. Cerrar [Medline] [Descargar cita] |
9. Altman DG, Bland JM.. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219. Cerrar [Medline] [Descargar cita] |
9. Altman DG, Bland JM.. Interaction revisited: the difference between two estimates. BMJ. 2003;326:219. Cerrar [Medline] [Descargar cita] |
18. Panidou ET, Trikalinos TA, Ioannidis JPA.. Limited benefit of antiretroviral resistance testing in treatment-experienced patients: a meta-analysis. AIDS. 2004;18:2153-61. Cerrar [Medline] [Descargar cita] |
19. Lanier ER, Givens N, Stone C, Griffin P, Gibb D, Walker S, et al.. Effect of concurrent zidovudine use on the resistance pathway selected by abacavir-containing regimens. HIV Med. 2004;5:394-9. Cerrar [Medline] [Descargar cita] |
20. Tebas P, Patick AK, Kane EM, Klebert MK, Simpson JH, Erice A, et al.. Virologic response to a ritonavir-saquinavir-containing regimen in patients who had previously failed nelfinavir. AIDS. 1999;13:F23-F8. Cerrar [Medline] [Descargar cita] |
21. Zolopa AR, Shafer RW, Warford A, Montoya JG, Hsu P, Katzenstein D, et al.. HIV-1 genotypic resistance patterns predicts response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed. Ann Intern Med. 1999;131:813-21. Cerrar [Medline] [Descargar cita] |
22. Lazzarin A, Clotet B, Cooper D, Reynes J, Arasteh K, Nelson M, et al.. Efficacy of enfurtivide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med. 2003;348:2186-95. Cerrar [Medline] [Descargar cita] |
23. Fellay J, Boubaker K, Ledergerber B, Bernasconi E, Furrer H, Battegay M, et al.. Prevalence of adverse events associated with potent antiretroviral regimen: Swiss HIV cohort study. Lancet. 2001;358:1322-7. Cerrar [Medline] [Descargar cita] |
24. The PLATO Collaboration.. Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet. 2004;364:51-62. Cerrar [Medline] [Descargar cita] |
1. Cooper DA, Gold J, Maclean P, Donovan B, Finlayson R, Barnes TG, et al.. Acute AIDS retrovirus infection. Definition of a clinical illness associated with seroconversion. Lancet. 1985;1:537-40. Cerrar [Medline] [Descargar cita] |
2. Vanhems P, Dassa C, Lambert J, Cooper DA, Perrin L, Vizzard J, et al.. Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection. J Acquir Immune Defic Syndr. 1999;21:99-106. [Medline] [Descargar cita] 3. Lavreys L, Thompson ML, Martin HL Jr, Mandaliya K, Ndinya-Achola JO, Bwayo JJ, et al.. Primary Human Immunodeficiency Virus type 1 infection: clinical manifestations among women in Mombasa, Kenya. Clin Infect Dis. 2000;30:486-90. [Medline] [Descargar cita] 4. Daar ES, Little S, Pitt J, Santangelo J, Ho P, Harawa N, et al.. Diagnosis of primary HIV-1 infection. Los Angeles County Primary HIV Infection Recruitment Network. Ann Intern Med. 2001;134:25-9. [Medline] [Descargar cita] Cerrar |
5. Miro JM, Sued O, Plana M, Pumarola T, Gallart T.. Avances en el diagn�stico y tratamiento de la infecci�n aguda por el Virus de la Inmunodeficiencia Humana tipo 1 (VIH-1). Enferm Infecc Microbiol Clin. 2004;22:643-59. Cerrar [Medline] [Descargar cita] [Art�culo] |
6. Pilcher CD, Eron JJ Jr, Galvin S, Gay C, Cohen MS.. Acute HIV revisited: new opportunities for treatment and prevention. J Clin Invest. 2004;113:937-45. Cerrar [Medline] [Descargar cita] |
7. Johnson VA, Brun-Vezinet F, Clotet B, Conway B, Kuritzkes DR, Pillay D, et al.. Update of the drug resistance mutations in HIV-1: 2005. Top HIV Med. 2005;13:51-7. Cerrar [Medline] [Descargar cita] |
3. Lavreys L, Thompson ML, Martin HL Jr, Mandaliya K, Ndinya-Achola JO, Bwayo JJ, et al.. Primary Human Immunodeficiency Virus type 1 infection: clinical manifestations among women in Mombasa, Kenya. Clin Infect Dis. 2000;30:486-90. Cerrar [Medline] [Descargar cita] |
3. Lavreys L, Thompson ML, Martin HL Jr, Mandaliya K, Ndinya-Achola JO, Bwayo JJ, et al.. Primary Human Immunodeficiency Virus type 1 infection: clinical manifestations among women in Mombasa, Kenya. Clin Infect Dis. 2000;30:486-90. Cerrar [Medline] [Descargar cita] |
3. Lavreys L, Thompson ML, Martin HL Jr, Mandaliya K, Ndinya-Achola JO, Bwayo JJ, et al.. Primary Human Immunodeficiency Virus type 1 infection: clinical manifestations among women in Mombasa, Kenya. Clin Infect Dis. 2000;30:486-90. Cerrar [Medline] [Descargar cita] |
3. Lavreys L, Thompson ML, Martin HL Jr, Mandaliya K, Ndinya-Achola JO, Bwayo JJ, et al.. Primary Human Immunodeficiency Virus type 1 infection: clinical manifestations among women in Mombasa, Kenya. Clin Infect Dis. 2000;30:486-90. Cerrar [Medline] [Descargar cita] |
3. Lavreys L, Thompson ML, Martin HL Jr, Mandaliya K, Ndinya-Achola JO, Bwayo JJ, et al.. Primary Human Immunodeficiency Virus type 1 infection: clinical manifestations among women in Mombasa, Kenya. Clin Infect Dis. 2000;30:486-90. Cerrar [Medline] [Descargar cita] |
3. Lavreys L, Thompson ML, Martin HL Jr, Mandaliya K, Ndinya-Achola JO, Bwayo JJ, et al.. Primary Human Immunodeficiency Virus type 1 infection: clinical manifestations among women in Mombasa, Kenya. Clin Infect Dis. 2000;30:486-90. Cerrar [Medline] [Descargar cita] |
3. Lavreys L, Thompson ML, Martin HL Jr, Mandaliya K, Ndinya-Achola JO, Bwayo JJ, et al.. Primary Human Immunodeficiency Virus type 1 infection: clinical manifestations among women in Mombasa, Kenya. Clin Infect Dis. 2000;30:486-90. Cerrar [Medline] [Descargar cita] |
8. Pilcher CD, Price MA, Hoffman IF, Galvin S, Martinson FE, Kazembe PN, et al.. Frequent detection of acute primary HIV infection in men in Malawi. AIDS. 2004;18:517-24. Cerrar [Medline] [Descargar cita] |
9. Pilcher CD, McPherson JT, Leone PA, Smurzynski M, Owen-O'Dowd J, Peace-Brewer AL, et al.. Real-time, universal screening for acute HIV infection in a routine HIV counseling and testing population. JAMA. 2002; 288:216-21. Cerrar [Medline] [Descargar cita] |
10. Pincus JM, Crosby SS, Losina E, King ER, LaBelle C, Freedberg KA.. Acute Human Immunodeficiency Virus infection in patients presenting to an urban urgent care center. Clin Infect Dis. 2003;37:1699-704. Cerrar [Medline] [Descargar cita] |
11. Jaen A, Casabona J, Esteve A, Mir� JM, Tural C, Ferrer E, et al.. Caracter�sticas cl�nico-epidemiol�gicas y tendencias en el tratamiento antirretroviral de una cohorte de pacientes con infecci�n por el virus de la inmunodeficiencia humana. Cohorte Piscis. Med Clin (Barc). 2005;124:525-31. Cerrar [Medline] [Descargar cita] [Art�culo] |
2. Vanhems P, Dassa C, Lambert J, Cooper DA, Perrin L, Vizzard J, et al.. Comprehensive classification of symptoms and signs reported among 218 patients with acute HIV-1 infection. J Acquir Immune Defic Syndr. 1999;21:99-106. Cerrar [Medline] [Descargar cita] |
12. Hecht FM, Busch MP, Rawal B, Webb M, Rosenberg E, Swanson M, et al.. Use of laboratory tests and clinical symptoms for identification of primary HIV infection. AIDS. 2002;16:1119-29. Cerrar [Medline] [Descargar cita] |
13. Vanhems P, Voirin N, Hirschel B, Cooper DA, Vizzard J, Carr A, et al.. Brief report: incubation and duration of specific symptoms at acute retroviral syndrome as independent predictors of progression to AIDS. J Acquir Immune Defic Syndr. 2003;32:542-4. Cerrar [Medline] [Descargar cita] |
14. Vanhems P, Hirschel B, Phillips AN, Cooper DA, Vizzard J, Brassard J, et al.. Incubation time of acute Human Immunodeficiency Virus (HIV) infection and duration of acute HIV infection are independent prognostic factors of progression to AIDS. J Infect Dis. 2000;182:334-7. Cerrar [Medline] [Descargar cita] |
15. Mellors JW, Mu�oz A, Giorgi JV, Margolick JB, Tassoni CJ, Gupta P, et al.. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med. 1997;126:946-54. Cerrar [Medline] [Descargar cita] |
16. Lavreys L, Baeten JM, Overbaugh J, Panteleeff DD, Chohan BH, Richardson BA, et al.. Virus load during primary Human Immunodeficiency Virus (HIV) type 1 infection is related to the severity of acute HIV illness in Kenyan women. Clin Infect Dis. 2002;35:77-81. Cerrar [Medline] [Descargar cita] |
17. Schacker T, Collier AC, Hughes J, Shea T, Corey L.. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996;125:257-64. Cerrar [Medline] [Descargar cita] |
18. Bollinger RC, Brookmeyer RS, Mehendale SM, Paranjape RS, Shepherd ME, Gadkari DA, et al.. Risk factors and clinical presentation of acute primary HIV infection in India. JAMA. 1997;278:2085-9. Cerrar [Medline] [Descargar cita] |
19. Vanhems P, Allard R, Cooper DA, Perrin L, Vizzard J, Hirschel B, et al.. Acute Human Immunodeficiency Virus type 1 disease as a mononucleosis-like illness: is the diagnosis too restrictive? Clin Infect Dis. 1997;24:965-70. Cerrar |
20. Tambussi G, Gori A, Capiluppi B, Balotta C, Papagno L, Morandini B, et al.. Neurological symptoms during primary Human Immunodeficiency Virus (HIV) infection correlate with high levels of HIV RNA in cerebrospinal fluid. Clin Infect Dis. 2000;30:962-5. Cerrar [Medline] [Descargar cita] |
21. Boufassa F, Bachmeyer C, Carre N, Deveau C, Persoz A, Jadand C, et al.. Influence of neurologic manifestations of primary Human Immunodeficiency Virus infection on disease progression. SEROCO Study Group. J Infect Dis. 1995;171:1190-5. Cerrar [Medline] [Descargar cita] |
22. Routy JP, Vanhems P, Rouleau D, Tsoukas C, Lefebvre E, Cote P, et al.. Comparison of clinical features of acute HIV-1 infection in patients infected sexually or through injection drug use. J Acquir Immune Defic Syndr. 2000;24:425-32. Cerrar |
23. Vanhems P, Routy JP, Hirschel B, Baratin D, Vora S, Maenza J, et al.. Clinical features of acute retroviral syndrome differ by route of infection but not by gender and age. J Acquir Immune Defic Syndr. 2002;31:318-21. Cerrar [Medline] [Descargar cita] |
24. Pena JM, Mart�nez-L�pez MA, Arnalich F, Barbado FJ, V�zquez JJ.. Esophageal candidiasis associated with acute infection due to Human Immunodeficiency Virus: case report and review. Rev Infect Dis. 1991;13:872-5. Cerrar [Medline] [Descargar cita] |
25. Mateos Rodr�guez F, Fuertes Mart�n A, Marcos Toledano M, Jim�nez L�pez A.. Primoinfecci�n VIH con candidiasis esof�gica y toxoplasmosis aguda. An Med Interna. 1998;1:50-1. 26. Szabo S, James CW, Telford G.. Unusual presentations of primary Human Immunodeficiency Virus infection. AIDS Patient Care STDS. 2002;16:251-4. [Medline] [Descargar cita] 27. Moss PJ, Read RC, Kudesia G, McKendrick MW.. Prolonged cryptosporidiosis during primary HIV infection. J Infect. 1995;30:51-3. [Medline] [Descargar cita] Cerrar |
28. Kinloch-De Loes S, Hirschel BJ, Hoen B, Cooper DA, Tindall B, Carr A, et al.. A controlled trial of zidovudine in primary Human Immunodeficiency Virus infection. N Engl J Med. 1995;333:408-13. Cerrar [Medline] [Descargar cita] |
29. Oxenius A, Price DA, Easterbrook PJ, O'Callaghan CA, Kelleher AD, Whelan JA, et al.. Early highly active antiretroviral therapy for acute HIV-1 infection preserves immune function of CD8+ and CD4+ T lymphocytes. Proc Natl Acad Sci U S A. 2000;97:3382-7. Cerrar [Medline] [Descargar cita] |
30. Malhotra U, Berrey MM, Huang Y, Markee J, Brown DJ, Ap S, et al.. Effect of combination antiretroviral therapy on T-cell immunity in acute Human Immunodeficiency Virus type 1 infection. J Infect Dis. 2000;181:121-31. Cerrar [Medline] [Descargar cita] |
31. Markowitz M, Vesanen M, Tenner-Racz K, Cao Y, Binley JM, Talal A, et al.. The effect of commencing combination antiretroviral therapy soon after Human Immunodeficiency Virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis. 1999;179:527-37. Cerrar [Medline] [Descargar cita] |
32. Yerly S, Kaiser L, Perneger TV, Cone RW, Opravil M, Chave JP, et al.. Time of initiation of antiretroviral therapy: impact on HIV-1 viraemia. The Swiss HIV Cohort Study. AIDS. 2000;14:243-9. Cerrar [Medline] [Descargar cita] |
33. Lisziewicz J, Rosenberg E, Lieberman J, Jessen H, Lopalco L, Siliciano R, et al.. Control of HIV despite the discontinuation of antiretroviral therapy. N Engl J Med. 1999;340:1683-4. Cerrar [Medline] [Descargar cita] |
34. Kaufmann DE, Lichterfeld M, Altfeld M, Addo MM, Johnston MN, Lee PK, et al.. Limited durability of viral control following treated acute HIV infection. PLoS Med. 2004;1:e36. Cerrar [Medline] [Descargar cita] |
35. Smith DE, Walker BD, Cooper DA, Rosenberg ES, Kaldor JM.. Is antiretroviral treatment of primary HIV infection clinically justified on the basis of current evidence? AIDS. 2004;18:709-18. Cerrar |
36. Berrey MM, Schacker T, Collier AC, Shea T, Brodie SJ, Mayers D, et al.. Treatment of primary Human Immunodeficiency Virus type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis. 2001;183:1466-75. Cerrar [Medline] [Descargar cita] |
37. Schiffer V, Deveau C, Meyer L, Iraqui I, Nguyen-Wartel A, Chaix ML, et al.. Recent changes in the management of primary HIV-1 infection: results from the French PRIMO cohort. HIV Med. 2004;5:326-33. Cerrar [Medline] [Descargar cita] |
1. Ravioglione M, Sudre P, Rieder H, Spinaci S, Kochi A.. Secular trends of tuberculosis Western Europe: epidemiology situation in 14 countries. WHO/ TB/92.170. Cerrar |
2. Rodr�guez Valin E.. Situaci�n actual de la tuberculosis en Espa�a: incidencia y mortalidad desde 1995. Caracter�sticas de los casos de tuberculosis y meningitis tuberculosa declarados en 2000. Sermergen. 2002;28:395-400. Cerrar |
3. Antonucci G, Girardi E, Raviglione MC, Ippolito G for the Gruppo Italiano di Studio Tubercolosi ed AIDS.. Risk factor for the tuberculosis in HIV-infected subjects: a prospective cohort study. JAMA. 1995;274:143-8. Cerrar [Medline] [Descargar cita] |
4. Shafer RW, Edlin BR.. Tuberculosis in patients infected with human immunodeficiency virus: perspective on the past decade. Clin Infect Dis. 1996;22: 683-704. Cerrar [Medline] [Descargar cita] |
5. Shafer RW, Kim DS, Weiss JP, Quale JM.. Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection. Medicine. 1991;70: 384-97. Cerrar [Medline] [Descargar cita] |
6. Berenger J, Moreno S, Laguna F, Vicente T, Adrados M, Ortega A, et al.. Tuberculous meningitis in patients with the human immunodeficiency virus infection. N Engl J Med. 1992;326:668-72. Cerrar [Medline] [Descargar cita] |
5. Shafer RW, Kim DS, Weiss JP, Quale JM.. Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection. Medicine. 1991;70: 384-97. Cerrar [Medline] [Descargar cita] |
7. McArthur JC, Harrison DM.. Cerebral infections in AIDS: mycobacterial and other bacterial infections. Infect Med. 1997;14:162-8. Cerrar |
6. Berenger J, Moreno S, Laguna F, Vicente T, Adrados M, Ortega A, et al.. Tuberculous meningitis in patients with the human immunodeficiency virus infection. N Engl J Med. 1992;326:668-72. Cerrar [Medline] [Descargar cita] |
7. McArthur JC, Harrison DM.. Cerebral infections in AIDS: mycobacterial and other bacterial infections. Infect Med. 1997;14:162-8. Cerrar |
8. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: Treatment of Tuberculosis.. Am J Respir Crit Care Med. 2003;167:603-62. Cerrar [Medline] [Descargar cita] |
9. Protocolo de la Sociedad Espa�ola de Enfermedades Infecciosas y Microbiolog�a Cl�nica.. Protoloco de Tratamiento de Tuberculosis. Disponible en: www.seimc.org/protocolos/clinicos/index.htm Cerrar |
10. Daley CL, Small PM, Schecter GF, Schoolink G, McAdam R, Phil D, et al.. An outbreak of tuberculosis with accelerated progression among persons infected with the human immunodeficiency virus. An analysis using restriction-fragment-length polymorphisms. N Engl J Med. 1992;326:231-5. Cerrar [Medline] [Descargar cita] |
2. Rodr�guez Valin E.. Situaci�n actual de la tuberculosis en Espa�a: incidencia y mortalidad desde 1995. Caracter�sticas de los casos de tuberculosis y meningitis tuberculosa declarados en 2000. Sermergen. 2002;28:395-400. Cerrar |
11. Grupo de trabajo del PMIT.. Incidencia de la tuberculosis en Espa�a: resultados del Proyecto de Investigaci�n en Tuberculosis (PMIT). Med Clin (Barc). 2000;114:530-7. Cerrar [Medline] [Descargar cita] [Art�culo] |
6. Berenger J, Moreno S, Laguna F, Vicente T, Adrados M, Ortega A, et al.. Tuberculous meningitis in patients with the human immunodeficiency virus infection. N Engl J Med. 1992;326:668-72. Cerrar [Medline] [Descargar cita] |
12. Gutman LT.. Extrapulmonary tuberculosis. Semin Pediatr Infect Dis. 1993; 4:250-60. 13. Yechoor VK, Shandera WX, Rodr�guez P.. Tuberculous meningitis among adults with and without HIV infection: experience in an urban public hospital. Arch Intern Med. 1996;15:1710-6. 14. Lanjewar DN, Jain PP, Shetty CR.. Profile of central nervous system pathology in patients with AIDS: an autopsy study from India. AIDS. 1998;12: 309-13. [Medline] [Descargar cita] 15. Dube MP, Holtom PD, Larsen RA.. Tuberculous meningitis in patients with and without the human immunodeficiency virus infection. Am J Med. 1992; 93:520-4. [Medline] [Descargar cita] Cerrar |
16. Braun MM, Byers RH, Heyward WL, Shriner KA, Mathisen GE, Goetz MW, et al.. Acquired immunodeficiency syndrome and extrapulmonary tuberculosis en the United States. Arch Intern Med. 1990;150:1913-6. [Medline] [Descargar cita] 17. Alpert PL, Munsiff SS, Gourevith BG, Klein RS.. A prospective study of tuberculosis and human immunodeficiency virus Infection: clinical manifestations and factors associated with survival. Clin Infect Dis. 1997;24:661-8. [Medline] [Descargar cita] 18. �lvarez S, McCabe WR.. Extrapulmonary tuberculosis revisited: a review of experience at Boston City and other hospitals. Medicine. 1984;63:25-55. [Medline] [Descargar cita] Cerrar |
6. Berenger J, Moreno S, Laguna F, Vicente T, Adrados M, Ortega A, et al.. Tuberculous meningitis in patients with the human immunodeficiency virus infection. N Engl J Med. 1992;326:668-72. Cerrar [Medline] [Descargar cita] |
15. Dube MP, Holtom PD, Larsen RA.. Tuberculous meningitis in patients with and without the human immunodeficiency virus infection. Am J Med. 1992; 93:520-4. Cerrar [Medline] [Descargar cita] |
6. Berenger J, Moreno S, Laguna F, Vicente T, Adrados M, Ortega A, et al.. Tuberculous meningitis in patients with the human immunodeficiency virus infection. N Engl J Med. 1992;326:668-72. Cerrar [Medline] [Descargar cita] |
19. Mart�n-Casabona N, Oca�a I, Vidal R, Codina G, Cayla J, Gonz�lez T.. Diagnosis of mycobacterial infection in acquired immunodeficiency syndrome (AIDS) patients and HIV carriers. J Hyg Epidemiol Microbiol Immunol. 1992;36:293-302. Cerrar [Medline] [Descargar cita] |
20. Elcuaz R, Mart�n-Casabona N, Gonz�lez F, Rossell� J.. Infecciones por micobacterias: rendimiento de la baciloscopia en diferentes muestras cl�nicas (1975-1988). Med Clin (Barc). 1991;97:211-4. Cerrar [Medline] [Descargar cita] |
21. Orcau MA, Mart�n-Casabona N, Gonz�lez T, Bonaventura I, Aguilar A, Ferrer A.. Meningitis tuberculosa: estudio de 28 casos con aislamiento de Mycobacterium tuberculosis en LCR. Med Clin (Barc). 1987;27:333-7. Cerrar |
22. Pai M, Flores L, Pai N, Hubbard A, Riley L, Colford M Jr.. Diagnostic accuracy of nucleic acid amplification test for tuberculous meningitis: systematic review and meta-analysis. Lancet Infect Dis. 2003;3:633-43. Cerrar [Medline] [Descargar cita] |
6. Berenger J, Moreno S, Laguna F, Vicente T, Adrados M, Ortega A, et al.. Tuberculous meningitis in patients with the human immunodeficiency virus infection. N Engl J Med. 1992;326:668-72. Cerrar [Medline] [Descargar cita] |
6. Berenger J, Moreno S, Laguna F, Vicente T, Adrados M, Ortega A, et al.. Tuberculous meningitis in patients with the human immunodeficiency virus infection. N Engl J Med. 1992;326:668-72. Cerrar [Medline] [Descargar cita] |
23. Ribera E, Mart�nez-V�zquez JM, Oca�a I, Segura RM, Pascual C.. Activity of adenosine desaminase in cerebrospinal fluid for the diagnosis and follow up of tuberculous meningitis in adults. J Infect Dis. 1987;155:603-7. Cerrar [Medline] [Descargar cita] |
24. Whiteman M, Espinoza L, Donovan J, Bell MD, Falcone S.. Central nervous system tuberculosis in HIV-infected patients: clinical and radiographic findings. Am J Neuroradiol. 1995;16:1319-27. Cerrar [Medline] [Descargar cita] |
25. Corral I, Quereda C, Navas E, Mart�n-D�vila P, P�rez-El�as MJ, Casado JL, et al.. Adenosine deaminase activity in cerebrospinal fluid of HIV-infected patients: limited value for diagnosis of tuberculous meningitis. Eur J Clin Microbiol. 2004;23:471-6. Cerrar |
26. Engin G, Acunas B, Acunas G, Tunaci M.. Imaging of extrapulmonary tuberculosis. Radiographics. 2000;20:471-88. Cerrar [Medline] [Descargar cita] |
6. Berenger J, Moreno S, Laguna F, Vicente T, Adrados M, Ortega A, et al.. Tuberculous meningitis in patients with the human immunodeficiency virus infection. N Engl J Med. 1992;326:668-72. Cerrar [Medline] [Descargar cita] |
12. Gutman LT.. Extrapulmonary tuberculosis. Semin Pediatr Infect Dis. 1993; 4:250-60. 13. Yechoor VK, Shandera WX, Rodr�guez P.. Tuberculous meningitis among adults with and without HIV infection: experience in an urban public hospital. Arch Intern Med. 1996;15:1710-6. 14. Lanjewar DN, Jain PP, Shetty CR.. Profile of central nervous system pathology in patients with AIDS: an autopsy study from India. AIDS. 1998;12: 309-13. [Medline] [Descargar cita] 15. Dube MP, Holtom PD, Larsen RA.. Tuberculous meningitis in patients with and without the human immunodeficiency virus infection. Am J Med. 1992; 93:520-4. [Medline] [Descargar cita] Cerrar |
5. Shafer RW, Kim DS, Weiss JP, Quale JM.. Extrapulmonary tuberculosis in patients with human immunodeficiency virus infection. Medicine. 1991;70: 384-97. Cerrar [Medline] [Descargar cita] |
14. Lanjewar DN, Jain PP, Shetty CR.. Profile of central nervous system pathology in patients with AIDS: an autopsy study from India. AIDS. 1998;12: 309-13. Cerrar [Medline] [Descargar cita] |
25. Corral I, Quereda C, Navas E, Mart�n-D�vila P, P�rez-El�as MJ, Casado JL, et al.. Adenosine deaminase activity in cerebrospinal fluid of HIV-infected patients: limited value for diagnosis of tuberculous meningitis. Eur J Clin Microbiol. 2004;23:471-6. Cerrar |
6. Berenger J, Moreno S, Laguna F, Vicente T, Adrados M, Ortega A, et al.. Tuberculous meningitis in patients with the human immunodeficiency virus infection. N Engl J Med. 1992;326:668-72. Cerrar [Medline] [Descargar cita] |
27. Small PM, Schecter GF, Goodman PC, Sande MA, Chaisson RE, Hopewell PC.. Treatment of tuberculosis in patients with advanced human immunodeficiency virus infection. N Engl J Med. 1991;324:289-94. Cerrar [Medline] [Descargar cita] |
28. Thwaites G, Duc Bang N, Huy Dung N, Thi Quy H, Tuong DT, Thi Cam Thoa N, et al.. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351:1741-51. Cerrar [Medline] [Descargar cita] |
6. Berenger J, Moreno S, Laguna F, Vicente T, Adrados M, Ortega A, et al.. Tuberculous meningitis in patients with the human immunodeficiency virus infection. N Engl J Med. 1992;326:668-72. Cerrar [Medline] [Descargar cita] |
29. Bishburg E, Sunderam G, Reichman LB, Kapila A.. Central nervous system tuberculosis with the acquired immunodeficiency syndrome and its related complex. Ann Intern Med. 1986;105:210-3. Cerrar [Medline] [Descargar cita] |
6. Berenger J, Moreno S, Laguna F, Vicente T, Adrados M, Ortega A, et al.. Tuberculous meningitis in patients with the human immunodeficiency virus infection. N Engl J Med. 1992;326:668-72. Cerrar [Medline] [Descargar cita] |
6. Berenger J, Moreno S, Laguna F, Vicente T, Adrados M, Ortega A, et al.. Tuberculous meningitis in patients with the human immunodeficiency virus infection. N Engl J Med. 1992;326:668-72. Cerrar [Medline] [Descargar cita] |
15. Dube MP, Holtom PD, Larsen RA.. Tuberculous meningitis in patients with and without the human immunodeficiency virus infection. Am J Med. 1992; 93:520-4. Cerrar [Medline] [Descargar cita] |
18. �lvarez S, McCabe WR.. Extrapulmonary tuberculosis revisited: a review of experience at Boston City and other hospitals. Medicine. 1984;63:25-55. Cerrar [Medline] [Descargar cita] |
6. Berenger J, Moreno S, Laguna F, Vicente T, Adrados M, Ortega A, et al.. Tuberculous meningitis in patients with the human immunodeficiency virus infection. N Engl J Med. 1992;326:668-72. Cerrar [Medline] [Descargar cita] |
28. Thwaites G, Duc Bang N, Huy Dung N, Thi Quy H, Tuong DT, Thi Cam Thoa N, et al.. Dexamethasone for the treatment of tuberculous meningitis in adolescents and adults. N Engl J Med. 2004;351:1741-51. Cerrar [Medline] [Descargar cita] |
1. Wolinsky JS.. Rubella. En: Fields BN, Knipe DM, Howley PM, editors. Fields virology. 3rd ed. Philadelphia: Lippincott-Raven Publishers; 1996. p. 899-929. Cerrar |
2. Amela C, Pach�n I.. La Vigilancia Epidemiol�gica del sarampi�n en el contexto del Cerrar |
3. Strategic plan for measles and congenital rubella infection in the European Region of WHO.. Copenhagen, WHO Regional Office For Europe. 2003 [consultada 26 abril 2005]. Disponible en: http://www.euro.who.int/document/e81567.pdf Cerrar |
4. Surveillance guidelines for measles and congenital rubella infections in the WHO European Region.. Copenhagen, WHO Regional Office For Europe. 2003 [consultada 26 abril 2005]. Disponible en: http://www.euro.who.int/document/E82183.pdf Cerrar |
2. Amela C, Pach�n I.. La Vigilancia Epidemiol�gica del sarampi�n en el contexto del Cerrar |
5. Mosquera MM, De Ory F, Moreno M, Echevarr�a JE.. Simultaneous detection of measles virus, rubella virus, and parvovirus B19 by using multiplex PCR. J Clin Microbiol. 2002;40:111-6. Cerrar [Medline] [Descargar cita] |
3. Strategic plan for measles and congenital rubella infection in the European Region of WHO.. Copenhagen, WHO Regional Office For Europe. 2003 [consultada 26 abril 2005]. Disponible en: http://www.euro.who.int/document/e81567.pdf Cerrar |
4. Surveillance guidelines for measles and congenital rubella infections in the WHO European Region.. Copenhagen, WHO Regional Office For Europe. 2003 [consultada 26 abril 2005]. Disponible en: http://www.euro.who.int/document/E82183.pdf Cerrar |
6. Amela C, Pachon I, De Ory F.. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey. Eur J Epidemiol. 2003;18:71-9. Cerrar [Medline] [Descargar cita] |
7. III Encuesta de Serovigilancia de la Comunidad de Madrid.. Bolet�n Epidemiol�gico de la Comunidad de Madrid. 2002;8:3-43. Cerrar |
6. Amela C, Pachon I, De Ory F.. Evaluation of the measles, mumps and rubella immunisation programme in Spain by using a sero-epidemiological survey. Eur J Epidemiol. 2003;18:71-9. Cerrar [Medline] [Descargar cita] |
8. Rafila A, Marin M, Pistol A, Nicolaiciuc D, Lupulescu E, Uzicanin A, et al.. A large rubella outbreak, Romania-2003. Euro Surveill. 2004;9:7-8. Cerrar [Medline] [Descargar cita] |
9. Panagiotopoulos T, Georgakopoulou T.. Epidemiology of rubella and congenital rubella syndrome in Greece, 1994-2003. Euro Surveill. 2004. p. 9. Cerrar |
10. Garc�a Rodr�guez J, Clerig Arnau U, Palacios Vaca F, Mart�nez Montero JC.. Brote de rub�ola en Puerto de Santa Mar�a (C�diz). Aten Primaria. 1993;11: 276-80. Cerrar [Medline] [Descargar cita] |
11. Cooper LZ.. Current lessons from 20th century serosurveillance data on rubella. Clin Infect Dis. 2001;33:1287. Cerrar [Medline] [Descargar cita] |
12. Tookey P.. Rubella in England, Scotland and Wales. Euro Surveill. 2004;9: 21-3. Cerrar [Medline] [Descargar cita] |
13. Sanz JC, Lemos C, Herrera D, Ram�rez-Fern�ndez R.. Brote de rub�ola en poblaci�n inmigrante de origen latinoamericano. Enferm Infecc Microbiol Clin. 2004;22:197. Cerrar |
1. Wolinsky JS.. Rubella. En: Fields BN, Knipe DM, Howley PM, editors. Fields virology. 3rd ed. Philadelphia: Lippincott-Raven Publishers; 1996. p. 899-929. Cerrar |
1. Singh N.. Trends in the epidemiology of opportunistic fungal infections: Predisposing factors and the impact of antimicrobial use practices. Clin Infect Dis. 2001;33:1692-6. Cerrar [Medline] [Descargar cita] |
2. G�mez J, Ba�os V, Simarro E, Ruiz J, Requena L, P�rez J, et al.. Fungemias nosocomiales en un hospital general: epidemiolog�a y factores pron�sticos. Estudio prospectivo 1993-1998. Enferm Infecc Microbiol Clin. 2001;19:304-7. Cerrar [Medline] [Descargar cita] [Art�culo] |
3. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al.. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:161-89. Cerrar [Medline] [Descargar cita] |
4. Lumbreras C, Lizasoain M, Aguado JM.. Antif�ngicos de uso sist�mico. Enferm Infecc Microbiol Clin. 2003;21:366-79. Cerrar [Medline] [Descargar cita] [Art�culo] |
5. Gross PA, Barrett TL, Dellinger P, Krause PJ, Martone WJ, McGowan JE Jr, et al.. Purpose of quality standars for Infectious Diseases. Clin Infect Dis. 1994;18:421. Cerrar [Medline] [Descargar cita] |
6. Rex JH, Bennett JE, Sugar AM, Pappas PG, Van der Horst CM, Edwards JE, et al.. A randomized trial comparing fluconazole with amphotericin B for the treatment of candidemia in patients without neutropenia. N Engl J Med. 1994;331:1325-30. Cerrar [Medline] [Descargar cita] |
7. Phillips P, Shafran S, Garber G, Rotsein C, Smaill F, Fong I, et al.. Multicenter randomized trial of fluconazole versus amphotericin B for treatment of candidemia in non-neutropenic patients. Eur J Clin Microbiol Infect Dis. 1997;16:337-45. Cerrar [Medline] [Descargar cita] |
8. Anaissie EJ, White M, Uzun O, Anaissie EJ, White M, Uzun O.. Amphotericin B lipid complex (ABLC) versus amphotericin B (AMB) for treatment of hematogenous and invasive candidiasis: a prospective, randomized, multicenter trial [abstract LM21]. En: Program and abstracts of the 35th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Francisco). Washington: American Society for Microbiology; 1995. Cerrar |
9. Mora-Duarte J, Betts R, Rotstein R, Colombo AL, Thompson-Moya L, Smietana J, et al.. Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl J Med. 2002;347:2020-9. Cerrar [Medline] [Descargar cita] |
10. Kullberg BJ, Sobel JD, Ruhnke M, Pappas PG, Viscoli C, Rex JH, et al.. Voriconazol versus a regimen of amphotericin B followed by fluconazole for candidemia in non-neutropenic patients: a randomized non-inferiority trial. Lancet. 2005;366:1435-42. Cerrar [Medline] [Descargar cita] |
11. Rex JH, Pappas PG, Karchmer AW, Sobel J, Edwards JE, Hadley, et al.. A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects. Clin Infect Dis. 2003;36: 1221-8. Cerrar [Medline] [Descargar cita] |
12. Eriksson U, Seifert B, Schaffner A.. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ. 2001;322:1-6. [Medline] [Descargar cita] 13. Imhof A, Walter RB, Schaffner A.. Continous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis. 2003;36:943-51. [Medline] [Descargar cita] 14. Peleg AY, Woods ML.. Continous and 4 h infusion of amphotericin B: A comparative study involving high-risk haematology patients. J Antimicrob Chemother. 2004;54:803-8. [Medline] [Descargar cita] Cerrar |
13. Imhof A, Walter RB, Schaffner A.. Continous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis. 2003;36:943-51. Cerrar [Medline] [Descargar cita] |
12. Eriksson U, Seifert B, Schaffner A.. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. BMJ. 2001;322:1-6. [Medline] [Descargar cita] 13. Imhof A, Walter RB, Schaffner A.. Continous infusion of escalated doses of amphotericin B deoxycholate: an open-label observational study. Clin Infect Dis. 2003;36:943-51. [Medline] [Descargar cita] 14. Peleg AY, Woods ML.. Continous and 4 h infusion of amphotericin B: A comparative study involving high-risk haematology patients. J Antimicrob Chemother. 2004;54:803-8. [Medline] [Descargar cita] Cerrar |
15. Walsh TJ, Rex JH.. All catheter-related candidemia is not the same: assessment of the balance between the risks and benefits of removal of vascular catheters. Clin Infect Dis. 2002;34:600-2. Cerrar [Medline] [Descargar cita] |
16. Sora F, Chiusolo P, Piccirillo N, Pagano L, Laurenti L, Farina G, et al.. Successful treatment with caspofungin of hepatosplenic candidiasis resistant to liposomal amphotericin B. Clin Infect Dis. 2002;35:1135-6. Cerrar |
17. Edwards JE Jr, Bodey GP, Bowden RA, Buchner T, De Pauw BE, Filler SG, et al.. International conference for the development of a consensus on the management and prevention of severe candidal infections. Clin Infect Dis. 1997;25:43-59. Cerrar [Medline] [Descargar cita] |
18. Kauffman CA, V�zquez JA, Sobel JD, Gallis HA, McKinsey DS, Karchmer AW, et al.. Prospective multicenter surveillance study of funguria in hospitalized patients. Clin Infect Dis. 2000;30:14-8. Cerrar [Medline] [Descargar cita] |
19. Sobel JD, Kauffman CA, McKinsey D, Zervos M, V�zquez JA, Karchmer AW, et al.. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. Clin Infect Dis. 2000;30:19-24. Cerrar [Medline] [Descargar cita] |
3. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al.. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:161-89. Cerrar [Medline] [Descargar cita] |
20. Sandven P, Qvist H, Skovlund E, Giercksky KE.. Significance of Candida recovered from intraoperative specimens in patients with intraabdominal perforations. Crit Care Med. 2002;30:541-7. Cerrar [Medline] [Descargar cita] |
21. Salvaggio MR, Pappas PG.. Current concepts in the management of fungal peritonitis. Curr Infect Dis Rep. 2003;5:120-4. Cerrar [Medline] [Descargar cita] |
22. Goldie SJ, Kiernan-Tridle L, Torres C, Gorban-Brennan N, Dunne D, Kliger AS, et al.. Fungal peritonitis in a large chronic peritoneal dialysis population: A report of 55 episodes. Am J Kidney Dis. 1996;28:86-91. Cerrar [Medline] [Descargar cita] |
3. Pappas PG, Rex JH, Sobel JD, Filler SG, Dismukes WE, Walsh TJ, et al.. Guidelines for treatment of candidiasis. Clin Infect Dis. 2004;38:161-89. Cerrar [Medline] [Descargar cita] |
23. Akler ME, Vellend H, McNeely DM, Walmsley SL, Gold WL.. Use of fluconazole in the treatment of candidal endophthalmitis. Clin Infect Dis. 1995; 20:657-64. Cerrar [Medline] [Descargar cita] |
24. Breit SM, Hariprasad SM, Mieler WF, Shah GK, Mills MD, Grand MG.. Management of endogenous fungal endophthalmitis with voriconazole and caspofungin. Am J Ophthalmol. 2005;139:135-40. Cerrar [Medline] [Descargar cita] |
25. Sarria JC, Bradley JC, Habash R, Mitchell KT, Kimbrough RC, Vidal AM.. Candida glabrata endophthalmitis treated successfully with caspofungin. Clin Infect Dis. 2005;40:e46-8. Cerrar [Medline] [Descargar cita] |
26. Results of the endophthalmitis vitrectomy study: a randomized trial of immediate vitrectomy and of intravenous antibiotics for the treatment of postoperative bacterial endophthalmitis.. Endophthalmitis vitrectomy study group. Arch Ophthalmol. 1995;113:1479-96. Cerrar [Medline] [Descargar cita] |
27. Mart�nez V�zquez C, Fern�ndez Ulloa J, Bord�n J.. Candida albicans endophtalmitis in brown heroin addicts: Response to early vitrectomy preceded and followed by antifungal therapy. Clin Infect Dis. 1998;27:1130-3. Cerrar [Medline] [Descargar cita] |
28. S�nchez-Portocarrero J, P�rez-Cecilia E, Corral O, Romero-Vivas J, Picazo JJ.. The central nervous system and infection by Candida species. Diagn Microbiol Infect Dis. 2000;37:169-79. Cerrar [Medline] [Descargar cita] |
29. Scarcella A, Pasquariello MB, Giugliano B, Vendemiia M, De Lucia A.. Liposomal amphotericin B treatment for neonatal fungal infections. Pediatr Infect Dis J. 1998;17:146-8. Cerrar [Medline] [Descargar cita] |
30. Casado JL, Quereda C, Oliva J, Navas E, Moreno A, Pintado V, et al.. Candidal meningitis in HIV-infected patients: Analysis of 14 Cases. Clin Infect Dis. 1997;25:673-6. Cerrar [Medline] [Descargar cita] |
31. Liu KH, Wu CJ, Chou CH, Lee HC, Lee NY, Hung ST, et al.. Refractory candidal meningitis in an immunocompromised patient cured by caspofungin. J Clin Microbiol. 2004;42:5950-3. Cerrar [Medline] [Descargar cita] |
32. Melamed R, Leibovitz E, Abramson O, Levitas A, Zucker N, Gorodisher R.. Successful non-surgical treatment of Candida tropicalis endocarditis with liposomal amphotericin-B (AmBisome). Scand J Infect Dis. 2000;32:86-9. Cerrar [Medline] [Descargar cita] |
33. Hauser M, Hess J, Belohradsky BH.. Treatment of Candida albicans endocarditis: Case report and a review. Infection. 2003;31:125-7. Cerrar [Medline] [Descargar cita] |
34. Nevado J, Alarc�n A, Hern�ndez A.. Caspofungin: A new therapeutic option for fungal endocarditis. Clin Microbiol Infect. 2005;11:248. [Medline] [Descargar cita] 35. Rajendram R, Alp NJ, Mitchell AR, Bowler IC, Forfar JC.. Candida prosthetic valve endocarditis cured by caspofungin therapy without valve replacement. Clin Infect Dis. 2005;40:e72-4. [Medline] [Descargar cita] 36. Jim�nez-Exp�sito MJ, Torres G, Barald�s A, Benito N, Marco F, Pare JC, et al.. Native valve endocarditis due to Candida glabrata treated without valvular replacement: A potential role for caspofungin in the induction and maintenance treatment. Clin Infect Dis. 2004;39:e70-3. [Medline] [Descargar cita] Cerrar |
37. Ghannoum MA, Kuhn DM.. Voriconazole-Better chances for patients with invasive mycoses. Eur J Med Res. 2002;7:242-56. Cerrar [Medline] [Descargar cita] |
38. Gavald� J, Ruiz I.. Grupos de estudio de la infecci�n f�ngica invasora (MICOMED) y de estudio de la infecci�n en el trasplante (GESITRA) de la Sociedad Espa�ola de Enfermedades Infecciosas y Microbiolog�a Cl�nica (SEIMC). Recomendaciones para el tratamiento de la infecci�n f�ngica invasiva. Infecci�n f�ngica invasora por Candida spp. Enferm Infecc Microbiol Clin. 2003;21:498-508. Cerrar [Medline] [Descargar cita] [Art�culo] |
39. Sim JP, Kho BC, Liu HS, Yung R, Chan JC.. Candida tropicalis arthritis of the knee in a patient with acute lymphoblastic leukaemia: successful treatment with caspofungin. Hong Kong Med J. 2005;11:120-3. Cerrar [Medline] [Descargar cita] |
40. Tunkel AR, Thomas CY, Wispelwey B.. Candida prosthetic arthritis: report of a case treated with fluconazole and review of the literature. Am J Med. 1993;94:100-3. Cerrar [Medline] [Descargar cita] |
41. Chuck SL, Sande MA.. Infections with Cryptococcus neoformans in the acquired immunodeficiency syndrome. N Engl J Med. 1989;321:794-9. Cerrar [Medline] [Descargar cita] |
42. Smith DK, Neal JJ, Holmberg SD.. Unexplained opportunistic infections and CD4+ T-lymphocytopenia without HIV infection. An investigation of cases in the United States. The Centers for Disease Control Idiopathic CD4+ T-lymphocytopenia Task Force. N Engl J Med. 1993;328:373-9. Cerrar [Medline] [Descargar cita] |
43. Duncan RA, Von Reyn CF, Alliegro GM, Toossi Z, Sugar AM, Levitz SM.. Idiopathic CD4+ T-lymphocytopenia�four patients with opportunistic infections and no evidence of HIV infection. N Engl J Med. 1993;328:393-8. Cerrar [Medline] [Descargar cita] |
44. Van der Horst CM, Saag NS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al.. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 1997;337:15-21. Cerrar [Medline] [Descargar cita] |
45. Saag MS, Graybill JR, Larsen R, Pappas PG, Perfect JR, Powderly WG, et al.. Practice guidelines for the management of cryptococcal meningitis. Clin Infect Dis. 2000;30:710-8. Cerrar [Medline] [Descargar cita] |
44. Van der Horst CM, Saag NS, Cloud GA, Hamill RJ, Graybill JR, Sobel JD, et al.. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. N Engl J Med. 1997;337:15-21. Cerrar [Medline] [Descargar cita] |
45. Saag MS, Graybill JR, Larsen R, Pappas PG, Perfect JR, Powderly WG, et al.. Practice guidelines for the management of cryptococcal meningitis. Clin Infect Dis. 2000;30:710-8. Cerrar [Medline] [Descargar cita] |
46. Saag MS, Cloud GA, Graybill JR, Sobel JD, Tuazon CU, Johnson PC, et al.. A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis. 1999;28:291-6. Cerrar [Medline] [Descargar cita] |
45. Saag MS, Graybill JR, Larsen R, Pappas PG, Perfect JR, Powderly WG, et al.. Practice guidelines for the management of cryptococcal meningitis. Clin Infect Dis. 2000;30:710-8. Cerrar [Medline] [Descargar cita] |
47. Coker RJ, Viviani M, Gazzard BG, Du Pont B, Pohle HD, Murphy SM, et al.. Treatment of cryptococcosis with liposomal amphotericin B (AmBisome) in 23 patients with AIDS. AIDS. 1993;7:829-35. Cerrar [Medline] [Descargar cita] |
48. Leenders AC, Reiss P, Portegies P, Clezy K, Hop WC, Hoy J, et al.. Liposomal amphotericin B (AmBisome) compared with amphotericin B both followed by oral fluconazole in the treatment of AIDS-associated cryptococcal meningitis. AIDS. 1997;11:1463-71. Cerrar [Medline] [Descargar cita] |
49. Larsen RA, Bozzette SA, Jones BE, Haghighat D, Leal MA, Forthal D, et al.. Fluconazole combined with flucytosine for the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1994;19:741-7. Cerrar [Medline] [Descargar cita] |
49. Larsen RA, Bozzette SA, Jones BE, Haghighat D, Leal MA, Forthal D, et al.. Fluconazole combined with flucytosine for the treatment of cryptococcal meningitis in patients with AIDS. Clin Infect Dis. 1994;19:741-7. Cerrar [Medline] [Descargar cita] |
50. Centers for Disease Control and Prevention.. Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents. MMWR. 2004;53(RR15): 1-112. Cerrar |
51. Perfect JR, Lutsar I, Gonz�lez-Ruiz A.. Voriconazole for the treatment of resistant and rare fungal pathogens. Clin Infet Dis. 2000;31:265. Cerrar |
50. Centers for Disease Control and Prevention.. Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents. MMWR. 2004;53(RR15): 1-112. Cerrar |
52. Powderly WG, Saag MS, Cloud GA, Robinson P, Meyer RD, Jacobson JM, et al.. A controlled trial of fluconazole or amphotericin B to prevent relapse of cryptococcal meningitis in patients with the acquired immunodeficiency syndrome. N Engl J Med. 1992;326:793-8. Cerrar [Medline] [Descargar cita] |
53. Larsen RA.. Editorial response: A comparison of itraconazole versus fluconazole as maintenance therapy for AIDS-associated cryptococcal meningitis. Clin Infect Dis. 1999;28:297-8. Cerrar [Medline] [Descargar cita] |
50. Centers for Disease Control and Prevention.. Treating Opportunistic Infections Among HIV-Infected Adults and Adolescents. MMWR. 2004;53(RR15): 1-112. Cerrar |
54. Latge JP.. Aspergillus fumigatus and aspergillosis. Clin Microbiol Rev. 1999;12:310-50. Cerrar [Medline] [Descargar cita] |
55. Denning DW.. Invasive aspergillosis. Clin Infect Dis. 1998;26:781-803. Cerrar [Medline] [Descargar cita] |
56. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, et al.. Practice guideline for diseases caused by Aspergillus. Clin Infect Dis. 2000;30:696-709. Cerrar [Medline] [Descargar cita] |
57. Schwartz S, Thiel E.. Clinical presentation of invasive aspergillosis. Mycoses. 1997;40 Suppl 2:21-4. Cerrar |
58. Mallie M, Bastide JM, Blancard A, Bonnin A, Bretagne S, Cambon M, et al.. In vitro susceptibility testing of Candida and Aspergillus spp. to voriconazole and other antifungal agents using Etest: results of a French multicentre study. Int J Antimicrob Agents. 2005;25:321-8. [Medline] [Descargar cita] 59. Garc�a-Martos P, Garc�a-Agudo L, Guti�rrez-Calzada J, Ruiz-Arag�n J, Saldarreaga A, Mar�n P.. In vitro activity of amphotericin B, itraconazole and voriconazole against 20 species of Aspergillus using the Sensititre microdilution method. Enferm Infecc Microbiol Clin. 2005;23:15-8. [Art�culo] 60. Hsueh PR, Lau YJ, Chuang YC, Wan JH, Huang WK, Shyr JM, et al.. Antifungal susceptibilities of clinical isolates of Candida species, Cryptococcus neoformans, and Aspergillus species from Taiwan: surveillance of multicenter antimicrobial resistance in Taiwan program data from 2003. Antimicrob Agents Chemother. 2005;49:512-7. [Medline] [Descargar cita] 61. Diekema DJ, Messer SA, Hollis RJ, Jones RN, Pfaller MA.. Activities of caspofungin, itraconazole, posaconazole, ravuconazole, voriconazole, and amphotericin B against 448 recent clinical isolates of filamentous fungi. J Clin Microbiol. 2003;41:3623-6. [Medline] [Descargar cita] Cerrar |
62. Von Eiff M, Roos N, Schulten R, Hesse M, Zuhlsdorf M, Van de Loo J.. Pulmonary aspergilosis: Early diagnosis improves survival. Respiration. 1995; 62:341-7. Cerrar [Medline] [Descargar cita] |
63. Maschmeyer G, Beinert T, Buchheidt D, Einsele H, Heussel CP, Kiehl M, et al.. Diagnosis and antimicrobial therapy of pulmonary infiltrates in febrile neutropenic patients. Ann Hematol. 2003;82 Suppl 2:118-26. Cerrar |
64. Patterson TF, Kirkpatrick WR, White M, Hiemenz JW, Wingard JR, Dupont B, et al.. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore). 2000;79:250-60. Cerrar [Medline] [Descargar cita] |
65. Roilides E, Uhlig K, Venzon D, Pizzo PA, Walsh TJ.. Enhancement of oxidative responses and damage caused by human neutrophils to Aspergillus fumigatus hyphae by granulocyte colony-stimulating factor and gamma interferon. Infect Immun. 1993;61:1185-93. Cerrar [Medline] [Descargar cita] |
66. Kullberg BJ, Vandewoude K, Aoun M, Jacobs J, Herbrecht R, Kujath P, et al.. A double-blind, randomized, placebo-controlled phase II study of filgrastim (recombinant granulocyte colony-stimulating factor) in combination with fluconazole for treatment of invasive candidiasis and candidemia in nonneutropenic patients [abstract J-100]. En: Program and abstracts of the 38th Interscience Conference on Antimicrobial Agents and Chemotherapy (San Diego). Washington: American Society for Microbiology; 1998. p. 479. Cerrar |
67. Pappas PG, Bustamante B, Ticona E, Hamill RJ, Johnson PC, Reboli A, et al.. Recombinant interferon-1b as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis. 2004;189:2185-91. Cerrar [Medline] [Descargar cita] |
68. Kullberg BJ, Oude Lashof AM, Netea MG.. Design of efficacy trials of cytokines in combination with antifungal drugs. Clin Infect Dis. 2004;39 Suppl 4: S218-S23. Cerrar |
56. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, et al.. Practice guideline for diseases caused by Aspergillus. Clin Infect Dis. 2000;30:696-709. Cerrar [Medline] [Descargar cita] |
69. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht D, Thiel E, et al.. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563-71. Cerrar [Medline] [Descargar cita] |
70. Herbrecht R, Denning DW, Patterson TF, Bennet JE, Greene RE, Oestmann JW, et al.. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-15. Cerrar [Medline] [Descargar cita] |
69. Denning DW, Ribaud P, Milpied N, Caillot D, Herbrecht D, Thiel E, et al.. Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis. Clin Infect Dis. 2002;34:563-71. Cerrar [Medline] [Descargar cita] |
71. Maertens J, Raad I, Petrikkos G, Boogaerts M, Selleslag D, Petersen FB, et al.. Efficacy and safety of Caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of convencional antifungal therapy. Clin Infect Dis. 2004;39:1563-71. Cerrar [Medline] [Descargar cita] |
56. Stevens DA, Kan VL, Judson MA, Morrison VA, Dummer S, Denning DW, et al.. Practice guideline for diseases caused by Aspergillus. Clin Infect Dis. 2000;30:696-709. Cerrar [Medline] [Descargar cita] |
72. Gavald� J, Ruiz I.. Recomendaciones para el tratamiento de la infecci�n por Aspergillus spp. Enferm Infecc Microbiol Clin. 2003;21:571-8. Cerrar [Medline] [Descargar cita] [Art�culo] |
73. Aliff TB, Maslak PG, Jurcic JG, Heaney ML, Cathcart KN, Sepkowitz KA, et al.. Refractory aspergillosis pneumonia in patients with acute leucemia. Cancer. 2003;97:1025-32. Cerrar [Medline] [Descargar cita] |
74. Marr KA, Boeckh M, Carter RA, Kim HW, Corey L.. Combination antifungal therapy for invasive aspergillosis. Clin Infect Dis. 2004:39:797-802. Cerrar [Medline] [Descargar cita] |
75. Kontoyannis DP, Bodey GP.. Invasive aspergillosis in 2002: An update. Eur J Clin Microbiol Infect Dis. 2002;21:161-72. Cerrar [Medline] [Descargar cita] |
70. Herbrecht R, Denning DW, Patterson TF, Bennet JE, Greene RE, Oestmann JW, et al.. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347:408-15. Cerrar [Medline] [Descargar cita] |
76. Caillot D, Casanovas O, Bernard A, Couaillier JF, Durand C, Cuisenier B, et al.. Improved management of invasive pulmonary aspergillosis in neutropenic patients using early thoracic computed tomographic scan and surgery. J Clin Oncol. 1997;15:139-47. Cerrar [Medline] [Descargar cita] |
78. Groll AH, Walsh TJ.. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect. 2001;7 Suppl 2:8-24. Cerrar |
79. Prabhu RM, Patel R.. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004;10 Suppl 1:31-47. Cerrar |
79. Prabhu RM, Patel R.. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004;10 Suppl 1:31-47. Cerrar |
80. Euker J, Sezer O, Graf B, Possinger K.. Mucormycoses. Mycoses. 2001;44: 253-60. Cerrar [Medline] [Descargar cita] |
79. Prabhu RM, Patel R.. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004;10 Suppl 1:31-47. Cerrar |
81. Mondy KE, Haughey B, Custer PL, Wippold FJ 2nd, Ritchie DJ, Mundy LM.. Rhinocerebral mucormycosis in the era of lipid-based amphotericin B: case report and literature review. Pharmacotherapy. 2002;22:519-26. Cerrar [Medline] [Descargar cita] |
82. Kimura M, Smith MB, McGinnis MR.. Zygomycosis due to Apophysomyces elegans. Report of 2 cases and review of the literature. Arch Pathol Lab Med. 1999;123:386-90. Cerrar [Medline] [Descargar cita] |
79. Prabhu RM, Patel R.. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004;10 Suppl 1:31-47. Cerrar |
83. Pagano L, Ricci P, Tonso A, Nosari A, Cudillo L, Montillo M, et al.. Mucormycosis in patients with haematological malignancies: a retrospective clinical study of 37 cases. Br J Haem. 1997;99:331-6. 84. Del R�o O, Santin M, Manos M, Rufi G, Gudiol F.. Mucormicosis: una infecci�n cl�sica con una alta mortalidad. Presentaci�n de 5 casos. Rev Clin Esp. 2001;201:184-7. [Medline] [Descargar cita] [Art�culo] 85. Herbrecht R, Letscher-Bru V, Bowden RA, Kusne S, Anaissie EJ, Graybill JR, et al.. Treatment of 21 cases of invasive mucormycosis with anfotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis. 2001;20:460-6. [Medline] [Descargar cita] Cerrar |
79. Prabhu RM, Patel R.. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004;10 Suppl 1:31-47. Cerrar |
80. Euker J, Sezer O, Graf B, Possinger K.. Mucormycoses. Mycoses. 2001;44: 253-60. Cerrar [Medline] [Descargar cita] |
85. Herbrecht R, Letscher-Bru V, Bowden RA, Kusne S, Anaissie EJ, Graybill JR, et al.. Treatment of 21 cases of invasive mucormycosis with anfotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis. 2001;20:460-6. Cerrar [Medline] [Descargar cita] |
80. Euker J, Sezer O, Graf B, Possinger K.. Mucormycoses. Mycoses. 2001;44: 253-60. Cerrar [Medline] [Descargar cita] |
85. Herbrecht R, Letscher-Bru V, Bowden RA, Kusne S, Anaissie EJ, Graybill JR, et al.. Treatment of 21 cases of invasive mucormycosis with anfotericin B colloidal dispersion. Eur J Clin Microbiol Infect Dis. 2001;20:460-6. Cerrar [Medline] [Descargar cita] |
78. Groll AH, Walsh TJ.. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect. 2001;7 Suppl 2:8-24. Cerrar |
79. Prabhu RM, Patel R.. Mucormycosis and entomophthoramycosis: a review of the clinical manifestations, diagnosis and treatment. Clin Microbiol Infect. 2004;10 Suppl 1:31-47. Cerrar |
86. Id�goras P, P�rez-Trallero E, Pi�eiro L, Larruskain J, L�pez-Lopategui MC, Rodr�guez N, et al.. Disseminated infection and colonization by Scedosporium prolificans: A review of 18 cases 1990-99. Clin Infect Dis. 2001;32:58-65. Cerrar |
87. Bouza E, Mu�oz P.. Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp. Clin Microbiol Infect. 2004;10:76-85. Cerrar [Medline] [Descargar cita] |
87. Bouza E, Mu�oz P.. Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp. Clin Microbiol Infect. 2004;10:76-85. [Medline] [Descargar cita] 88. Husain S, Mu�oz P, Forrest G , Alexander BD, Somani J, Brennan K, et al.. Infections due to Scedosporium apiospermum and Scedosporium prolificans in transplant recipients: clinical characteristics and impact of antifungal agent therapy on outcome. Clin Infect Dis. 2005;40:89-100. [Medline] [Descargar cita] 89. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, De la Torre-Cisneros J, et al.. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122-31. [Medline] [Descargar cita] Cerrar |
90. Safdar A, Papadopoulos EB, Young JW.. Breakthrough Scedosporium apiospermum (Pseudallescheria boydii) brain abscess during therapy for invasive pulmonary aspergillosis following high-risk allogeneic hematopoietic stem cell transplantation. Recent Adv Antifungal Ther Transpl Infect Dis. 2002;4:212-7. Cerrar |
91. Howden BP, Slavin MA, Schwarer AP, Mijch AM.. Successful Control of Disseminated Scedosporium prolificans Infection with a Combination of Voriconazole and Terbinafine. Eur J Clin Microbiol Infect Dis. 2003;22:111-3. Cerrar [Medline] [Descargar cita] |
92. Meletiadis J, Mouton JW, Meis JF, Verweij PE.. In vitro drug interaction modeling of combinations of azoles with terbinafine against clinical Scedosporium prolificans isolates. Antimicrob Agents Chemother. 2003;47:106-17. Cerrar [Medline] [Descargar cita] |
87. Bouza E, Mu�oz P.. Invasive infections caused by Blastoschizomyces capitatus and Scedosporium spp. Clin Microbiol Infect. 2004;10:76-85. Cerrar [Medline] [Descargar cita] |
93. Nucci M, Anaissie EJ, Queiroz-Telles F, Martins CA, Trabasso P, Costa S, et al.. Outcome predictors of 84 patients with hematologic malignancies and Fusarium infection. Cancer. 2003;98:315-9. Cerrar [Medline] [Descargar cita] |
94. Dignani MC, Anaissie E.. Human fusariosis. Clin Microbiol Infect. 2004; 10:67-75. Cerrar [Medline] [Descargar cita] |
95. Lionakis MS, Kontoyiannis DP.. Fusarium Infections in Critically Ill Patients. Semin Respir Crit Care Med. 2004;25:159-69. Cerrar [Medline] [Descargar cita] |
94. Dignani MC, Anaissie E.. Human fusariosis. Clin Microbiol Infect. 2004; 10:67-75. Cerrar [Medline] [Descargar cita] |
95. Lionakis MS, Kontoyiannis DP.. Fusarium Infections in Critically Ill Patients. Semin Respir Crit Care Med. 2004;25:159-69. Cerrar [Medline] [Descargar cita] |
96. Guarro J, Pujol I, Mayayo E.. In vitro and in vivo experimental activities of antifungal agents against Fusarium solani. Antimicrob Agents Chemother. 1999;43:1256-7. Cerrar [Medline] [Descargar cita] |
97. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH.. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother. 2001;45:327-30. Cerrar [Medline] [Descargar cita] |
97. Arikan S, Lozano-Chiu M, Paetznick V, Rex JH.. In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob Agents Chemother. 2001;45:327-30. Cerrar [Medline] [Descargar cita] |
98. Spelman D, Morrissey CO.. Miscellaneous and emerging fungal infections. En: UpToDate, Rose, BD (Ed), UpToDate, Wellesley, MA, 2004. Cerrar |
99. Rothe A, Seibold M, Hoppe T, Seifert H, Engert A, Caspar C, et al.. Combination therapy of disseminated Fusarium oxysporum infection with terbinafine and amphotericin B. Ann Hematol. 2004;83:394-7. Cerrar [Medline] [Descargar cita] |
100. Durand-Joly I, Alfandari S, Benchikh Z, Rodrigue M, Espinel-Ingroff A, Catteau B, et al.. Successful outcome of disseminated Fusarium infection with skin localization treated with voriconazole and amphotericin B-lipid complex in a patient with acute leukemia. J Clin Microbiol. 2003;41:4898-900. Cerrar [Medline] [Descargar cita] |
89. Perfect JR, Marr KA, Walsh TJ, Greenberg RN, DuPont B, De la Torre-Cisneros J, et al.. Voriconazole treatment for less-common, emerging, or refractory fungal infections. Clin Infect Dis. 2003;36:1122-31. Cerrar [Medline] [Descargar cita] |
101. Lionakis MS, Lewis RE, Samonis G, Kontoyiannis DP.. Pentamidine is active in vitro against Fusarium species. Antimicrob Agents Chemother. 2003; 47:3252-9. Cerrar [Medline] [Descargar cita] |
78. Groll AH, Walsh TJ.. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect. 2001;7 Suppl 2:8-24. Cerrar |
102. Saldarreaga A, Garc�a Martos P, Ruiz Arag�n J, Garc�a Agudo L, Montes de Oca M, Puerto JL, et al.. Sensibilidad a antif�ngicos de especies de Acremonium mediante los m�todos E-test y Sensititre. Rev Esp Quimioter. 2004;17:44-7. Cerrar [Medline] [Descargar cita] |
103. Mattei D, Mordini N, Lo Nigro, Gallamini A, Osenda M, Pugno F, et al.. Successful treatment of Acremonium fungemia with voriconazole. Mycoses. 2003;46:511-4. Cerrar [Medline] [Descargar cita] |
104. Schinabeck MK, Ghannoum MA.. Human hyalohyphomycoses: a review of human infections due to Acremonium spp., Paecilomyces spp., Penicillium spp., and Scopulariopsis spp. J Chemother. 2003;15 Suppl 2:5-15. Cerrar |
105. Martin CA, Roberts S, Greenberg RN.. Voriconazole treatment of disseminated Paecilomyces infection in a patient with acquired immunodeficiency syndrome. Clin Infect Dis. 2002;35:78-81. Cerrar |
106. Kantarcioglu AS, Hatemi G, Yucel A.. Paecilomyces variotii central nervous system infection in a patient with cancer. Mycoses. 2003;46:45-50. Cerrar [Medline] [Descargar cita] |
105. Martin CA, Roberts S, Greenberg RN.. Voriconazole treatment of disseminated Paecilomyces infection in a patient with acquired immunodeficiency syndrome. Clin Infect Dis. 2002;35:78-81. Cerrar |
78. Groll AH, Walsh TJ.. Uncommon opportunistic fungi: new nosocomial threats. Clin Microbiol Infect. 2001;7 Suppl 2:8-24. Cerrar |
107. Garbino J, Ondrusova A, Baglivo E, Lew D, Bouchuiguir-Wafa K, Rohner P.. Successful treatment of Paecilomyces lilacinus endophthalmitis with voriconazole. Scand J Infect Dis. 2002;34:701-3. Cerrar [Medline] [Descargar cita] |
1. Anderson D.. Waterborne Hepatitis. En: Specter S, Hodinka R, Young S, editors. Clinical Virology Manual. 3rd ed. Washington: ASM Press; 2000. p. 295-305. Cerrar |
2. Hollinger FB, Emerson SU.. Hepatitis A virus. En: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 799-840. Cerrar |
3. Martin A, Lemon SM.. Hepatitis A virus. From discovery to vaccines. Hepatology. 2006; Suppl 1:164-72. Cerrar |
4. WHO/CDS/CSR/EDC/2000.7. 7: Hepatitis A. Disponible en: http://www.who. int/emc 5. Koff R.. Hepatitis A. Lancet. 1998;341:1643-9. 6. Brown E, Stapleton J.. Hepatitis A virus. En: Murray P, Baron E, Jorgensen J, Pfaller M, Yolken R, editors. Manual of Clinical Microbiology. 8th ed. Washington: ASM Press; 2003. p. 1452-63. Cerrar |
4. WHO/CDS/CSR/EDC/2000.7. 7: Hepatitis A. Disponible en: http://www.who. int/emc Cerrar |
7. Dom�nguez A, Vidal J, Bruguera M, Salleras L.. Epidemiolog�a de las hepatitis virales. Enferm Infecc Microbiol Clin. 1995;13 Supl 1:50-61. Cerrar |
8. Bell BP, Anderson DA, Feinstone SM.. Virus de la hepatitis A. En: Mandell G, Bennett J, Dolin R, editors. Enfermedades Infecciosas. Principios y Pr�ctica. 6.� ed. Madrid: Elsevier; 2006. p. 2162-85. Cerrar |
1. Anderson D.. Waterborne Hepatitis. En: Specter S, Hodinka R, Young S, editors. Clinical Virology Manual. 3rd ed. Washington: ASM Press; 2000. p. 295-305. Cerrar |
9. Feinstone S, Gust I.. Hepatitis A virus. En: Richman DD, Whitley RJ, Hayden FG, editors. Clinical Virology. New York: Churchill Livingstone; 1997. p. 1049-72. Cerrar |
2. Hollinger FB, Emerson SU.. Hepatitis A virus. En: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 799-840. Cerrar |
5. Koff R.. Hepatitis A. Lancet. 1998;341:1643-9. Cerrar |
10. Melnick J.. History and epidemiology of hepatitis A virus. J Infect Dis. 1995;171 Suppl 1:2-8. Cerrar |
9. Feinstone S, Gust I.. Hepatitis A virus. En: Richman DD, Whitley RJ, Hayden FG, editors. Clinical Virology. New York: Churchill Livingstone; 1997. p. 1049-72. Cerrar |
4. WHO/CDS/CSR/EDC/2000.7. 7: Hepatitis A. Disponible en: http://www.who. int/emc Cerrar |
2. Hollinger FB, Emerson SU.. Hepatitis A virus. En: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 799-840. Cerrar |
1. Anderson D.. Waterborne Hepatitis. En: Specter S, Hodinka R, Young S, editors. Clinical Virology Manual. 3rd ed. Washington: ASM Press; 2000. p. 295-305. Cerrar |
11. Schlauder G, Dawson G.. Hepatitis E virus. En: Murray P, Baron E, Jorgensen J, Pfaller M, Yolken R, editors. Manual of Clinical Microbiology. 8th ed. Washington: ASM Press; 2003. p. 1495-511. Cerrar |
11. Schlauder G, Dawson G.. Hepatitis E virus. En: Murray P, Baron E, Jorgensen J, Pfaller M, Yolken R, editors. Manual of Clinical Microbiology. 8th ed. Washington: ASM Press; 2003. p. 1495-511. Cerrar |
12. Pina S, Buti M, Cotrina M, Piella J, Girones R.. HEV identified in serum from humans with acute hepatitis and in sewage of animal origen in Spain. J Hepatol. 2000;33:826-33. Cerrar [Medline] [Descargar cita] |
13. Purcell RH, Emerson SU.V. Virus de la hepatitis E. En: Mandell G, Bennett J, Dolin R, editors. Enfermedades Infecciosas. Principios y Pr�ctica. 6.� ed. Madrid: Elsevier; 2006. p. 2162-85. Cerrar |
1. Anderson D.. Waterborne Hepatitis. En: Specter S, Hodinka R, Young S, editors. Clinical Virology Manual. 3rd ed. Washington: ASM Press; 2000. p. 295-305. Cerrar |
11. Schlauder G, Dawson G.. Hepatitis E virus. En: Murray P, Baron E, Jorgensen J, Pfaller M, Yolken R, editors. Manual of Clinical Microbiology. 8th ed. Washington: ASM Press; 2003. p. 1495-511. Cerrar |
14. Harrison TJ.. Hepatitis E virus-an update. Liver. 1999;19:171-6. Cerrar [Medline] &nbs; p;[Descargar cita] |
15. Purcell RH.. Hepatitis E virus. En: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 3051-62. Cerrar |
11. Schlauder G, Dawson G.. Hepatitis E virus. En: Murray P, Baron E, Jorgensen J, Pfaller M, Yolken R, editors. Manual of Clinical Microbiology. 8th ed. Washington: ASM Press; 2003. p. 1495-511. Cerrar |
16. WHO/CDS/CSR/EDC/2001.1. 12: Hepatitis E. Disponible en: http://www.who. int/emc Cerrar |
16. WHO/CDS/CSR/EDC/2001.1. 12: Hepatitis E. Disponible en: http://www.who. int/emc Cerrar |
16. WHO/CDS/CSR/EDC/2001.1. 12: Hepatitis E. Disponible en: http://www.who. int/emc Cerrar |
14. Harrison TJ.. Hepatitis E virus-an update. Liver. 1999;19:171-6. Cerrar [Medline] [Descargar cita] |
14. Harrison TJ.. Hepatitis E virus-an update. Liver. 1999;19:171-6. Cerrar [Medline] [Descargar cita] |
11. Schlauder G, Dawson G.. Hepatitis E virus. En: Murray P, Baron E, Jorgensen J, Pfaller M, Yolken R, editors. Manual of Clinical Microbiology. 8th ed. Washington: ASM Press; 2003. p. 1495-511. Cerrar |
13. Purcell RH, Emerson SU.V. Virus de la hepatitis E. En: Mandell G, Bennett J, Dolin R, editors. Enfermedades Infecciosas. Principios y Pr�ctica. 6.� ed. Madrid: Elsevier; 2006. p. 2162-85. Cerrar |
16. WHO/CDS/CSR/EDC/2001.1. 12: Hepatitis E. Disponible en: http://www.who. int/emc Cerrar |
12. Pina S, Buti M, Cotrina M, Piella J, Girones R.. HEV identified in serum from humans with acute hepatitis and in sewage of animal origen in Spain. J Hepatol. 2000;33:826-33. Cerrar [Medline] [Descargar cita] |
13. Purcell RH, Emerson SU.V. Virus de la hepatitis E. En: Mandell G, Bennett J, Dolin R, editors. Enfermedades Infecciosas. Principios y Pr�ctica. 6.� ed. Madrid: Elsevier; 2006. p. 2162-85. Cerrar |
11. Schlauder G, Dawson G.. Hepatitis E virus. En: Murray P, Baron E, Jorgensen J, Pfaller M, Yolken R, editors. Manual of Clinical Microbiology. 8th ed. Washington: ASM Press; 2003. p. 1495-511. Cerrar |
17. Lee W.. Hepatitis B virus infection. N Engl J Med. 1997;337:1733-45. Cerrar [Medline] [Descargar cita] |
18. WHO/CDS/CSR/EDC/2002.2. 2: Hepatitis B. Disponible en: http://www.who. int/emc Cerrar |
19. Lai C, Ratziu V, Yuen M, Poynard T.. Viral hepatitis B. Lancet. 2003;362: 2089-94. Cerrar [Medline] [Descargar cita] |
20. Bendinelli M, Pistello M, Maggi F, Vatterroni M.. Bloodborne Hepatitis Viruses: Hepatitis B, C, D, and G Viruses and TT Virus. En: Specter S, Hodinka R, Young S, editors. Clinical Virology Manual. 3rd ed. Washington: ASM Press; 2000. p. 306-37. Cerrar |
21. Hollinger FB, Liang TJ.. Hepatitis B virus. En: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 2971-3036. Cerrar |
21. Hollinger FB, Liang TJ.. Hepatitis B virus. En: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 2971-3036. Cerrar |
22. Koziel MJ, Siddiqui A.. Virus de la hepatitis B y virus de la hepatitis delta. En: Mandell G, Bennett J, Dolin R, editors. Enfermedades Infecciosas. Principios y Pr�ctica 6.� ed. Madrid: Elsevier; 2006. p. 1864-90. Cerrar |
21. Hollinger FB, Liang TJ.. Hepatitis B virus. En: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 2971-3036. Cerrar |
22. Koziel MJ, Siddiqui A.. Virus de la hepatitis B y virus de la hepatitis delta. En: Mandell G, Bennett J, Dolin R, editors. Enfermedades Infecciosas. Principios y Pr�ctica 6.� ed. Madrid: Elsevier; 2006. p. 1864-90. Cerrar |
21. Hollinger FB, Liang TJ.. Hepatitis B virus. En: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 2971-3036. Cerrar |
18. WHO/CDS/CSR/EDC/2002.2. 2: Hepatitis B. Disponible en: http://www.who. int/emc Cerrar |
18. WHO/CDS/CSR/EDC/2002.2. 2: Hepatitis B. Disponible en: http://www.who. int/emc Cerrar |
23. Mahoney F.. Update on diagnosis, management, and prevention of hepatitis B virus infection. Clin Microbiol Rev. 1999;12:351-66. Cerrar [Medline] [Descargar cita] |
24. Maddrey W.. Hepatitis B: an important public health issue. J Med Virol. 2000;61:362-6. Cerrar [Medline] [Descargar cita] |
7. Dom�nguez A, Vidal J, Bruguera M, Salleras L.. Epidemiolog�a de las hepatitis virales. Enferm Infecc Microbiol Clin. 1995;13 Supl 1:50-61. Cerrar |
18. WHO/CDS/CSR/EDC/2002.2. 2: Hepatitis B. Disponible en: http://www.who. int/emc Cerrar |
24. Maddrey W.. Hepatitis B: an important public health issue. J Med Virol. 2000;61:362-6. Cerrar [Medline] [Descargar cita] |
25. Alter M.. Epidemiology and prevention of hepatitis B. Semin Liver Dis. 2003;23:39-46. Cerrar [Medline] [Descargar cita] |
18. WHO/CDS/CSR/EDC/2002.2. 2: Hepatitis B. Disponible en: http://www.who. int/emc Cerrar |
26. WHO/CDS/CSR/LYO/2003.2. 2: Hepatitis C. Disponible en: http://www.who. int/emc Cerrar |
27. Alter M.. Epidemiology of hepatitis C. Hepatology. 1997;26 Suppl 1:62-5. Cerrar |
28. Simmonds P.. Viral heterogeneity of the hepatitis C virus. J Hepatol. 1999; 31:54-60. Cerrar [Medline] [Descargar cita] |
26. WHO/CDS/CSR/LYO/2003.2. 2: Hepatitis C. Disponible en: http://www.who. int/emc Cerrar |
27. Alter M.. Epidemiology of hepatitis C. Hepatology. 1997;26 Suppl 1:62-5. Cerrar |
29. Thomas D, Ray S, Lemon S.. Hepatitis C. En: Mandell G, Bennett J, Dolin R, editors. Enfermedades Infecciosas. Principios y Pr�ctica. 6.� ed. Madrid: Elsevier; 2006. p. 1950-81. Cerrar |
30. Booth JC, O'Grady J, Neuberger J, The Royal College of Physicians of London and the British Society of Gastroenterology.. Clinical guidelines on the management of hepatitis C. Gut. 2001;49 Suppl I:1-21. Cerrar |
26. WHO/CDS/CSR/LYO/2003.2. 2: Hepatitis C. Disponible en: http://www.who. int/emc Cerrar |
29. Thomas D, Ray S, Lemon S.. Hepatitis C. En: Mandell G, Bennett J, Dolin R, editors. Enfermedades Infecciosas. Principios y Pr�ctica. 6.� ed. Madrid: Elsevier; 2006. p. 1950-81. Cerrar |
30. Booth JC, O'Grady J, Neuberger J, The Royal College of Physicians of London and the British Society of Gastroenterology.. Clinical guidelines on the management of hepatitis C. Gut. 2001;49 Suppl I:1-21. Cerrar |
31. Di Bisceglie A.. Hepatitis C. Lancet. 1998;351:351-5. Cerrar [Medline] [Descargar cita] |
26. WHO/CDS/CSR/LYO/2003.2. 2: Hepatitis C. Disponible en: http://www.who. int/emc Cerrar |
29. Thomas D, Ray S, Lemon S.. Hepatitis C. En: Mandell G, Bennett J, Dolin R, editors. Enfermedades Infecciosas. Principios y Pr�ctica. 6.� ed. Madrid: Elsevier; 2006. p. 1950-81. Cerrar |
26. WHO/CDS/CSR/LYO/2003.2. 2: Hepatitis C. Disponible en: http://www.who. int/emc Cerrar |
32. Alter M.. Prevention of spread of hepatitis C. Hepatology. 2002;36 Suppl 1:93-8. Cerrar |
26. WHO/CDS/CSR/LYO/2003.2. 2: Hepatitis C. Disponible en: http://www.who. int/emc Cerrar |
26. WHO/CDS/CSR/LYO/2003.2. 2: Hepatitis C. Disponible en: http://www.who. int/emc Cerrar |
29. Thomas D, Ray S, Lemon S.. Hepatitis C. En: Mandell G, Bennett J, Dolin R, editors. Enfermedades Infecciosas. Principios y Pr�ctica. 6.� ed. Madrid: Elsevier; 2006. p. 1950-81. Cerrar |
33. Rall C, Dienstag J.. Epidemiology of hepatitis C virus infection. Semin Gastrointest Dis. 1995;6:3-12. Cerrar [Medline] [Descargar cita] |
32. Alter M.. Prevention of spread of hepatitis C. Hepatology. 2002;36 Suppl 1:93-8. Cerrar |
33. Rall C, Dienstag J.. Epidemiology of hepatitis C virus infection. Semin Gastrointest Dis. 1995;6:3-12. Cerrar [Medline] [Descargar cita] |
26. WHO/CDS/CSR/LYO/2003.2. 2: Hepatitis C. Disponible en: http://www.who. int/emc Cerrar |
34. Lauer G, Waker B.. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52. Cerrar [Medline] [Descargar cita] |
35. WHO/CDS/CSR/EDC/2001.1. 1: Hepatitis D. Disponible en: http://www.who. int/emc Cerrar |
36. Gerin JL, Casey JL, Purcell RH.. Hepatitis Delta virus. En: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 3037-50. Cerrar |
36. Gerin JL, Casey JL, Purcell RH.. Hepatitis Delta virus. En: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 3037-50. Cerrar |
37. Smedile A, Niro G, Rizzetto M.. Hepatitis D virus. En: Richman DD, Whitley RJ, Hayden FG, editors. Clinical Virology. New York: Churchill Livingstone; 1997. p. 1273-84. Cerrar |
37. Smedile A, Niro G, Rizzetto M.. Hepatitis D virus. En: Richman DD, Whitley RJ, Hayden FG, editors. Clinical Virology. New York: Churchill Livingstone; 1997. p. 1273-84. Cerrar |
37. Smedile A, Niro G, Rizzetto M.. Hepatitis D virus. En: Richman DD, Whitley RJ, Hayden FG, editors. Clinical Virology. New York: Churchill Livingstone; 1997. p. 1273-84. Cerrar |
35. WHO/CDS/CSR/EDC/2001.1. 1: Hepatitis D. Disponible en: http://www.who. int/emc Cerrar |
35. WHO/CDS/CSR/EDC/2001.1. 1: Hepatitis D. Disponible en: http://www.who. int/emc Cerrar |
38. Hadziyannis S.. Hepatitis delta: an overview. En: Rizzetto M, Percell RH, Gerin JL, Verme G, editors. Viral hepatitis and liver disease. Turin: Edizioni Minerva Medica; 1997. p. 283-9. Cerrar |
39. Hadziyannis S.. Review: Hepatitis delta. J Gastroenterol Hepatol. 1997;12: 289-98. Cerrar [Medline] [Descargar cita] |
35. WHO/CDS/CSR/EDC/2001.1. 1: Hepatitis D. Disponible en: http://www.who. int/emc Cerrar |
36. Gerin JL, Casey JL, Purcell RH.. Hepatitis Delta virus. En: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 3037-50. Cerrar |
38. Hadziyannis S.. Hepatitis delta: an overview. En: Rizzetto M, Percell RH, Gerin JL, Verme G, editors. Viral hepatitis and liver disease. Turin: Edizioni Minerva Medica; 1997. p. 283-9. Cerrar |
39. Hadziyannis S.. Review: Hepatitis delta. J Gastroenterol Hepatol. 1997;12: 289-98. Cerrar [Medline] [Descargar cita] |
36. Gerin JL, Casey JL, Purcell RH.. Hepatitis Delta virus. En: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 3037-50. Cerrar |
7. Dom�nguez A, Vidal J, Bruguera M, Salleras L.. Epidemiolog�a de las hepatitis virales. Enferm Infecc Microbiol Clin. 1995;13 Supl 1:50-61. Cerrar |
40. Smedile A, Rizzetto M, Gerin JL.. Advances in hepatitis D virus biology and disease. Prog Liver Dis. 1994;12:157-75. Cerrar [Medline] [Descargar cita] |
7. Dom�nguez A, Vidal J, Bruguera M, Salleras L.. Epidemiolog�a de las hepatitis virales. Enferm Infecc Microbiol Clin. 1995;13 Supl 1:50-61. Cerrar |
41. Walsh K, Alexander G.. Update on chronic viral hepatitis. Postgrad Med J. 2001;77:498-505. Cerrar [Medline] [Descargar cita] |
3. Martin A, Lemon SM.. Hepatitis A virus. From discovery to vaccines. Hepatology. 2006; Suppl 1:164-72. Cerrar |
5. Koff R.. Hepatitis A. Lancet. 1998;341:1643-9. Cerrar |
42. Koff R.. Viral hepatitis. En: Schiff L, Schiff E, editors. Diseases of the liver. 7th ed. Philadelphia: JB Lippincott; 1993. p. 492-577. Cerrar |
8. Bell BP, Anderson DA, Feinstone SM.. Virus de la hepatitis A. En: Mandell G, Bennett J, Dolin R, editors. Enfermedades Infecciosas. Principios y Pr�ctica. 6.� ed. Madrid: Elsevier; 2006. p. 2162-85. Cerrar |
9. Feinstone S, Gust I.. Hepatitis A virus. En: Richman DD, Whitley RJ, Hayden FG, editors. Clinical Virology. New York: Churchill Livingstone; 1997. p. 1049-72. Cerrar |
43. Yao G.. Clinical spectrum and natural history of viral hepatitis A in a 1988 Shanghai epidemic. En: Hollinger FB, Lemon SM, Margolis HS, editors. Viral hepatitis and liver disease. Baltimore: Williams & Wilkins; 1991. p. 76-8. Cerrar |
13. Purcell RH, Emerson SU.V. Virus de la hepatitis E. En: Mandell G, Bennett J, Dolin R, editors. Enfermedades Infecciosas. Principios y Pr�ctica. 6.� ed. Madrid: Elsevier; 2006. p. 2162-85. Cerrar |
14. Harrison TJ.. Hepatitis E virus-an update. Liver. 1999;19:171-6. Cerrar [Medline] [Descargar cita] |
15. Purcell RH.. Hepatitis E virus. En: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 3051-62. Cerrar |
13. Purcell RH, Emerson SU.V. Virus de la hepatitis E. En: Mandell G, Bennett J, Dolin R, editors. Enfermedades Infecciosas. Principios y Pr�ctica. 6.� ed. Madrid: Elsevier; 2006. p. 2162-85. Cerrar |
14. Harrison TJ.. Hepatitis E virus-an update. Liver. 1999;19:171-6. Cerrar [Medline] [Descargar cita] |
36. Gerin JL, Casey JL, Purcell RH.. Hepatitis Delta virus. En: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 3037-50. Cerrar |
18. WHO/CDS/CSR/EDC/2002.2. 2: Hepatitis B. Disponible en: http://www.who. int/emc Cerrar |
41. Walsh K, Alexander G.. Update on chronic viral hepatitis. Postgrad Med J. 2001;77:498-505. Cerrar [Medline] [Descargar cita] |
19. Lai C, Ratziu V, Yuen M, Poynard T.. Viral hepatitis B. Lancet. 2003;362: 2089-94. Cerrar [Medline] [Descargar cita] |
22. Koziel MJ, Siddiqui A.. Virus de la hepatitis B y virus de la hepatitis delta. En: Mandell G, Bennett J, Dolin R, editors. Enfermedades Infecciosas. Principios y Pr�ctica 6.� ed. Madrid: Elsevier; 2006. p. 1864-90. Cerrar |
21. Hollinger FB, Liang TJ.. Hepatitis B virus. En: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 2971-3036. Cerrar |
44. Hilleman MR.. Critical overview and outlook: pathogenesis, prevention, and treatment of hepatitis and hepatocarcinoma caused by hepatitis B virus. Vaccine. 2003;21:4626-49. Cerrar [Medline] [Descargar cita] |
45. Bonilla Guerrero R, Roberts LR.. The role of hepatitis B virus in the pathogenesis of human hepatocellular carcinoma. J Hepatol. 2005;42:760-77. Cerrar [Medline] [Descargar cita] |
21. Hollinger FB, Liang TJ.. Hepatitis B virus. En: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 2971-3036. Cerrar |
22. Koziel MJ, Siddiqui A.. Virus de la hepatitis B y virus de la hepatitis delta. En: Mandell G, Bennett J, Dolin R, editors. Enfermedades Infecciosas. Principios y Pr�ctica 6.� ed. Madrid: Elsevier; 2006. p. 1864-90. Cerrar |
24. Maddrey W.. Hepatitis B: an important public health issue. J Med Virol. 2000;61:362-6. Cerrar [Medline] [Descargar cita] |
29. Thomas D, Ray S, Lemon S.. Hepatitis C. En: Mandell G, Bennett J, Dolin R, editors. Enfermedades Infecciosas. Principios y Pr�ctica. 6.� ed. Madrid: Elsevier; 2006. p. 1950-81. Cerrar |
46. Racanelli V, Reherman B.. Hepatitis C virus: infection when silence is deception. Trends Immunol. 2003;24:456-64. Cerrar [Medline] [Descargar cita] |
47. Major ME, Reherman B, Feinstone SM.. Hepatitis C viruses. En: Knipe DM, Howley PM, editors. Fields Virology. 4th ed. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 1127-63. Cerrar |
30. Booth JC, O'Grady J, Neuberger J, The Royal College of Physicians of London and the British Society of Gastroenterology.. Clinical guidelines on the management of hepatitis C. Gut. 2001;49 Suppl I:1-21. Cerrar |
31. Di Bisceglie A.. Hepatitis C. Lancet. 1998;351:351-5. Cerrar [Medline] [Descargar cita] |
41. Walsh K, Alexander G.. Update on chronic viral hepatitis. Postgrad Med J. 2001;77:498-505. Cerrar [Medline] [Descargar cita] |
48. Pawlotsky JM.. Pathophysiology of hepatitis C virus infection and related liver disease. Trends Microbiol. 2004;12:96-102. Cerrar [Medline] [Descargar cita] |
49. Sansonno D, Dammacco F.. Hepatitis C virus, cryoglobulinaemia, and vasculitis: immune complex relations. Lancet Infect Dis. 2005;5:227-36. Cerrar [Medline] [Descargar cita] |
34. Lauer G, Waker B.. Hepatitis C virus infection. N Engl J Med. 2001;345:41-52. Cerrar [Medline] [Descargar cita] |
37. Smedile A, Niro G, Rizzetto M.. Hepatitis D virus. En: Richman DD, Whitley RJ, Hayden FG, editors. Clinical Virology. New York: Churchill Livingstone; 1997. p. 1273-84. Cerrar |
38. Hadziyannis S.. Hepatitis delta: an overview. En: Rizzetto M, Percell RH, Gerin JL, Verme G, editors. Viral hepatitis and liver disease. Turin: Edizioni Minerva Medica; 1997. p. 283-9. Cerrar |
41. Walsh K, Alexander G.. Update on chronic viral hepatitis. Postgrad Med J. 2001;77:498-505. Cerrar [Medline] [Descargar cita] |
1. Young NS, Brown KE.. Parvovirus B19. N Engl J Med. 2004;350:586-97. Cerrar [Medline] [Descargar cita] |
1. Young NS, Brown KE.. Parvovirus B19. N Engl J Med. 2004;350:586-97. Cerrar [Medline] [Descargar cita] |
2. Woolf AD, Campion GV, Chishick A, Wise S, Cohen BJ, Klouda PT, et al.. Clinical manifestations of human parvovirus B19 in adults. Arch Intern Med. 1989;149:1153-6. Cerrar [Medline] [Descargar cita] |
3. Garc�a-Tapia AM, Fern�ndez-Guti�rrez del �lamo C, Gir�n JA, Mira J, De la Rubia F, Mart�nez-Rodr�guez A, et al.. Spectrum of parvovirus B19 infection: an�lisis of an outbreak of 43 cases in C�diz, Spain. Clin Infect Dis. 1995;21:1424-30. Cerrar [Medline] [Descargar cita] |
4. Seishima M, Kanoh H, Izumi T.. The spectrum of cutaneous eruptions in 22 patients with isolated serological evidence of infection by parvovirus B19. Arch Dermatol. 1999;135:1556-7. Cerrar [Medline] [Descargar cita] |
5. Yamada Y, Iwasa A, Kuroki M, Yoshida M, Itoh M.. Human parvovirus B19 infection showing follicular purpuric papules with a baboon s�ndrome-like distribution. Br J Dermatol. 2004;150:788. Cerrar [Medline] [Descargar cita] |
6. Allegue F, Morano-Amado L, Rodr�guez A, Fachal C.. Fiebre, estomatitis y erupci�n cut�nea en manos y pies. S�ndrome popular purp�rico en guantes y calcet�n. Enf Inf Microbiol Clin. 1996;14:271-27. Cerrar |
7. Garc�a-Bermejo, Auffray P, Jim�nez-Reyes J, Cacho J, Garc�a-Barrionuevo A.. S�ndrome purp�rico en guantes y calcet�n causado por parvovirus humano B19. Enf Inf Microbiol Clin. 1996;14:398-9. Cerrar |
8. Higashi N, Fukai K, Tsuruta D, Nagao J, Ohira H, Ishii M, et al.. Papular-purpuric gloves and socks syndrome with bloody bullae. J Dermatol. 2002; 29:371. Cerrar [Medline] [Descargar cita] |
9. Smith PT, Landry ML, Carey H, Krasnoff J, Cooney E.. Papular-purpuric gloves and socks syndrome associated with acute parvovirus B19 infection: case report and review. Clin Infect Dis. 1998;27:164-8. Cerrar [Medline] [Descargar cita] |
10. Smith SB, Libow LF, Lest�n DM, Bernert RA, Warschaw KE.. Gloves and socks syndrome: early and late histopathologic features. J Am Acad Dermatol. 2002;47:749-54. Cerrar [Medline] [Descargar cita] |
4. Seishima M, Kanoh H, Izumi T.. The spectrum of cutaneous eruptions in 22 patients with isolated serological evidence of infection by parvovirus B19. Arch Dermatol. 1999;135:1556-7. Cerrar [Medline] [Descargar cita] |
11. Aractingi S, Bakhos D, Flageul B, Verola O, Brunet M, Dubertret L, et al.. Immunohistochemical and virological study of skin in the papular-purpuric gloves and socks syndrome. Br J Dermatol. 1996;135:599-602. Cerrar [Medline] [Descargar cita] |
12. Trattner A, David M.. Purpuric gloves and socks syndrome: histologic, immunofluorescence and polymerase chain reaction study. J Am Acad Dermatol. 1994;30:267-8. Cerrar [Medline] [Descargar cita] |
13. Le�n-Ruiz L, Guti�rrez-Cabello F, Garc�a Mellado V, Jim�nez-Alonso J.. S�ndrome popular purp�rico en guantes y calcet�n secundario a infecci�n por parvovirus B19. Rev Clin Esp. 2001;4:225-6. Cerrar |
11. Aractingi S, Bakhos D, Flageul B, Verola O, Brunet M, Dubertret L, et al.. Immunohistochemical and virological study of skin in the papular-purpuric gloves and socks syndrome. Br J Dermatol. 1996;135:599-602. Cerrar [Medline] [Descargar cita] |
14. Grilli R, Izquierdo MJ, Farina MC, Kutzner H, Gadea I, Martin L, et al.. Papular-purpuric gloves and socks syndrome: polymerase chain reaction demonstration of parvovirus B19 DNA in cutaneous lesions and sera. J Am Acad Dermatol. 1999;41:793. Cerrar [Medline] [Descargar cita] |
15. Ruzicka T, Kalka K, Diercks K, Schuppe HC.. Papular-purpuric gloves and socks syndrome associated with human herpesvirus 6 infection. Arch Dermatol. 1998;134:242-4. Cerrar [Medline] [Descargar cita] |
16. Harms M, Feldmann R, Saurat JH.. Papular-purpuric gloves and socks syndrome. J Am Acad Dermatol. 1990;23:850-4. Cerrar [Medline] [Descargar cita] |
17. Feldmann R, Harms M, Saurat J.. Papular-purpuric gloves and socks syndrome. Not only parvovirus B19. Dermatology. 1994;188:85-7. Cerrar [Medline] [Descargar cita] |
1. Schuster FL.. Cultivation of pathogenic and opportunistic free-living amebas. Clin Microbiol Rev. 2002;15:342-54. Cerrar [Medline] [Descargar cita] |
2. Walochnik J, Obwaller A, Asp�ck H.. Correlation between morphological, molecular biological, and physiological characteristics in clinical and nonclinical isolates of Acanthamoeba spp. J Clin Microbiol. 2000;66:4408-13. Cerrar |
3. Cruz M, Ortiz JV, Ladr�n de Guevara C.. Estudio cl�nico-microbiol�gico de tres casos de queratitis por Acanthamoeba spp. Enf Emerg 2004;6:98-102. Cerrar |
4. Illingworth CD, CooK SD.. Acanthamoeba keratitis. Surv Ophthalmol. 1998; 42:493-508. Cerrar [Medline] [Descargar cita] |
5. Fulcher T, Dart J.. Queratitis por Acanthamoeba. En: Dur�n de la Colina JA, editor. Complicaciones de las lentes de contacto. 1.� ed. Madrid: Tecnimedia Editorial; 1998. p. 263-78. Cerrar |
4. Illingworth CD, CooK SD.. Acanthamoeba keratitis. Surv Ophthalmol. 1998; 42:493-508. Cerrar [Medline] [Descargar cita] |
5. Fulcher T, Dart J.. Queratitis por Acanthamoeba. En: Dur�n de la Colina JA, editor. Complicaciones de las lentes de contacto. 1.� ed. Madrid: Tecnimedia Editorial; 1998. p. 263-78. Cerrar |
3. Cruz M, Ortiz JV, Ladr�n de Guevara C.. Estudio cl�nico-microbiol�gico de tres casos de queratitis por Acanthamoeba spp. Enf Emerg 2004;6:98-102. Cerrar |
6. Garc�a LS.. Diagnostic Medical Parasitology. 4.� ed. Washington: ASM; 2001. Cerrar |
3. Cruz M, Ortiz JV, Ladr�n de Guevara C.. Estudio cl�nico-microbiol�gico de tres casos de queratitis por Acanthamoeba spp. Enf Emerg 2004;6:98-102. Cerrar |
6. Garc�a LS.. Diagnostic Medical Parasitology. 4.� ed. Washington: ASM; 2001. Cerrar |
3. Cruz M, Ortiz JV, Ladr�n de Guevara C.. Estudio cl�nico-microbiol�gico de tres casos de queratitis por Acanthamoeba spp. Enf Emerg 2004;6:98-102. Cerrar |
6. Garc�a LS.. Diagnostic Medical Parasitology. 4.� ed. Washington: ASM; 2001. Cerrar |
3. Cruz M, Ortiz JV, Ladr�n de Guevara C.. Estudio cl�nico-microbiol�gico de tres casos de queratitis por Acanthamoeba spp. Enf Emerg 2004;6:98-102. Cerrar |
1. Schuster FL.. Cultivation of pathogenic and opportunistic free-living amebas. Clin Microbiol Rev. 2002;15:342-54. Cerrar [Medline] [Descargar cita] |
6. Garc�a LS.. Diagnostic Medical Parasitology. 4.� ed. Washington: ASM; 2001. Cerrar |
1. Schuster FL.. Cultivation of pathogenic and opportunistic free-living amebas. Clin Microbiol Rev. 2002;15:342-54. Cerrar [Medline] [Descargar cita] |
7. Pasricha G, Sharma G, Garg P, Aggarwal RK.. Use of 18S rRNA gene-based PCR assay for diagnosis of Acanthamoeba keratitis in non-contact lens wearers in India. J Clin Microbiol. 2003;41:3206-211. Cerrar [Medline] [Descargar cita] |
2. Walochnik J, Obwaller A, Asp�ck H.. Correlation between morphological, molecular biological, and physiological characteristics in clinical and nonclinical isolates of Acanthamoeba spp. J Clin Microbiol. 2000;66:4408-13. Cerrar |
8. Claerhout I, Goegebuer A, Van Den Broecke C, Kestelyn P.. Delay in diagnosis and outcome of acathamoeba keratitis. Graefes Arch Clin Exp Ophthalmol. 2004;242:648-53. Cerrar [Medline] [Descargar cita] |
9. Cardine S, Bourcier T, Chaumeil C, Zamfir O, Borderie V, Laroche L.. Clinical management and prognosis in Acanthamoeba keratitis: a retrospective study of 25 cases. J Fr Ophtalmol. 2002;25:1007-13. Cerrar [Medline] [Descargar cita] |
10. Schuster FL, Visvesvara GS.. Opportunistic amoebae: challenges in prophylaxis and treatment. Drug Resist Updat. 2004;7:41-51. Cerrar [Medline] [Descargar cita] |
4. Illingworth CD, CooK SD.. Acanthamoeba keratitis. Surv Ophthalmol. 1998; 42:493-508. Cerrar [Medline] [Descargar cita] |
5. Fulcher T, Dart J.. Queratitis por Acanthamoeba. En: Dur�n de la Colina JA, editor. Complicaciones de las lentes de contacto. 1.� ed. Madrid: Tecnimedia Editorial; 1998. p. 263-78. Cerrar |
1. Stevens DL.. Invasive Group A Streptococcus infections. Clin Infect Dis. 1992;14:2-11. Cerrar [Medline] [Descargar cita] |
2. L�pez-Bernaldo JC.. Estreptococo del grupo A: las nuevas caras de un viejo conocido. Enferm Infecc Microbiol Clin. 1995;13:273-7. Cerrar [Medline] [Descargar cita] |
3. The Working Group on Severe Streptococcal Infections.. Defining the group A streptococcal toxic shock syndrome. Rationale and consensus definition. JAMA. 1993;269:390-1. Cerrar [Medline] [Descargar cita] |
1. Stevens DL.. Invasive Group A Streptococcus infections. Clin Infect Dis. 1992;14:2-11. Cerrar [Medline] [Descargar cita] |
4. Stevens DL.. Streptococcal toxic-syndrome: spectrome of disease, pathogenesis, and new concepts in the treatment. Emerg Infect Dis. 1995;1:69-78. Cerrar [Medline] [Descargar cita] |
5. Bisno AL, Stevens DL.. Streptococcus pyogenes (Including Streptococcal Toxic Shock Syndrome and Necrotizing Fasciitis). En: Mandell GL, Bennett JE, Dolin R, editors. Principles and Practice of Infectious Diseases. 5th ed. New York: Churchill Livingstone; 2000. p. 2101-17. Cerrar |
6. Stevens DL, Tanner NH, Winship J, Swart s R, Ries KM, Schlievert PM, et al.. Severe group A streptococcal infections associated with a toxic shock-like syndrome and scarlet fever toxin A. N Engl J Med. 1989;321:1-7. Cerrar [Medline] [Descargar cita] |
7. Darenberg J, Ihendyane N, Sjolin J, Aufwerber E, Haidl S, Follin P, et al.. Intravenous immunoglobulin G therapy in streptococcal toxic shock syndrome: a European randomized, double-blind, placebo-controlled trial. Clin Infect Dis. 2003;37:341-3. Cerrar [Medline] [Descargar cita] |
1. Llor C, Cots JM, Boada A, Bjerrum, Gahrn-Hansen B, Munck A, For�s D, Miravitlles M y grupo de estudio AUDITINF02.. Variabilidad de la prescripci�n antibi�tica en las infecciones respiratorias de dos pa�ses de Europa. Enferm Infecc Microbiol Clin. 2005;23:598-604. Cerrar [Medline] [Descargar cita] [Art�culo] |
2. Cars O, M�lstad S, Melander A.. Variation in antibiotic use in the European Union. Lancet. 2001;357:1851-3. Cerrar [Medline] [Descargar cita] |
3. L�zaro E, Madurga M, De Abajo FJ.. Evoluci�n del consumo de antibi�ticos en Espa�a, 1985-2000. Med Clin (Barc). 2002;118:561-8. Cerrar [Medline] [Descargar cita] [Art�culo] |
4. Branthwaite AR, Pech�re JC.. Pan-European Survey of Patients. Attitudes to antibiotics and use. J Int Med Res. 1996;24:229-38. Cerrar [Medline] [Descargar cita] |
5. Picazo JJ, P�rez-Cecilia E, Herreras A y Grupo DIRA en Atenci�n Primaria.. Estudio de las infecciones respiratorias extrahospitalarias. Estudio DIRA. Enferm Infecc Microbiol Clin. 2003;21:410-6. Cerrar [Medline] [Descargar cita] [Art�culo] |
6. Ripoll MA, Orero A, Prieto J en representaci�n del Grupo URANO.. Etiolog�a y tratamiento de elecci�n de las infecciones respiratorias en atenci�n primaria. Opini�n de los m�dicos. Aten Primaria. 1999;23:296-300. Cerrar [Medline] [Descargar cita] [Art�culo] |
7. Ripoll MA, Orero A, Prieto J.. Resistencias bacterianas. Opini�n de los m�dicos de Atenci�n Primaria espa�oles. Medicina General. 2000;25:539-45. Cerrar |
8. Llor C, Hern�ndez S, Calvi�o O, Moragas A.. Prescripci�n diferida de antibi�ticos en Espa�a. Med Clin (Barc). 2005;125:75-9. Cerrar [Medline] [Descargar cita] [Art�culo] |
9. SEIP, SEIMC-IAP, SEMERGEN, SEMG, SEPEAP, SEQ.. Gu�a para el control de la infecci�n en Atenci�n Primaria 2001-2002. Madrid: GSK; 2001. Cerrar |
10. SEQ, SEOPC, SEIP, SEMG, SEMERGEN, SEMUE.. Documento de consenso sobre tratamiento antimicrobiano de la faringoamigdalitis. Rev Esp Quimioterap. 2003;16(11): 74-88. Cerrar |
1. World Health Organization.. World Health Organization website. Report on Infectious Diseases 2000. Overcoming antimicrobial resistance, Chapter 4. Big guns of resistance. Disponible en: http://www.who.int/infectious-disease-report/2000 [�ltimo acceso: 2 de abril de 2006]. Cerrar |
2. Arroll B.. Antibiotics for upper respiratory tract infections: an overview of Cochrane reviews. Respir Med. 2005;99:255-61. Cerrar [Medline] [Descargar cita] |
3. Smucny J, Fahey T, Becker L, Glazier R.. Antibiotics for acute bronchitis. Cochrane Database Syst Rev. 2004;4:CD000245. Cerrar [Medline] [Descargar cita] |
4. Hopstaken RM, Coenen S, Butler CC.. Treating patients not diagnoses: challenging assumptions underlying the investigation and management of LRTI in general practice. J Antimicrob Chemother. 2005;56:941-3. Cerrar [Medline] [Descargar cita] |
5. Goossens H, Ferech M, Vander Stichele R, Elseviers M, ESAC Project Group.. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365:579-87. Cerrar [Medline] [Descargar cita] |
5. Goossens H, Ferech M, Vander Stichele R, Elseviers M, ESAC Project Group.. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365:579-87. Cerrar [Medline] [Descargar cita] |
5. Goossens H, Ferech M, Vander Stichele R, Elseviers M, ESAC Project Group.. Outpatient antibiotic use in Europe and association with resistance: a cross-national database study. Lancet. 2005;365:579-87. Cerrar [Medline] [Descargar cita] |
6. Akkerman AE, Kuyvenhoven MM, Van der Wouden JC, Verheij TJ.. Determinants of antibiotic overprescribing in respiratory tract infections in general practice. J Antimicrob Chemother. 2005;56:930-6. Cerrar [Medline] [Descargar cita] |
7. SEQ, SEOPC, SEIP, SEMG, SEMERGEN, SEMUE.. Documento de consenso sobre tratamiento antimicrobiano de la faringoamigdalitis. Rev Esp Quimioterap. 2003;16:74-88. Cerrar |
8. McIsaac WJ, Kellner JD, Aufricht P, Vanjaka A, Low DE.. Empirical validation of guidelines for the management of pharyngitis in children and adults. JAMA. 2004;291:1587-95. Cerrar [Medline] [Descargar cita] |
9. Bisno AL, Peters GS, Kaplan EL.. Diagnosis of strep throat in adults: are clinical criteria really good enough? Clin Infect Dis. 2002;35: 126-9. Cerrar |
10. Van Duijn NP, Brouwer HJ, Lamberts H.. Use of symptoms and signs to diagnose maxillary sinusitis in general practice: comparison with ultrasonography. BMJ. 1992;305:684-7. Cerrar [Medline] [Descargar cita] |
11. Van Buchem FL, Peeters MF, Van't Hof MA.. Acute otitis media: a new treatment strategy. BMJ. 1985;290:1033-7. Cerrar [Medline] [Descargar cita] |
12. Metlay JP, Kapoor WN, Fine MJ.. Does this patient have community acquired pneumonia? Diagnosing pneumonia by history and physical examination. JAMA. 1997;278:1440-5. Cerrar [Medline] [Descargar cita] |
13. Andr� M, Eriksson M, M�lstad A, St�lsbylundborg C, Jacobsson A, Odenholt I; the Swedish Group on Antibiotic Use.. The management of infections in children in general practice in Sweden. A repeated 1-week diagnosis-prescribing study in 5 counties in 2000 and 2002. Scand J Infect Dis. 2005;37:863-9. Cerrar [Medline] [Descargar cita] |
14. Arnold S, Straus S, Arnold S.. Interventions to improve antibiotic prescribing practices in ambulatory care. Cochrane Database Syst Rev. 2005;4:CD003539. Cerrar [Medline] [Descargar cita] |
1. CDC.. Pneumocystis pneumonia. Los Angeles. MMWR Morb Mortal Wkly Rep. 1981;30: 250-2. Cerrar [Medline] [Descargar cita] |
2. Gottlieb MS, Schroff R, Schanker HM.. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men. N Engl J Med. 1981;305:1425-31. Cerrar [Medline] [Descargar cita] |
3. Katz HH.. Infecci�n por VIH. En: Lawrence M, Termy S, Stephent MP, Papadakis MA, editores. Diagn�stico cl�nico y tratamiento. Colombia: Manual Moderno; 2000. p. 1213-63. Cerrar |
4. Chamberland ME, Wold JW, Curran JW.. Epidemiolog�a y prevenci�n del sida y la infecci�n por VIH. En: Mandelll GL, Bennett JE, Dolin R, editores. Enfermedad Infecciosa. Principios y Pr�cticas. 4a ed. New York: Panamericana; 1997. p. 1308. Cerrar |
5. Steinbrook R.. The AIDS Epidemic in 2004. N Engl J Med. 2004;352:115-7. Cerrar |
6. Plano Estrat�gico do Programa Nacional de luta contra o SIDA (PNLS) 1999-2002.. Rep�blica de Angola. Minist�rio da Sa�de. Direcci�n Nacional de Sa�de P�blica. 1999. Cerrar |
7. Situaci�n de la epidemia de sida: 2004.. ONUSIDA/OMS-2004. Programa Conjunto de las Naciones Unidas sobre el VIH/sida (ONUSIDA) Organizaci�n Mundial de la Salud (OMS). Disponible en: http://www.unaids.org/wad 200y/Eplupdate 2004_html_sp/epi04_00_sp. htm Cerrar |
8. Centers For Disease Control: 1993 revised clasification system for HIV infection and expanded surveillence case definition for AIDs among adolescents and adults.. MMWR. 1992;41:1-108. Cerrar |
9. WHO.. Interim proposal for a WHO staging system for HIV infection and disease. Wkly Epidem Rec. 1990;65:221-8. Cerrar |
10. Chien-Ching H, Mao-Yuan C, Chin-Fu H, et al.. Improved Outcomes of HIV-1-Infected Adults With Tuberculosis in the Era of Highly Active Antiretroviral Therapy. AIDS. 2003;17:2615-22. Cerrar [Medline] [Descargar cita] |
1. Gil-Salu JL.. Cerebral cryptococcosis in theoretically immunocompetent patients. Rev Neurol. 2005;40:318-9. Cerrar [Medline] [Descargar cita] |
2. True DG, Penmetcha M, Peckham SJ.. Disseminated cryptococcal infection in rheumatoid arthritis treated with methotrexate and infliximab. J Rheumatol. 2002;29:1561-3. Cerrar [Medline] [Descargar cita] |
3. Hage CA, Wood KL, Winer-Muram HT, Wilson SJ, Sarosi G, Knox KS.. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest. 2003;124:2395-7. [Medline] [Descargar cita] 4. Arend SM, Kuijper EJ, Allaart CF, Muller WH, Van Dissel JT.. Cavitating pneumonia after treatment with infliximab and prednisone. Eur J Clin Microbiol Infect Dis. 2004;23:638-41. [Medline] [Descargar cita] 5. Shrestha RK, Stoller JK, Honari G, Procop GW, Gordon SM.. Pneumonia due to Cryptococcus neoformans in a patient receiving infliximab: possible zoonotic transmission from a pet cockatiel. Respir Care. 2004;49:606-8. [Medline] [Descargar cita] Cerrar |
6. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO.. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis. 2004;38:1261-5. Cerrar [Medline] [Descargar cita] |
1. Nistal de Paz, Nistal de Paz C.. Fiebre Q. Med Clin (Barc). 1994;103:667-75. Cerrar [Medline] [Descargar cita] |
2. De Alarc�n A, Villanueva JL, Viciana P, L�pez-Cort�s L, Torronteras R, Bernabeu M, et al.. Q fever: epidemiology, clinical features and prognosis. A study from 1983 to 1999 in the South of Spain. J Infection. 2003;47:110-6. Cerrar |
1. Nistal de Paz, Nistal de Paz C.. Fiebre Q. Med Clin (Barc). 1994;103:667-75. Cerrar [Medline] [Descargar cita] |
1. Nistal de Paz, Nistal de Paz C.. Fiebre Q. Med Clin (Barc). 1994;103:667-75. [Medline] [Descargar cita] 2. De Alarc�n A, Villanueva JL, Viciana P, L�pez-Cort�s L, Torronteras R, Bernabeu M, et al.. Q fever: epidemiology, clinical features and prognosis. A study from 1983 to 1999 in the South of Spain. J Infection. 2003;47:110-6. 3. Lepe JA, Guerrero FJ, Ruiz-Calder�n A, Del Castillo E, G�mez-Salvago S, Jim�nez-Alonso M, et al.. Epidemiolog�a de la fiebre Q en la zona norte de Huelva. Enferm Infecc Microbiol Clin. 1999;17:65-8. [Medline] [Descargar cita] 4. Sabria M, Pedro-Botet ML, Melio R, Rey-Joly C.. Gammapat�a monoclonal transitoria e infecci�n aguda. Med Clin (Barc). 1987;89:575-6. 5. Collazos J, Y��ez R, Macarr�n P, Ben�tez C, Moldenhauer F, Abad JA, et al.. Absceso hep�tico, osteomielitis y gammapat�a monoclonal en el seno de una brucellosis cr�nica. Rev Clin Esp. 1984;174:131-3. [Medline] [Descargar cita] 6. Mseddi-Hdiji S, Haddouk S, Ben Ayed M, Tahrin N, Elloumi M, Baklouti S, et al.. Monoclonal gammapathies in Tunisia: epidemiological, immunochemical and etiological analysis of 288 cases. Pathol Biol (Paris). 2005;53: 19-25. [Medline] [Descargar cita] 7. Schlaieferd D, Jallais P, Arlet P, Ollier S, Abbal M, Cerene A, et al.. Fievre Q, insuffisance aortique, hipersplenism et composat monoclonal. Rev Med Intern. 1989;10:578-9. 8. Arlet P, Duffaut M, Le Tallec Y.. Association gammapathie monoclonale hepatopathies. Press Med. 1983;12:645. 9. Marschall HU, Doller G.. Chronic Q fever infection (Q fever endocarditis) with benign monoclonal gammopathy. Internist (Berl). 1985; 26:640-2. [Medline] [Descargar cita] 10. Garc�a J, Garc�a JM, Fern�ndez P, Gilsanz C.. Fiebre Q asociada a paniculitis lobulillar y gammapat�a monoclonal tansitoria. Med Clin (Barc). 1989;92:678. [Medline] [Descargar cita] 11. Montejo M, Aguirrebengoa K, Ruiz-Irastorza G, Urquijo JC, De la Prieta R, Aguirre C.. Gammapat�a monoclonal transitoria y fiebre Q aguda. Enferm Infecc Microbiol Clin. 1995; 13:442. 12. Ordi-Ros J, Selva-O'Callaghan A, Monegal-Ferran F, Monasterio-Aspiri Y, Juste-S�nchez C, Vilardell-Tarres M.. Prevalence, significance and specificity of antibodies to phospholipids in Q fever. Clin Infect Dis. 1994;18:213-8. [Medline] [Descargar cita] Cerrar |
2. De Alarc�n A, Villanueva JL, Viciana P, L�pez-Cort�s L, Torronteras R, Bernabeu M, et al.. Q fever: epidemiology, clinical features and prognosis. A study from 1983 to 1999 in the South of Spain. J Infection. 2003;47:110-6. Cerrar |
12. Ordi-Ros J, Selva-O'Callaghan A, Monegal-Ferran F, Monasterio-Aspiri Y, Juste-S�nchez C, Vilardell-Tarres M.. Prevalence, significance and specificity of antibodies to phospholipids in Q fever. Clin Infect Dis. 1994;18:213-8. Cerrar [Medline] [Descargar cita] |
12. Ordi-Ros J, Selva-O'Callaghan A, Monegal-Ferran F, Monasterio-Aspiri Y, Juste-S�nchez C, Vilardell-Tarres M.. Prevalence, significance and specificity of antibodies to phospholipids in Q fever. Clin Infect Dis. 1994;18:213-8. Cerrar [Medline] [Descargar cita] |
12. Ordi-Ros J, Selva-O'Callaghan A, Monegal-Ferran F, Monasterio-Aspiri Y, Juste-S�nchez C, Vilardell-Tarres M.. Prevalence, significance and specificity of antibodies to phospholipids in Q fever. Clin Infect Dis. 1994;18:213-8. Cerrar [Medline] [Descargar cita] |
1. Cohen JI, Corey GR.. Cytomegalovirus infection in the normal host. Medicine (Baltimore). 1985;64:100-14. Cerrar [Medline] [Descargar cita] |
2. Horwitz CA, Henle W, Henle G, Snover D, Rudnick H, Balfour HH Jr, et al.. Clinical and laboratory evaluation of cytomegalovirus-induced mononucleosis in previously healthy individuals. Report of 82 cases. Medicine (Baltimore). 1986. p. 65. Cerrar |
3. Duchowny M, Caplan L, Siber G.. Cytomegalovirus infection of the adult nervous system. Ann Neurol. 1979;5:458. Cerrar [Medline] [Descargar cita] |
4. Kleinschmidt-DeMaters BK, Gilden DH.. The expanding spectrum of Herpesvirus infections of the nervous system. Brain Pathology. 2001;11:440-51. Cerrar [Medline] [Descargar cita] |
5. Donnet A, Gouirand R, Zandotti C, Grisoli F.. Cytomegalovirus encephalitis in an immunocompetent adult. Revue Neurologique. 1996;152 :640-1. [Medline] [Descargar cita] 6. Pantoni L, Inzitari D, Colao MG, De Mayo E, Marini P, Mazzota F.. Cytomegalovirus encephalitis in an non-immunocompromised patient: CSF diagnosis by in situ hybridization cells. Acta Neurol Scand. 1991;84:56-8. [Medline] [Descargar cita] 7. Saliba WR, Raz R, Keness Y, Goldstein LH, Reshef A, El�as M.. Cytomegalovirus encephalitis in an immunocompetent pregnant woman. Eur J Clin Microbiol Infect Dis. 2004;23: 563-6. [Medline] [Descargar cita] 8. Salamano R, Gervaz E, Manana G, Pena S, Panuncio A, Puppo C, et al.. Cytomegalovirus encephalitis in an immunocompetent patient: clinical, neuropathological and ultrastructural analysis. Arq Neuropsiquiatr. 2001;59:954-8. [Medline] [Descargar cita] 9. Prosch S, Schielke E, Reip A, Meisel H, Volk HD, Einhaupl KM, et al.. Human cytomegalovirus (HCMV) encephalitis in immunocompetent young person and diagnostic reliability of HCMV DNA PCR using cerebrospinal fluid of nonimmunosupressed patients. J Clin Microbiol. 1998;36:3636-40. [Medline] [Descargar cita] Cerrar |
10. Garc�a-Bardeci D, Pena MJ, Su�rez-Bord�n P, Aladro Y, P�rez-Gonz�lez C, Lafarga B.. Value of the polymerase chain reaction in the diagnosis of herpes infections of the nervous system. Enferm Infecc Microbiol Clin. 2004;22:150-5. Cerrar [Medline] [Descargar cita] [Art�culo] |
1. Schacker T, Collier AC, Hughes J, Shea T, Corey L.. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996; 125:257-64. Cerrar [Medline] [Descargar cita] |
2. Niu MT, Stein DS, Schnittman SM.. Primary human inmunodeficiency virus type 1 infection: review of pathogenesis and early treatment intervention in humans and animal retrovirus infections. J Infect Dis. 1993;168:1490-501. Cerrar [Medline] [Descargar cita] |
3. Newton PJ, Newsholme W, Brink NS, Manji H, Williams IG, Miller RF.. Acute meningoencephalitis and mening itis due to primary HIV infection. BMJ. 2002;325:1225-7. Cerrar |
1. Schacker T, Collier AC, Hughes J, Shea T, Corey L.. Clinical and epidemiologic features of primary HIV infection. Ann Intern Med. 1996; 125:257-64. Cerrar [Medline] [Descargar cita] |
4. Flanigan T, Tashima KT.. Diagnosis of acute HIV infection: it's time to get moving! Ann Intern Med. 2001;34:75-7. Cerrar |
5. Iribarren JA, Labarga P, Rubio R, Berenguer J, Mir� JM, Antela A, et al.. Spanish GESIDA/Nacional AIDS Plan Recomendations for antiretroviral therapy in HIV infected adults (October 2004). Enferm Infecc Microbiol Clin. 2004;22:564-642. [Medline] [Descargar cita] [Art�culo] 6. Mir� JM, Sued O, Plana M, Pumarola T, Gallart T.. Avances en el diagn�stico y tratamiento de la infecci�n aguda por virus de la inmunodeficiencia humana. Enferm Infecc Microbiol Clin. 2004;22:643-59. [Medline] [Descargar cita] 7. Pilcher CD, Eron JJ Jr, Galvin S, Gay C, Cohen MS.. Acute HIV revisited: new oportunities for treatment and prevention. J Clin Invest. 2004;113:937-45. [Medline] [Descargar cita] Cerrar |
8. Ho DD, Sarngadharan MG, Resnick L, Dimarzoveronese E, Rota TR, Hirsch MS.. Primary human T-lymphotropic virus type III infection. Ann Intern Med. 1985;103:880-3. Cerrar [Medline] [Descargar cita] |
9. Carne CA, Tedder RS, Smith A, Sutherland S, Elkington SG, Daly HM, et al.. Acute encephalopathy coincident with seroconversion for anti-HTLV-III. Lancet. 1985;2:1206-8. Cerrar [Medline] [Descargar cita] |
6. Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD.. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res. 2003;60:81-5. Cerrar [Medline] [Descargar cita] |
6. Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD.. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res. 2003;60:81-5. Cerrar [Medline] [Descargar cita] |
1. Casas M, Roncero C, Rubio G.. Esquizofrenia y abuso de drogas. En: L�pez-Ibor JJ, editor. Resoluci�n de problemas en el manejo de la esquizofrenia. Madrid: Edipharma; 2002. p. 59-75. 2. Kavanagh DJ, McGrath J, Saunders JB, Dore G, Clark D.. Substance misuse in patients with schizophrenia: epidemiology and management. Drugs. 2002;62:743-55. [Medline] [Descargar cita] 3. Rubio G, L�pez-Mu�oz F, Alamo C, Santodomingo J.. Trastornos psiqui�tricos y abuso de sustancias. Madrid: Editorial Panamericana; 2002. Cerrar |
1. Casas M, Roncero C, Rubio G.. Esquizofrenia y abuso de drogas. En: L�pez-Ibor JJ, editor. Resoluci�n de problemas en el manejo de la esquizofrenia. Madrid: Edipharma; 2002. p. 59-75. Cerrar |
4. Roncero C, Ramos JA, Collazos F, Casas M.. Complicaciones psic�ticas del consumo de coca�na. Adicciones. 2001;13 Supl 2:179-89. Cerrar |
5. Zimmet SV, Strous RD, Burgess ES, Kohnstamm S, Green AI.. Effects of clozapine on substance use in patients with schizophrenia and schizoaffective disorder: a retrospective survey. J Clin Psychopharmacol. 2000;20:94-8. Cerrar [Medline] [Descargar cita] |
6. Green AI, Burgess ES, Dawson R, Zimmet SV, Strous RD.. Alcohol and cannabis use in schizophrenia: effects of clozapine vs. risperidone. Schizophr Res. 2003;60:81-5. Cerrar [Medline] [Descargar cita] |
3. Rubio G, L�pez-Mu�oz F, Alamo C, Santodomingo J.. Trastornos psiqui�tricos y abuso de sustancias. Madrid: Editorial Panamericana; 2002. Cerrar |
3. Rubio G, L�pez-Mu�oz F, Alamo C, Santodomingo J.. Trastornos psiqui�tricos y abuso de sustancias. Madrid: Editorial Panamericana; 2002. Cerrar |
3. Rubio G, L�pez-Mu�oz F, Alamo C, Santodomingo J.. Trastornos psiqui�tricos y abuso de sustancias. Madrid: Editorial Panamericana; 2002. Cerrar |
3. Rubio G, L�pez-Mu�oz F, Alamo C, Santodomingo J.. Trastornos psiqui�tricos y abuso de sustancias. Madrid: Editorial Panamericana; 2002. Cerrar |
3. Rubio G, L�pez-Mu�oz F, Alamo C, Santodomingo J.. Trastornos psiqui�tricos y abuso de sustancias. Madrid: Editorial Panamericana; 2002. Cerrar |
3. Rubio G, L�pez-Mu�oz F, Alamo C, Santodomingo J.. Trastornos psiqui�tricos y abuso de sustancias. Madrid: Editorial Panamericana; 2002. Cerrar |
7. Casas M, Roncero C, Castells X, Ramos J.. Xantinas. En: Cervera G, Valderrama JC, P�rez de los Cobos J, Rubio G, San L, editores. Tratado de SET de Trastornos Adictivos. Madrid: Panamericana. 2006;315-20. Cerrar |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. 2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. 3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. 4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. 2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. 3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. 4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. 5. Doyon S.. The many faces ecstasy. Curr Opin Pediatr. 2001;13:170-6. [Medline] [Descargar cita] 6. Greene SL, Dargan PI, O'connor N, Jones AL, Kerins M.. Multiple toxicity from 3,4-methylenedyoxymethamphetamine (�ecstasy�). Am J Emerg Med. 2003;21:121-4. [Medline] [Descargar cita] 7. Carri�n JA, Escorsell A, Nogu� S, Mas A.. Insuficiencia hep�tica aguda grave por ��xtasis� y trasplante hep�tico urgente. Med Clin (Barc). 2003;121:118-9. [Medline] [Descargar cita] [Art�culo] 8. Patel MM, Wright DW, Ratcliff JJ, Miller MA.. Shedding new light on the �safe� club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities. Acad Emerg Med. 2004;11:208-10. [Medline] [Descargar cita] Cerrar |
9. Parrott AC.. Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behavior. 2002;71:837-44. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
6. Greene SL, Dargan PI, O'connor N, Jones AL, Kerins M.. Multiple toxicity from 3,4-methylenedyoxymethamphetamine (�ecstasy�). Am J Emerg Med. 2003;21:121-4. Cerrar [Medline] [Descargar cita] |
9. Parrott AC.. Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behavior. 2002;71:837-44. 10. Brown PL, Wise RA, Kiyatkin EA.. Brain hyperthermia is induced by methamphetamine and exacerbated by social interaction. J Neurosci. 2003;23:3924-9. [Medline] [Descargar cita] 11. Green AR, O'shea E, Colado MI.. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol. 2004;500:3-13. [Medline] [Descargar cita] Cerrar |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. 5. Doyon S.. The many faces ecstasy. Curr Opin Pediatr. 2001;13:170-6. [Medline] [Descargar cita] 6. Greene SL, Dargan PI, O'connor N, Jones AL, Kerins M.. Multiple toxicity from 3,4-methylenedyoxymethamphetamine (�ecstasy�). Am J Emerg Med. 2003;21:121-4. [Medline] [Descargar cita] Cerrar |
8. Patel MM, Wright DW, Ratcliff JJ, Miller MA.. Shedding new light on the �safe� club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities. Acad Emerg Med. 2004;11:208-10. Cerrar [Medline] [Descargar cita] |
12. Agaba EA, Lynch RM, Baskaran A, Jackson T.. Massive intracerebral hematoma and extradural hematoma in amphetamine abuse. Am J Emerg Med. 2002;20:55-7. Cerrar |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
11. Green AR, O'shea E, Colado MI.. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol. 2004;500:3-13. Cerrar [Medline] [Descargar cita] |
13. Caudevilla F.. El ��xtasis�: una revisi�n de la bibliograf�a cient�fica sobre la 3,4-metilendioximetanfetamina. Med Clin (Barc). 2003;120:505-15. Cerrar [Medline] [Descargar cita] [Art�culo] |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. 3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. 4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
9. Parrott AC.. Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behavior. 2002;71:837-44. Cerrar |
11. Green AR, O'shea E, Colado MI.. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol. 2004;500:3-13. Cerrar [Medline] [Descargar cita] |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
10. Brown PL, Wise RA, Kiyatkin EA.. Brain hyperthermia is induced by methamphetamine and exacerbated by social interaction. J Neurosci. 2003;23:3924-9. Cerrar [Medline] [Descargar cita] |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. Cerrar |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. 2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. 3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. 4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
13. Caudevilla F.. El ��xtasis�: una revisi�n de la bibliograf�a cient�fica sobre la 3,4-metilendioximetanfetamina. Med Clin (Barc). 2003;120:505-15. Cerrar [Medline] [Descargar cita] [Art�culo] |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
6. Greene SL, Dargan PI, O'connor N, Jones AL, Kerins M.. Multiple toxicity from 3,4-methylenedyoxymethamphetamine (�ecstasy�). Am J Emerg Med. 2003;21:121-4. Cerrar [Medline] [Descargar cita] |
8. Patel MM, Wright DW, Ratcliff JJ, Miller MA.. Shedding new light on the �safe� club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities. Acad Emerg Med. 2004;11:208-10. Cerrar [Medline] [Descargar cita] |
14. Lai TI, Hwang JJ, Fang CC, Chen WJ.. Methylene 3,4 dioxymethamphetamine-induced acute myocardial infarction. Ann Emerg Med. 2003;42:759-62. Cerrar [Medline] [Descargar cita] |
15. Turnipseed SD, Richards JR, Kirk JD, Diercks DB, Amsterdam EA.. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after metamphetamine use. J Emerg Med. 2003;24:369-73. Cerrar [Medline] [Descargar cita] |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. 2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. 3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. 4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
7. Carri�n JA, Escorsell A, Nogu� S, Mas A.. Insuficiencia hep�tica aguda grave por ��xtasis� y trasplante hep�tico urgente. Med Clin (Barc). 2003;121:118-9. Cerrar [Medline] [Descargar cita] [Art�culo] |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. 2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. 3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
7. Carri�n JA, Escorsell A, Nogu� S, Mas A.. Insuficiencia hep�tica aguda grave por ��xtasis� y trasplante hep�tico urgente. Med Clin (Barc). 2003;121:118-9. Cerrar [Medline] [Descargar cita] [Art�culo] |
8. Patel MM, Wright DW, Ratcliff JJ, Miller MA.. Shedding new light on the �safe� club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities. Acad Emerg Med. 2004;11:208-10. Cerrar [Medline] [Descargar cita] |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
15. Turnipseed SD, Richards JR, Kirk JD, Diercks DB, Amsterdam EA.. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after metamphetamine use. J Emerg Med. 2003;24:369-73. Cerrar [Medline] [Descargar cita] |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. 2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. 3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. 4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
11. Green AR, O'shea E, Colado MI.. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol. 2004;500:3-13. Cerrar [Medline] [Descargar cita] |
15. Turnipseed SD, Richards JR, Kirk JD, Diercks DB, Amsterdam EA.. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after metamphetamine use. J Emerg Med. 2003;24:369-73. Cerrar [Medline] [Descargar cita] |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
8. Patel MM, Wright DW, Ratcliff JJ, Miller MA.. Shedding new light on the �safe� club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities. Acad Emerg Med. 2004;11:208-10. Cerrar [Medline] [Descargar cita] |
15. Turnipseed SD, Richards JR, Kirk JD, Diercks DB, Amsterdam EA.. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after metamphetamine use. J Emerg Med. 2003;24:369-73. Cerrar [Medline] [Descargar cita] |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
7. Carri�n JA, Escorsell A, Nogu� S, Mas A.. Insuficiencia hep�tica aguda grave por ��xtasis� y trasplante hep�tico urgente. Med Clin (Barc). 2003;121:118-9. Cerrar [Medline] [Descargar cita] [Art�culo] |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. 2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. 3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. 4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
6. Greene SL, Dargan PI, O'connor N, Jones AL, Kerins M.. Multiple toxicity from 3,4-methylenedyoxymethamphetamine (�ecstasy�). Am J Emerg Med. 2003;21:121-4. Cerrar [Medline] [Descargar cita] |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. 2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. 3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. 4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
6. Greene SL, Dargan PI, O'connor N, Jones AL, Kerins M.. Multiple toxicity from 3,4-methylenedyoxymethamphetamine (�ecstasy�). Am J Emerg Med. 2003;21:121-4. Cerrar [Medline] [Descargar cita] |
14. Lai TI, Hwang JJ, Fang CC, Chen WJ.. Methylene 3,4 dioxymethamphetamine-induced acute myocardial infarction. Ann Emerg Med. 2003;42:759-62. [Medline] [Descargar cita] 15. Turnipseed SD, Richards JR, Kirk JD, Diercks DB, Amsterdam EA.. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after metamphetamine use. J Em erg Med. 2003;24:369-73. [Medline] [Descargar cita] 16. Rawson RA, Gonzales R, Brethen P.. Treatment of methamphetamine use disorders: an update. J Subst Abuse Treat. 2002;23:145-50. [Medline] [Descargar cita] Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. 2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. 3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. 4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. 2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. 3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. 4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. 5. Doyon S.. The many faces ecstasy. Curr Opin Pediatr. 2001;13:170-6. [Medline] [Descargar cita] 6. Greene SL, Dargan PI, O'connor N, Jones AL, Kerins M.. Multiple toxicity from 3,4-methylenedyoxymethamphetamine (�ecstasy�). Am J Emerg Med. 2003;21:121-4. [Medline] [Descargar cita] 7. Carri�n JA, Escorsell A, Nogu� S, Mas A.. Insuficiencia hep�tica aguda grave por ��xtasis� y trasplante hep�tico urgente. Med Clin (Barc). 2003;121:118-9. [Medline] [Descargar cita] [Art�culo] 8. Patel MM, Wright DW, Ratcliff JJ, Miller MA.. Shedding new light on the �safe� club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities. Acad Emerg Med. 2004;11:208-10. [Medline] [Descargar cita] Cerrar |
9. Parrott AC.. Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behavior. 2002;71:837-44. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
6. Greene SL, Dargan PI, O'connor N, Jones AL, Kerins M.. Multiple toxicity from 3,4-methylenedyoxymethamphetamine (�ecstasy�). Am J Emerg Med. 2003;21:121-4. Cerrar [Medline] [Descargar cita] |
9. Parrott AC.. Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behavior. 2002;71:837-44. 10. Brown PL, Wise RA, Kiyatkin EA.. Brain hyperthermia is induced by methamphetamine and exacerbated by social interaction. J Neurosci. 2003;23:3924-9. [Medline] [Descargar cita] 11. Green AR, O'shea E, Colado MI.. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol. 2004;500:3-13. [Medline] [Descargar cita] Cerrar |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. 5. Doyon S.. The many faces ecstasy. Curr Opin Pediatr. 2001;13:170-6. [Medline] [Descargar cita] 6. Greene SL, Dargan PI, O'connor N, Jones AL, Kerins M.. Multiple toxicity from 3,4-methylenedyoxymethamphetamine (�ecstasy�). Am J Emerg Med. 2003;21:121-4. [Medline] [Descargar cita] Cerrar |
8. Patel MM, Wright DW, Ratcliff JJ, Miller MA.. Shedding new light on the �safe� club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities. Acad Emerg Med. 2004;11:208-10. Cerrar [Medline] [Descargar cita] |
12. Agaba EA, Lynch RM, Baskaran A, Jackson T.. Massive intracerebral hematoma and extradural hematoma in amphetamine abuse. Am J Emerg Med. 2002;20:55-7. Cerrar |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
11. Green AR, O'shea E, Colado MI.. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol. 2004;500:3-13. Cerrar [Medline] [Descargar cita] |
13. Caudevilla F.. El ��xtasis�: una revisi�n de la bibliograf�a cient�fica sobre la 3,4-metilendioximetanfetamina. Med Clin (Barc). 2003;120:505-15. Cerrar [Medline] [Descargar cita] [Art�culo] |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. 3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. 4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
9. Parrott AC.. Recreational ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behavior. 2002;71:837-44. Cerrar |
11. Green AR, O'shea E, Colado MI.. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol. 2004;500:3-13. Cerrar [Medline] [Descargar cita] |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
10. Brown PL, Wise RA, Kiyatkin EA.. Brain hyperthermia is induced by methamphetamine and exacerbated by social interaction. J Neurosci. 2003;23:3924-9. Cerrar [Medline] [Descargar cita] |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. Cerrar |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. 2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. 3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. 4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
13. Caudevilla F.. El ��xtasis�: una revisi�n de la bibliograf�a cient�fica sobre la 3,4-metilendioximetanfetamina. Med Clin (Barc). 2003;120:505-15. Cerrar [Medline] [Descargar cita] [Art�culo] |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
6. Greene SL, Dargan PI, O'connor N, Jones AL, Kerins M.. Multiple toxicity from 3,4-methylenedyoxymethamphetamine (�ecstasy�). Am J Emerg Med. 2003;21:121-4. Cerrar [Medline] [Descargar cita] |
8. Patel MM, Wright DW, Ratcliff JJ, Miller MA.. Shedding new light on the �safe� club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities. Acad Emerg Med. 2004;11:208-10. Cerrar [Medline] [Descargar cita] |
14. Lai TI, Hwang JJ, Fang CC, Chen WJ.. Methylene 3,4 dioxymethamphetamine-induced acute myocardial infarction. Ann Emerg Med. 2003;42:759-62. Cerrar [Medline] [Descargar cita] |
15. Turnipseed SD, Richards JR, Kirk JD, Diercks DB, Amsterdam EA.. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after metamphetamine use. J Emerg Med. 2003;24:369-73. Cerrar [Medline] [Descargar cita] |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. 2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. 3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. 4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
7. Carri�n JA, Escorsell A, Nogu� S, Mas A.. Insuficiencia hep�tica aguda grave por ��xtasis� y trasplante hep�tico urgente. Med Clin (Barc). 2003;121:118-9. Cerrar [Medline] [Descargar cita] [Art�culo] |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. 2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. 3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
7. Carri�n JA, Escorsell A, Nogu� S, Mas A.. Insuficiencia hep�tica aguda grave por ��xtasis� y trasplante hep�tico urgente. Med Clin (Barc). 2003;121:118-9. Cerrar [Medline] [Descargar cita] [Art�culo] |
8. Patel MM, Wright DW, Ratcliff JJ, Miller MA.. Shedding new light on the �safe� club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities. Acad Emerg Med. 2004;11:208-10. Cerrar [Medline] [Descargar cita] |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
15. Turnipseed SD, Richards JR, Kirk JD, Diercks DB, Amsterdam EA.. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after metamphetamine use. J Emerg Med. 2003;24:369-73. Cerrar [Medline] [Descargar cita] |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. 2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. 3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. 4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
11. Green AR, O'shea E, Colado MI.. A review of the mechanisms involved in the acute MDMA (ecstasy)-induced hyperthermic response. Eur J Pharmacol. 2004;500:3-13. Cerrar [Medline] [Descargar cita] |
15. Turnipseed SD, Richards JR, Kirk JD, Diercks DB, Amsterdam EA.. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after metamphetamine use. J Emerg Med. 2003;24:369-73. Cerrar [Medline] [Descargar cita] |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
8. Patel MM, Wright DW, Ratcliff JJ, Miller MA.. Shedding new light on the �safe� club drug: methylenedioxymethamphetamine (ecstasy)-related fatalities. Acad Emerg Med. 2004;11:208-10. Cerrar [Medline] [Descargar cita] |
15. Turnipseed SD, Richards JR, Kirk JD, Diercks DB, Amsterdam EA.. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after metamphetamine use. J Emerg Med. 2003;24:369-73. Cerrar [Medline] [Descargar cita] |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. Cerrar |
3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
7. Carri�n JA, Escorsell A, Nogu� S, Mas A.. Insuficiencia hep�tica aguda grave por ��xtasis� y trasplante hep�tico urgente. Med Clin (Barc). 2003;121:118-9. Cerrar [Medline] [Descargar cita] [Art�culo] |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. 2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. 3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. 4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
6. Greene SL, Dargan PI, O'connor N, Jones AL, Kerins M.. Multiple toxicity from 3,4-methylenedyoxymethamphetamine (�ecstasy�). Am J Emerg Med. 2003;21:121-4. Cerrar [Medline] [Descargar cita] |
1. Goldfrank LR, Flomenbaum NE, Lewin NA, Howland MA, Hoffman RS, Nelson LS, editors.. Goldfrank's: Toxicologic emergencies. 7th ed. New York: McGraw-Hill; 2002. 2. Kalant H.. The parmacology and toxicology of �ecstasy� (MDMA) and related drugs. Can Med Assoc J. 2001;165:917-28. 3. Nogu� S, Munn� P, Nicol�s JM, Sanz P, Amig� M, editores.. Intoxicaciones agudas. Protocolos de tratamiento. Barcelona: Morales i Torres; 2003. 4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
6. Greene SL, Dargan PI, O'connor N, Jones AL, Kerins M.. Multiple toxicity from 3,4-methylenedyoxymethamphetamine (�ecstasy�). Am J Emerg Med. 2003;21:121-4. Cerrar [Medline] [Descargar cita] |
14. Lai TI, Hwang JJ, Fang CC, Chen WJ.. Methylene 3,4 dioxymethamphetamine-induced acute myocardial infarction. Ann Emerg Med. 2003;42:759-62. [Medline] [Descargar cita] 15. Turnipseed SD, Richards JR, Kirk JD, Diercks DB, Amsterdam EA.. Frequency of acute coronary syndrome in patients presenting to the emergency department with chest pain after metamphetamine use. J Emerg Med. 2003;24:369-73. [Medline] [Descargar cita] 16. Rawson RA, Gonzales R, Brethen P.. Treatment of methamphetamine use disorders: an update. J Subst Abuse Treat. 2002;23:145-50. [Medline] [Descargar cita] Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
4. Lloret J, Mu�oz J, Artigas V, Allende LH, V�zquez G, editores.. Protocolos terap�uticos de Urgencias. Hospital de la Santa Creu i Sant Pau. 4.a ed. Barcelona: Masson; 2004. Cerrar |
1. Encuesta Domiciliaria sobre abuso de Drogas en Espa�a 2003.. Delegaci�n de Gobierno para el Plan Nacional sobre Drogas. Observatorio Espa�ol Sobre Drogas (consultado 26 de julio de 2005). Madrid: Delegaci�n del Gobierno para el Plan Nacional sobre Drogas; 2004. Disponible en: http://www.msc.es/pnd/observa/ pdf/domiciliaria2003.pdf Cerrar |
2. Encuesta Estatal sobre uso de Drogas en las Ense�anzas Secundarias 2004.. Delegaci�n de Gobierno para el Plan Nacional sobre Drogas. Observatorio Espa�ol Sobre Drogas (consultado 26 de julio de 2005). Madrid: Delegaci�n del Gobierno para el Plan Nacional sobre Drogas; 2005. Disponible en: http://www.msc.es/pnd/ observa/pdf/escolar2004.pdf Cerrar |
1. Encuesta Domiciliaria sobre abuso de Drogas en Espa�a 2003.. Delegaci�n de Gobierno para el Plan Nacional sobre Drogas. Observatorio Espa�ol Sobre Drogas (consultado 26 de julio de 2005). Madrid: Delegaci�n del Gobierno para el Plan Nacional sobre Drogas; 2004. Disponible en: http://www.msc.es/pnd/observa/ pdf/domiciliaria2003.pdf Cerrar |
1. Encuesta Domiciliaria sobre abuso de Drogas en Espa�a 2003.. Delegaci�n de Gobierno para el Plan Nacional sobre Drogas. Observatorio Espa�ol Sobre Drogas (consultado 26 de julio de 2005). Madrid: Delegaci�n del Gobierno para el Plan Nacional sobre Drogas; 2004. Disponible en: http://www.msc.es/pnd/observa/ pdf/domiciliaria2003.pdf Cerrar |
2. Encuesta Estatal sobre uso de Drogas en las Ense�anzas Secundarias 2004.. Delegaci�n de Gobierno para el Plan Nacional sobre Drogas. Observatorio Espa�ol Sobre Drogas (consultado 26 de julio de 2005). Madrid: Delegaci�n del Gobierno para el Plan Nacional sobre Drogas; 2005. Disponible en: http://www.msc.es/pnd/ observa/pdf/escolar2004.pdf Cerrar |
2. Encuesta Estatal sobre uso de Drogas en las Ense�anzas Secundarias 2004.. Delegaci�n de Gobierno para el Plan Nacional sobre Drogas. Observatorio Espa�ol Sobre Drogas (consultado 26 de julio de 2005). Madrid: Delegaci�n del Gobierno para el Plan Nacional sobre Drogas; 2005. Disponible en: http://www.msc.es/pnd/ observa/pdf/escolar2004.pdf Cerrar |
1. Encuesta Domiciliaria sobre abuso de Drogas en Espa�a 2003.. Delegaci�n de Gobierno para el Plan Nacional sobre Drogas. Observatorio Espa�ol Sobre Drogas (consultado 26 de julio de 2005). Madrid: Delegaci�n del Gobierno para el Plan Nacional sobre Drogas; 2004. Disponible en: http://www.msc.es/pnd/observa/ pdf/domiciliaria2003.pdf Cerrar |
3. Zador PL.. Alcohol-related relative risk of fatal driver injuries in relation to driver age and sex. J Stud Alcohol. 1991;52:302-10. [Medline] [Descargar cita] 4. Maycock G.. Drinking and driving in Great Britain � a review. TRL report 232. Crowthorn: TRL; 1997. 5. �lvarez FJ, Del R�o MC.. Alcohol y accidentes de tr�fico: �Prevenir qu�? Trastornos Adictivos. 2001;3:172-80. Cerrar |
3. Zador PL.. Alcohol-related relative risk of fatal driver injuries in relation to driver age and sex. J Stud Alcohol. 1991;52:302-10. Cerrar [Medline] [Descargar cita] |
4. Maycock G.. Drinking and driving in Great Britain � a review. TRL report 232. Crowthorn: TRL; 1997. Cerrar |
6. Council on Scientific Affaire.. Alcohol and the driver. JAMA. 1986;255:522-7. Cerrar [Medline] [Descargar cita] |
3. Zador PL.. Alcohol-related relative risk of fatal driver injuries in relation to driver age and sex. J Stud Alcohol. 1991;52:302-10. Cerrar [Medline] [Descargar cita] |
5. �lvarez FJ, Del R�o MC.. Alcohol y accidentes de tr�fico: �Prevenir qu�? Trastornos Adictivos. 2001;3:172-80. Cerrar |
7. Direcci�n General de Tr�fico.. Estudio sobre la reducci�n de los l�mites de alcoholemia. Grupo de trabajo 36. Madrid: Consejo Superior de Tr�fico y Seguridad de la Circulaci�n Vial; 1998. Cerrar |
5. �lvarez FJ, Del R�o MC.. Alcohol y accidentes de tr�fico: �Prevenir qu�? Trastornos Adictivos. 2001;3:172-80. Cerrar |
3. Zador PL.. Alcohol-related relative risk of fatal driver injuries in relation to driver age and sex. J Stud Alcohol. 1991;52:302-10. Cerrar [Medline] [Descargar cita] |
8. Gonz�lez-Luque JC.. Alcohol y accidentes de circulaci�n. JANO. 1998;54:214-7. Cerrar |
1. Encuesta Domiciliaria sobre abuso de Drogas en Espa�a 2003.. Delegaci�n de Gobierno para el Plan Nacional sobre Drogas. Observatorio Espa�ol Sobre Drogas (consultado 26 de julio de 2005). Madrid: Delegaci�n del Gobierno para el Plan Nacional sobre Drogas; 2004. Disponible en: http://www.msc.es/pnd/observa/ pdf/domiciliaria2003.pdf Cerrar |
2. Encuesta Estatal sobre uso de Drogas en las Ense�anzas Secundarias 2004.. Delegaci�n de Gobierno para el Plan Nacional sobre Drogas. Observatorio Espa�ol Sobre Drogas (consultado 26 de julio de 2005). Madrid: Delegaci�n del Gobierno para el Plan Nacional sobre Drogas; 2005. Disponible en: http://www.msc.es/pnd/ observa/pdf/escolar2004.pdf Cerrar |
1. Encuesta Domiciliaria sobre abuso de Drogas en Espa�a 2003.. Delegaci�n de Gobierno para el Plan Nacional sobre Drogas. Observatorio Espa�ol Sobre Drogas (consultado 26 de julio de 2005). Madrid: Delegaci�n del Gobierno para el Plan Nacional sobre Drogas; 2004. Disponible en: http://www.msc.es/pnd/observa/ pdf/domiciliaria2003.pdf Cerrar |
1. Encuesta Domiciliaria sobre abuso de Drogas en Espa�a 2003.. Delegaci�n de Gobierno para el Plan Nacional sobre Drogas. Observatorio Espa�ol Sobre Drogas (consultado 26 de julio de 2005). Madrid: Delegaci�n del Gobierno para el Plan Nacional sobre Drogas; 2004. Disponible en: http://www.msc.es/pnd/observa/ pdf/domiciliaria2003.pdf Cerrar |
2. Encuesta Estatal sobre uso de Drogas en las Ense�anzas Secundarias 2004.. Delegaci�n de Gobierno para el Plan Nacional sobre Drogas. Observatorio Espa�ol Sobre Drogas (consultado 26 de julio de 2005). Madrid: Delegaci�n del Gobierno para el Plan Nacional sobre Drogas; 2005. Disponible en: http://www.msc.es/pnd/ observa/pdf/escolar2004.pdf Cerrar |
2. Encuesta Estatal sobre uso de Drogas en las Ense�anzas Secundarias 2004.. Delegaci�n de Gobierno para el Plan Nacional sobre Drogas. Observatorio Espa�ol Sobre Drogas (consultado 26 de julio de 2005). Madrid: Delegaci�n del Gobierno para el Plan Nacional sobre Drogas; 2005. Disponible en: http://www.msc.es/pnd/ observa/pdf/escolar2004.pdf Cerrar |
1. Encuesta Domiciliaria sobre abuso de Drogas en Espa�a 2003.. Delegaci�n de Gobierno para el Plan Nacional sobre Drogas. Observatorio Espa�ol Sobre Drogas (consultado 26 de julio de 2005). Madrid: Delegaci�n del Gobierno para el Plan Nacional sobre Drogas; 2004. Disponible en: http://www.msc.es/pnd/observa/ pdf/domiciliaria2003.pdf Cerrar |
3. Zador PL.. Alcohol-related relative risk of fatal driver injuries in relation to driver age and sex. J Stud Alcohol. 1991;52:302-10. [Medline] [Descargar cita] 4. Maycock G.. Drinking and driving in Great Britain � a review. TRL report 232. Crowthorn: TRL; 1997. 5. �lvarez FJ, Del R�o MC.. Alcohol y accidentes de tr�fico: �Prevenir qu�? Trastornos Adictivos. 2001;3:172-80. Cerrar |
3. Zador PL.. Alcohol-related relative risk of fatal driver injuries in relation to driver age and sex. J Stud Alcohol. 1991;52:302-10. Cerrar [Medline] [Descargar cita] |
4. Maycock G.. Drinking and driving in Great Britain � a review. TRL report 232. Crowthorn: TRL; 1997. Cerrar |
6. Council on Scientific Affaire.. Alcohol and the driver. JAMA. 1986;255:522-7. Cerrar [Medline] [Descargar cita] |
3. Zador PL.. Alcohol-related relative risk of fatal driver injuries in relation to driver age and sex. J Stud Alcohol. 1991;52:302-10. Cerrar [Medline] [Descargar cita] |
5. �lvarez FJ, Del R�o MC.. Alcohol y accidentes de tr�fico: �Prevenir qu�? Trastornos Adictivos. 2001;3:172-80. Cerrar |
7. Direcci�n General de Tr�fico.. Estudio sobre la reducci�n de los l�mites de alcoholemia. Grupo de trabajo 36. Madrid: Consejo Superior de Tr�fico y Seguridad de la Circulaci�n Vial; 1998. Cerrar |
5. �lvarez FJ, Del R�o MC.. Alcohol y accidentes de tr�fico: �Prevenir qu�? Trastornos Adictivos. 2001;3:172-80. Cerrar |
3. Zador PL.. Alcohol-related relative risk of fatal driver injuries in relation to driver age and sex. J Stud Alcohol. 1991;52:302-10. Cerrar [Medline] [Descargar cita] |
8. Gonz�lez-Luque JC.. Alcohol y accidentes de circulaci�n. JANO. 1998;54:214-7. Cerrar |
1. Millon T.. Negativistic (passive-aggressive) personality disorder. J Pers Disord. 1993;7:78-85. Cerrar |
2. Fine MA, Overholser JC, Berkoff K.. Diagnostic validity of the passive-aggressive personality disorder: suggestions for reform. Am J Psychother. 1992;46:470-84. Cerrar [Medline] [Descargar cita] |
3. American Psychiatric Association (APA).. Manual diagn�stico y estad�stico DSM-IV-TR. Barcelona: Masson; 2002. Cerrar |
4. Segarra Echevarr�a R, Eguiluz Uruchurtu I, Pikaza Ere�o, U, Guti�rrez Fraile M.. Trastorno negativista (pasivo-agresivo) de la personalidad. En: Roca Benasar M, coordinador. Trastornos de Personalidad. Barcelona: Ars M�dica; 2004. p. 677-710. Cerrar |
5. Millon T.. Trastornos negativistas de la personalidad: el patr�n vacilante. En: Millon T, Davis RD, editores. Trastornos de la personalidad. M�s all� del DSM-IV. Barcelona: Masson; 1998. p. 563-97. Cerrar |
5. Millon T.. Trastornos negativistas de la personalidad: el patr�n vacilante. En: Millon T, Davis RD, editores. Trastornos de la personalidad. M�s all� del DSM-IV. Barcelona: Masson; 1998. p. 563-97. Cerrar |
3. American Psychiatric Association (APA).. Manual diagn�stico y estad�stico DSM-IV-TR. Barcelona: Masson; 2002. Cerrar |
4. Segarra Echevarr�a R, Eguiluz Uruchurtu I, Pikaza Ere�o, U, Guti�rrez Fraile M.. Trastorno negativista (pasivo-agresivo) de la personalidad. En: Roca Benasar M, coordinador. Trastornos de Personalidad. Barcelona: Ars M�dica; 2004. p. 677-710. Cerrar |
6. Wetzler S, Morey LC.. Passive-aggressive personality disorder: the demise of a syndrome. Psychiatr. 1999;62:49-59. Cerrar |
7. Vereycken J, Vertommen H, Corveylen J.. Authority conflicts and personality disorders. J Pers Disord. 2002;16:41-51. Cerrar |
8. Fossati A, Maffei C, Bagnato M, Donati D, Donini M, Fiorilli M, et al.. A psychometric study of DSM-IV passive-aggressive (negativistic) personality disorder criteria. J Personal Disord. 2000;14:72-83. Cerrar [Medline] [Descargar cita] |
9. Joiner TE, Rudd MD.. The incremental validity of passive-agressive personality symptoms rivals or exceeds that of other personality symptoms in suicidal outpatients. J Pers Assess. 2002;79:161-70. Cerrar [Medline] [Descargar cita] |
4. Segarra Echevarr�a R, Eguiluz Uruchurtu I, Pikaza Ere�o, U, Guti�rrez Fraile M.. Trastorno negativista (pasivo-agresivo) de la personalidad. En: Roca Benasar M, coordinador. Trastornos de Personalidad. Barcelona: Ars M�dica; 2004. p. 677-710. Cerrar |
4. Segarra Echevarr�a R, Eguiluz Uruchurtu I, Pikaza Ere�o, U, Guti�rrez Fraile M.. Trastorno negativista (pasivo-agresivo) de la personalidad. En: Roca Benasar M, coordinador. Trastornos de Personalidad. Barcelona: Ars M�dica; 2004. p. 677-710. Cerrar |
10. Torgersen S, Kringlen E, Cramer V.. The prevalence of personality disorders in a community sample. Arch Gen Psychiat. 2001;58:590-6. Cerrar [Medline] [Descargar cita] |
11. Maffei C, Fossati A, Lingiardi V, Madeddu F, Borellini C, Petrachi M.. Personality maladjustment, defenses and psychopathological symptoms in nonclinical subjects. J Pers Disord. 1995;9:330-45. Cerrar |
12. Samuels JF, Nestadt G, Romanoski AJ, Folstein MF, McHugh PR.. DSM-III personality disorders in the community. Am J Psychiat. 1994;151:1055-62. Cerrar [Medline] [Descargar cita] |
13. Zimmerman M, Coryell W.. DSM-III personality disorder diagnoses in a nonpatient sample. Demographic correlates and comorbidity. Arch Gen Psychiat. 1989;46:682-9. [Medline] [Descargar cita] 14. Brennan KA, Shaver PR.. Attachment styles and personality disorders: their connections to each other and to parental divorce, parental death, and perceptions of parental caregiving. J Pers. 1998;66:835-78. [Medline] [Descargar cita] 15. Johnson JG, Bornstein RF, Sherman MF.. A modified scoring algorithm for the PDQ-R: psychiatric symptomatology and substance use in adolescents with personality disorders. Educ Psychol Meas. 1996;56:76-89. Cerrar |
16. Grilo CM, McGlashan TH, Quinlan DM, Walker ML, Greenfeld D, Edell WS.. Frequency of Personality Disorders in Two Age Cohorts of Psychiatric Inpatients. Am J Psychiat. 1998;155:140-2. Cerrar [Medline] [Descargar cita] |
9. Joiner TE, Rudd MD.. The incremental validity of passive-agressive personality symptoms rivals or exceeds that of other personality symptoms in suicidal outpatients. J Pers Assess. 2002;79:161-70. Cerrar [Medline] [Descargar cita] |
17. Sprock J, Hunsucker L.. Symptoms of prototypic patients with passive-aggressive disorders: DSM-III-R vs. DSM-IV negativistic. Comp Psychiat. 1998;39:289-95. Cerrar |
8. Fossati A, Maffei C, Bagnato M, Donati D, Donini M, Fiorilli M, et al.. A psychometric study of DSM-IV passive-aggressive (negativistic) personality disorder criteria. J Personal Disord. 2000;14:72-83. Cerrar [Medline] [Descargar cita] |
18. Grilo CM, Becker DF, Fehon DC, Walker ML, Edell WS, McGlashan TH.. Gender differences in personality disorders in psychiatrically hospitalized adolescents. Am J Psychiat. 1996;153:1089-91. Cerrar [Medline] [Descargar cita] |
19. Nadeau L, Landry M, Racine S.. Prevalence of personality disorders among clients in treatment for addiction. Can J Psychiat. 1999;44:592-6. Cerrar |
20. Pedrero EJ, Puerta C, Lagares A, S�ez A.. Prevalencia e intensidad de trastornos de personalidad en adictos a sustancias en tratamiento en un centro de atenci�n a las drogodependencias. Trastornos Adictivos. 2003;5:241-55. Cerrar |
21. Pedrero EJ.. Los trastornos de la personalidad en drogodependientes desde la perspectiva de los cinco grandes factores. Adicciones. 2003;15:203-20. Cerrar |
22. Marlowe DB, Festinger DS, Kirby KC, Rubenstein DF, Platt JJ.. Congruence of the MCMI-II and MCMI-III in cocaine dependence. J Pers Assess. 1998;71:15-28. Cerrar [Medline] [Descargar cita] |
23. Flynn PM, Luckey JW, Brown BS, Hoffman JA, Dunteman GH, Theisen AC, et al.. Relationship between drug preference and indicators of psychiatric impairment. Am J Drug Alcohol Ab. 1995;21:153-66. Cerrar |
24. Pedrero EJ, Segura I.. Los trastornos de la personalidad en drogodependientes y su relaci�n con la dificultad de manejo cl�nico. Trastornos Adictivos. 2003;5:229-49. Cerrar |
25. Pedrero P�rez EJ, De Ena S.. Diferencias de g�nero en personalidad en consumidores de drogas en tratamiento: rasgos, trastornos y variables interaccionales, �se justifican tratamientos diferentes? 1.er Premio de Investigaci�n de la Diputaci�n de C�diz, Chiclana de la Frontera; 2004 (en prensa). Cerrar |
26. Haller DL, Miles DR, Dawson KS.. Factors influencing treatment enrollment by pregnant substance abusers. Am J Drug Alcohol Ab. 2003;29:117-31. Cerrar |
27. Nielsen P, R�jskj�r S.. Dual disorder among alcohol addicted inpatient clients. Nordisk Alkohol- og Narkotikatidsskrift 2002;19:123-37. Cerrar |
28. Craig RJ.. Prevalence of personality disorders among cocaine and heroin addicts. Subst Abuse. 2000;21:87-94. Cerrar |
29. Campbell BK, Stark MJ.. Psychopathology and personality characteristics in different forms of substance abuse. Int J Addict. 1990;25:1467-74. Cerrar [Medline] [Descargar cita] |
30. Millon T.. MCMI-II. Inventario cl�nico multiaxial de Millon-II. Manual. Adaptaci�n espa�ola de �vila-Espada A, director, Jim�nez G�mez F, coordinador. Madrid: TEA; 1999. Cerrar |
31. Guti�rrez-Zotes JA, Bay�n C, Montserrat C, Valero J, Labad A, Cloninger CR, et al.. Inventario del Temperamento y el Car�cter-Revisado (TCI-R). Baremaci�n y datos normativos en una muestra de poblaci�n general. Actas Esp Psiquiatr. 2004;32:8-15. Cerrar [Medline] [Descargar cita] |
32. Cloninger CR.. A practical way to diagnosis personality disorder: a proposal. J Personal Disord. 2000;14:99-108. Cerrar [Medline] [Descargar cita] |
33. Caprara GV, Barbaranelli C, Borgogni L.. BFQ. Cuestionario �Big Five� (Versi�n espa�ola de J. Berm�dez). Madrid: TEA Ediciones; 1995. Cerrar |
34. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjam�n LS.. Gu�a del usuario para la entrevista estructurada para los trastornos de la personalidad del Eje II del DSM-IV. SCID-II. Barcelona: Masson; 1999. Cerrar |
2. Fine MA, Overholser JC, Berkoff K.. Diagnostic validity of the passive-aggressive personality disorder: suggestions for reform. Am J Psychother. 1992;46:470-84. Cerrar [Medline] [Descargar cita] |
35. Choca JP.. Evolution of Millon's Personality Prototypes. J Pers Assess. 1999;72:353-64. Cerrar |
36. Millon T.. Reflections on psychosynergy: A model for integrating science, theory, classification, assessment and therapy. J Pers Assess. 1999;(72):437-56. Cerrar |
37. Streiner DL, Goldberg JO, Miller HR.. MCMI-II Item Weights: Their Lack of Effectiveness. J Pers Assess. 1993;60:471-6. Cerrar [Medline] [Descargar cita] |
36. Millon T.. Reflections on psychosynergy: A model for integrating science, theory, classification, assessment and therapy. J Pers Assess. 1999;(72):437-56. Cerrar |
38. Cloninger CR.. A systematic method for clinical description and classification of personality variants. A proposal. Arch Gen Psychiat. 1987;44:573-88. Cerrar [Medline] [Descargar cita] |
39. Grabe HJ, Spitzer C, Freyberger HJ.. Relationship of Dissociation to Temperament and Character in Men and Women. Am J Psychiatr. 1999;156:1811-3. Cerrar [Medline] [Descargar cita] |
40. Vandamme M, Nandrino JL.. Temperament and character inventory in homicidal, nonaddicted paranoid schizofrenic patients: a preliminary study. Psychol Rep. 2004;95:393-406. Cerrar [Medline] [Descargar cita] |
41. Gillespie N, Cloninger C, Heath A, Martin N.. The genetic and environmental relationship between Cloninger's dimensions of temperament and character. Pers Indiv Differ. 2003;35:1931-46. Cerrar |
42. Kirk KM, Eaves LJ, Martin NG.. Self-transcendence as a measure of spirituality in a sample of older Australian twins. Twin Research. 1999;2:81-7. Cerrar [Medline] [Descargar cita] |
43. Pedrero P�rez EJ, P�rez L�pez M, Ena de la Cuesta S, Garrido Caballero C.. Validaci�n del Cuestionario de Variables de Interacci�n Psicosocial (VIP): hacia un modelo de tratamiento de las conductas adictivas �guiado por la personalidad�. Trastornos Adictivos. 2005;7:166-86. Cerrar |
14. Brennan KA, Shaver PR.. Attachment styles and personality disorders: their connections to each other and to parental divorce, parental death, and perceptions of parental caregiving. J Pers. 1998;66:835-78. Cerrar [Medline] [Descargar cita] |
44. Lende DH, Smith EO.. Evolution meets biopsychosociality: an analysis of addictive behavior. Addiction. 2002;97:447-58. Cerrar [Medline] [Descargar cita] |
45. Pedrero P�rez EJ, Olivar Arroyo �.. Revisi�n del Cuestionario de Cambio Educativo en Comunidad Terap�utica Profesional (CCE-R): estructura factorial y relaci�n de la socializaci�n con variables de personalidad y psicopatolog�a. Trastornos Adictivos. 2003;5:88-106. Cerrar |
3. American Psychiatric Association (APA).. Manual diagn�stico y estad�stico DSM-IV-TR. Barcelona: Masson; 2002. Cerrar |
46. Ross CN, Blanc HM.. Parenting stress in mothers of young children with oppositional defiant disorder and other severe behavior problems. Child Study J. 1998;28:93-110. Cerrar |
47. Rey JM, Walter G, Plapp JM, Denshire E.. Family environment in attention deficit hyperactivity, oppositional defiant and conduct disorders. Aust NZ J Psychiat. 2000;34:453-7. Cerrar |
48. Larroy Garc�a C, De la Puente Mu�oz ML.. Trastornos de conducta en ni�os. En: MA Vallejo Pareja, director. Manual de terapia de conducta. Vol II. Madrid: Dykinson; 1998. Cerrar |
49. May B, Bos J.. Personality characteristics of ADHD adults assessed with the Millon Clinical Multiaxial Inventory-II: evidence of four distinct subtypes. J Pers Assess. 2000;75:237-48. Cerrar [Medline] [Descargar cita] |
5. Millon T.. Trastornos negativistas de la personalidad: el patr�n vacilante. En: Millon T, Davis RD, editores. Trastornos de la personalidad. M�s all� del DSM-IV. Barcelona: Masson; 1998. p. 563-97. Cerrar |
50. Khantzian EJ.. Self-regulation and self-medication factors in alcoholism and the addictions. Similarities and differences. Recent Dev Alcohol. 1990;8:255-71. Cerrar [Medline] [Descargar cita] |
25. Pedrero P�rez EJ, De Ena S.. Diferencias de g�nero en personalidad en consumidores de drogas en tratamiento: rasgos, trastornos y variables interaccionales, �se justifican tratamientos diferentes? 1.er Premio de Investigaci�n de la Diputaci�n de C�diz, Chiclana de la Frontera; 2004 (en prensa). Cerrar |
51. Cervera G, Haro G, Mart�nez-Raga J, Bolinches F, De Vicente P, Valderrama JC.. Los trastornos relacionados con el uso de sustancias desde la perspectiva de la psicopatolog�a y las neurociencias. Trastornos Adictivos. 2001;3:164-71. Cerrar |
52. Davidson RJ, Jackson DC, Kalin NH.. Emotion, plasticity, context, and regulation: perspectives from affective neuroscience. Psychol Bull. 2000;126:890-909. Cerrar [Medline] [Descargar cita] |
53. Meg�as Valenzuela E, Rodr�guez San Juli�n E.. Valores sociales y drogas. Itaca. 2002;6:63-84. Cerrar |
1. Millon T.. Negativistic (passive-aggressive) personality disorder. J Pers Disord. 1993;7:78-85. Cerrar |
2. Fine MA, Overholser JC, Berkoff K.. Diagnostic validity of the passive-aggressive personality disorder: suggestions for reform. Am J Psychother. 1992;46:470-84. Cerrar [Medline] [Descargar cita] |
3. American Psychiatric Association (APA).. Manual diagn�stico y estad�stico DSM-IV-TR. Barcelona: Masson; 2002. Cerrar |
4. Segarra Echevarr�a R, Eguiluz Uruchurtu I, Pikaza Ere�o, U, Guti�rrez Fraile M.. Trastorno negativista (pasivo-agresivo) de la personalidad. En: Roca Benasar M, coordinador. Trastornos de Personalidad. Barcelona: Ars M�dica; 2004. p. 677-710. Cerrar |
5. Millon T.. Trastornos negativistas de la personalidad: el patr�n vacilante. En: Millon T, Davis RD, editores. Trastornos de la personalidad. M�s all� del DSM-IV. Barcelona: Masson; 1998. p. 563-97. Cerrar |
5. Millon T.. Trastornos negativistas de la personalidad: el patr�n vacilante. En: Millon T, Davis RD, editores. Trastornos de la personalidad. M�s all� del DSM-IV. Barcelona: Masson; 1998. p. 563-97. Cerrar |
3. American Psychiatric Association (APA).. Manual diagn�stico y estad�stico DSM-IV-TR. Barcelona: Masson; 2002. Cerrar |
4. Segarra Echevarr�a R, Eguiluz Uruchurtu I, Pikaza Ere�o, U, Guti�rrez Fraile M.. Trastorno negativista (pasivo-agresivo) de la personalidad. En: Roca Benasar M, coordinador. Trastornos de Personalidad. Barcelona: Ars M�dica; 2004. p. 677-710. Cerrar |
6. Wetzler S, Morey LC.. Passive-aggressive personality disorder: the demise of a syndrome. Psychiatr. 1999;62:49-59. Cerrar |
7. Vereycken J, Vertommen H, Corveylen J.. Authority conflicts and personality disorders. J Pers Disord. 2002;16:41-51. Cerrar |
8. Fossati A, Maffei C, Bagnato M, Donati D, Donini M, Fiorilli M, et al.. A psychometric study of DSM-IV passive-aggressive (negativistic) personality disorder criteria. J Personal Disord. 2000;14:72-83. Cerrar [Medline] [Descargar cita] |
9. Joiner TE, Rudd MD.. The incremental validity of passive-agressive personality symptoms rivals or exceeds that of other personality symptoms in suicidal outpatients. J Pers Assess. 2002;79:161-70. Cerrar [Medline] [Descargar cita] |
4. Segarra Echevarr�a R, Eguiluz Uruchurtu I, Pikaza Ere�o, U, Guti�rrez Fraile M.. Trastorno negativista (pasivo-agresivo) de la personalidad. En: Roca Benasar M, coordinador. Trastornos de Personalidad. Barcelona: Ars M�dica; 2004. p. 677-710. Cerrar |
4. Segarra Echevarr�a R, Eguiluz Uruchurtu I, Pikaza Ere�o, U, Guti�rrez Fraile M.. Trastorno negativista (pasivo-agresivo) de la personalidad. En: Roca Benasar M, coordinador. Trastornos de Personalidad. Barcelona: Ars M�dica; 2004. p. 677-710. Cerrar |
10. Torgersen S, Kringlen E, Cramer V.. The prevalence of personality disorders in a community sample. Arch Gen Psychiat. 2001;58:590-6. Cerrar [Medline] [Descargar cita] |
11. Maffei C, Fossati A, Lingiardi V, Madeddu F, Borellini C, Petrachi M.. Personality maladjustment, defenses and psychopathological symptoms in nonclinical subjects. J Pers Disord. 1995;9:330-45. Cerrar |
12. Samuels JF, Nestadt G, Romanoski AJ, Folstein MF, McHugh PR.. DSM-III personality disorders in the community. Am J Psychiat. 1994;151:1055-62. Cerrar [Medline] [Descargar cita] |
13. Zimmerman M, Coryell W.. DSM-III personality disorder diagnoses in a nonpatient sample. Demographic correlates and comorbidity. Arch Gen Psychiat. 1989;46:682-9. [Medline] [Descargar cita] 14. Brennan KA, Shaver PR.. Attachment styles and personality disorders: their connections to each other and to parental divorce, parental death, and perceptions of parental caregiving. J Pers. 1998;66:835-78. [Medline] [Descargar cita] 15. Johnson JG, Bornstein RF, Sherman MF.. A modified scoring algorithm for the PDQ-R: psychiatric symptomatology and substance use in adolescents with personality disorders. Educ Psychol Meas. 1996;56:76-89. Cerrar |
16. Grilo CM, McGlashan TH, Quinlan DM, Walker ML, Greenfeld D, Edell WS.. Frequency of Personality Disorders in Two Age Cohorts of Psychiatric Inpatients. Am J Psychiat. 1998;155:140-2. Cerrar [Medline] [Descargar cita] |
9. Joiner TE, Rudd MD.. The incremental validity of passive-agressive personality symptoms rivals or exceeds that of other personality symptoms in suicidal outpatients. J Pers Assess. 2002;79:161-70. Cerrar [Medline] [Descargar cita] |
17. Sprock J, Hunsucker L.. Symptoms of prototypic patients with passive-aggressive disorders: DSM-III-R vs. DSM-IV negativistic. Comp Psychiat. 1998;39:289-95. Cerrar |
8. Fossati A, Maffei C, Bagnato M, Donati D, Donini M, Fiorilli M, et al.. A psychometric study of DSM-IV passive-aggressive (negativistic) personality disorder criteria. J Personal Disord. 2000;14:72-83. Cerrar [Medline] [Descargar cita] |
18. Grilo CM, Becker DF, Fehon DC, Walker ML, Edell WS, McGlashan TH.. Gender differences in personality disorders in psychiatrically hospitalized adolescents. Am J Psychiat. 1996;153:1089-91. Cerrar [Medline] [Descargar cita] |
19. Nadeau L, Landry M, Racine S.. Prevalence of personality disorders among clients in treatment for addiction. Can J Psychiat. 1999;44:592-6. Cerrar |
20. Pedrero EJ, Puerta C, Lagares A, S�ez A.. Prevalencia e intensidad de trastornos de personalidad en adictos a sustancias en tratamiento en un centro de atenci�n a las drogodependencias. Trastornos Adictivos. 2003;5:241-55. Cerrar |
21. Pedrero EJ.. Los trastornos de la personalidad en drogodependientes desde la perspectiva de los cinco grandes factores. Adicciones. 2003;15:203-20. Cerrar |
22. Marlowe DB, Festinger DS, Kirby KC, Rubenstein DF, Platt JJ.. Congruence of the MCMI-II and MCMI-III in cocaine dependence. J Pers Assess. 1998;71:15-28. Cerrar [Medline] [Descargar cita] |
23. Flynn PM, Luckey JW, Brown BS, Hoffman JA, Dunteman GH, Theisen AC, et al.. Relationship between drug preference and indicators of psychiatric impairment. Am J Drug Alcohol Ab. 1995;21:153-66. Cerrar |
24. Pedrero EJ, Segura I.. Los trastornos de la personalidad en drogodependientes y su relaci�n con la dificultad de manejo cl�nico. Trastornos Adictivos. 2003;5:229-49. Cerrar |
25. Pedrero P�rez EJ, De Ena S.. Diferencias de g�nero en personalidad en consumidores de drogas en tratamiento: rasgos, trastornos y variables interaccionales, �se justifican tratamientos diferentes? 1.er Premio de Investigaci�n de la Diputaci�n de C�diz, Chiclana de la Frontera; 2004 (en prensa). Cerrar |
26. Haller DL, Miles DR, Dawson KS.. Factors influencing treatment enrollment by pregnant substance abusers. Am J Drug Alcohol Ab. 2003;29:117-31. Cerrar |
27. Nielsen P, R�jskj�r S.. Dual disorder among alcohol addicted inpatient clients. Nordisk Alkohol- og Narkotikatidsskrift 2002;19:123-37. Cerrar |
28. Craig RJ.. Prevalence of personality disorders among cocaine and heroin addicts. Subst Abuse. 2000;21:87-94. Cerrar |
29. Campbell BK, Stark MJ.. Psychopathology and personality characteristics in different forms of substance abuse. Int J Addict. 1990;25:1467-74. Cerrar [Medline] [Descargar cita] |
30. Millon T.. MCMI-II. Inventario cl�nico multiaxial de Millon-II. Manual. Adaptaci�n espa�ola de �vila-Espada A, director, Jim�nez G�mez F, coordinador. Madrid: TEA; 1999. Cerrar |
31. Guti�rrez-Zotes JA, Bay�n C, Montserrat C, Valero J, Labad A, Cloninger CR, et al.. Inventario del Temperamento y el Car�cter-Revisado (TCI-R). Baremaci�n y datos normativos en una muestra de poblaci�n general. Actas Esp Psiquiatr. 2004;32:8-15. Cerrar [Medline] [Descargar cita] |
32. Cloninger CR.. A practical way to diagnosis personality disorder: a proposal. J Personal Disord. 2000;14:99-108. Cerrar [Medline] [Descargar cita] |
33. Caprara GV, Barbaranelli C, Borgogni L.. BFQ. Cuestionario �Big Five� (Versi�n espa�ola de J. Berm�dez). Madrid: TEA Ediciones; 1995. Cerrar |
34. First MB, Gibbon M, Spitzer RL, Williams JBW, Benjam�n LS.. Gu�a del usuario para la entrevista estructurada para los trastornos de la personalidad del Eje II del DSM-IV. SCID-II. Barcelona: Masson; 1999. Cerrar |
2. Fine MA, Overholser JC, Berkoff K.. Diagnostic validity of the passive-aggressive personality disorder: suggestions for reform. Am J Psychother. 1992;46:470-84. Cerrar [Medline] [Descargar cita] |
36. Millon T.. Reflections on psychosynergy: A model for integrating science, theory, classification, assessment and therapy. J Pers Assess. 1999;(72):437-56. Cerrar |
37. Streiner DL, Goldberg JO, Miller HR.. MCMI-II Item Weights: Their Lack of Effectiveness. J Pers Assess. 1993;60:471-6. Cerrar [Medline] [Descargar cita] |
36. Millon T.. Reflections on psychosynergy: A model for integrating science, theory, classification, assessment and therapy. J Pers Assess. 1999;(72):437-56. Cerrar |
38. Cloninger CR.. A systematic method for clinical description and classification of personality variants. A proposal. Arch Gen Psychiat. 1987;44:573-88. Cerrar [Medline] [Descargar cita] |
39. Grabe HJ, Spitzer C, Freyberger HJ.. Relationship of Dissociation to Temperament and Character in Men and Women. Am J Psychiatr. 1999;156:1811-3. Cerrar [Medline] [Descargar cita] |
40. Vandamme M, Nandrino JL.. Temperament and character inventory in homicidal, nonaddicted paranoid schizofrenic patients: a preliminary study. Psychol Rep. 2004;95:393-406. Cerrar [Medline] [Descargar cita] |
41. Gillespie N, Cloninger C, Heath A, Martin N.. The genetic and environmental relationship between Cloninger's dimensions of temperament and character. Pers Indiv Differ. 2003;35:1931-46. Cerrar |
42. Kirk KM, Eaves LJ, Martin NG.. Self-transcendence as a measure of spirituality in a sample of older Australian twins. Twin Research. 1999;2:81-7. Cerrar [Medline] [Descargar cita] |
43. Pedrero P�rez EJ, P�rez L�pez M, Ena de la Cuesta S, Garrido Caballero C.. Validaci�n del Cuestionario de Variables de Interacci�n Psicosocial (VIP): hacia un modelo de tratamiento de las conductas adictivas �guiado por la personalidad�. Trastornos Adictivos. 2005;7:166-86. Cerrar |
14. Brennan KA, Shaver PR.. Attachment styles and personality disorders: their connections to each other and to parental divorce, parental death, and perceptions of parental caregiving. J Pers. 1998;66:835-78. Cerrar [Medline] [Descargar cita] |
44. Lende DH, Smith EO.. Evolution meets biopsychosociality: an analysis of addictive behavior. Addiction. 2002;97:447-58. Cerrar [Medline] [Descargar cita] |
45. Pedrero P�rez EJ, Olivar Arroyo �.. Revisi�n del Cuestionario de Cambio Educativo en Comunidad Terap�utica Profesional (CCE-R): estructura factorial y relaci�n de la socializaci�n con variables de personalidad y psicopatolog�a. Trastornos Adictivos. 2003;5:88-106. Cerrar |
3. American Psychiatric Association (APA).. Manual diagn�stico y estad�stico DSM-IV-TR. Barcelona: Masson; 2002. Cerrar |
46. Ross CN, Blanc HM.. Parenting stress in mothers of young children with oppositional defiant disorder and other severe behavior problems. Child Study J. 1998;28:93-110. Cerrar |
47. Rey JM, Walter G, Plapp JM, Denshire E.. Family environment in attention deficit hyperactivity, oppositional defiant and conduct disorders. Aust NZ J Psychiat. 2000;34:453-7. Cerrar |
48. Larroy Garc�a C, De la Puente Mu�oz ML.. Trastornos de conducta en ni�os. En: MA Vallejo Pareja, director. Manual de terapia de conducta. Vol II. Madrid: Dykinson; 1998. Cerrar |
49. May B, Bos J.. Personality characteristics of ADHD adults assessed with the Millon Clinical Multiaxial Inventory-II: evidence of four distinct subtypes. J Pers Assess. 2000;75:237-48. Cerrar [Medline] [Descargar cita] |
5. Millon T.. Trastornos negativistas de la personalidad: el patr�n vacilante. En: Millon T, Davis RD, editores. Trastornos de la personalidad. M�s all� del DSM-IV. Barcelona: Masson; 1998. p. 563-97. Cerrar |
50. Khantzian EJ.. Self-regulation and self-medication factors in alcoholism and the addictions. Similarities and differences. Recent Dev Alcohol. 1990;8:255-71. Cerrar [Medline] [Descargar cita] |
25. Pedrero P�rez EJ, De Ena S.. Diferencias de g�nero en personalidad en consumidores de drogas en tratamiento: rasgos, trastornos y variables interaccionales, �se justifican tratamientos diferentes? 1.er Premio de Investigaci�n de la Diputaci�n de C�diz, Chiclana de la Frontera; 2004 (en prensa). Cerrar |
51. Cervera G, Haro G, Mart�nez-Raga J, Bolinches F, De Vicente P, Valderrama JC.. Los trastornos relacionados con el uso de sustancias desde la perspectiva de la psicopatolog�a y las neurociencias. Trastornos Adictivos. 2001;3:164-71. Cerrar |
52. Davidson RJ, Jackson DC, Kalin NH.. Emotion, plasticity, context, and regulation: perspectives from affective neuroscience. Psychol Bull. 2000;126:890-909. Cerrar [Medline] [Descargar cita] |
53. Meg�as Valenzuela E, Rodr�guez San Juli�n E.. Valores sociales y drogas. Itaca. 2002;6:63-84. Cerrar |
1. Echeburua E.. Modificaci�n de conducta y psicolog�a cl�nica. Bilbao: Servicio de Publicaciones del Pa�s Vasco; 1993. Cerrar |
2. NIDA.. Principles of Drug Addiction Treatment. A Research-Based Guide. National Institute of Drug Abuse. Disponible en: http://www.nida. nih.gov/PODAT/PODATTindex.htlm; 1999. Cerrar |
3. NIDA.. Developing effective addiction treatments. Special supplement. Nida Notes. 2004;19:1. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
5. S�nchez-Herv�s E.. Tratamientos psicol�gicos emp�ricamente validados en drogodependencias. Ponencia presentada en el XXXVII Congreso Nacional de Socidrogalcohol. Ciudad Real; febrero 2005. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
6. Jacobson NS, Hollon SD.. Cognitive behavior therapy versus pharmacotherapy: Now that the jury�s returned its verdict, it�s time to present the rest of the evidence. J Consult Clin Psychol. 1996;64:295-304. Cerrar [Medline] [Descargar cita] |
7. Seligman ME.. The effectiveness of psychotherapy: The Consumer Reports Study. Am Psychol. 1995;50:965-74. Cerrar [Medline] [Descargar cita] |
8. Roberts G, Ogborne A, Leigh G, Adam L.. Mejores pr�cticas: alcoholismo y toxicoman�as, tratamiento y rehabilitaci�n. Office of alcohol, drugs and dependency issues. Health Canada: Minister of Public Work and Government Services; 1999. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
9. Telch M, Bandura A, Vincguerra P, Agras W, Stout A.. Social demand and the congruence between self-efficacy and performance. Behav Ther. 1982;13:694-701. Cerrar |
10. De Pablo J.. Psicofarmacolog�a y terapia de conducta. Madrid: Fundaci�n Universidad-Empresa; 1996. Cerrar |
11. Klerman GL.. Ideological conflicts in integrating pharmacotherapy and psychotherapy. En: Beitman BD, Klerman GL, editors. Inegrating pharmacotherapy and psychotherapy. Washington, DC: American Psychiatric Press; 1991. p. 3-19. Cerrar |
11. Klerman GL.. Ideological conflicts in integrating pharmacotherapy and psychotherapy. En: Beitman BD, Klerman GL, editors. Inegrating pharmacotherapy and psychotherapy. Washington, DC: American Psychiatric Press; 1991. p. 3-19. Cerrar |
12. Caroll K.. Tratamientos combinados para la dependencia de sustancias. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
13. Holder HD, Longabaugh R, Miller WR, Rubonis AV.. The cost effectiveness of treatment for alcoholism: a first approximation. J. Stud Alcohol. 1991;52:517-40. 14. Miller WR, Hester RK.. Inpatient treatment for alcoholism: Who benefits? Am Psychol. 1986;41:794-805. 15. Budney AJ, Higgins ST.. A Community Reinforcement Approach: Treating Cocaine Addiction. Rockville, MD: Institute of Drug Abuse; 1998. 16. Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg F, Badger G.. Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry. 1993;150:763-9. [Medline] [Descargar cita] 17. Carroll K, Rousanvilee B, Kleber D.. Relapse prevention strategies for the treatment of cocaine abuse. Am J Drug Alcohol Abuse. 1991;17: 249-65. [Medline] [Descargar cita] 18. Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirth PW, Gawin FH.. One year follow-up of psychotherapy and pharmacotherapy for cocaine dependence: delayed emergence of psycotherapy effects. Arch Gen Psychiatry. 1994;51:989-98. [Medline] [Descargar cita] 19. Jones HE, Haug NA, Stitzer ML, Svikis DS.. Improving treatment outcomes for pregnant drug dependent women using low magnitude woucher incentives. Addict Behav. 2000;7:285-90. 20. Gruber K, Chutuape MA, Stitzer ML.. Reinforcement based intensive outpatient treatment for inner city opiate abusers: a short-tern evaluation. Drug Alcohol Depend. 2000;57:211-23. [Medline] [Descargar cita] 21. Baker T, Fox B, Hasselbald V.. Treating tobacco use and dependence. Clinical practice guideline. Rockville: US Department of Health and Human Services, Public Health Service; 2000. 22. Carroll K, Onken L.. Behavioural therapies for drug abuse. Am J Psychiatry. 2005;162:1452-60. [Medline] [Descargar cita] Cerrar |
23. Vocci F, Acri J, Elkashef A.. Medication development for addictive disorders: the state of the science. Am J Psychiatry. 2005;162:1423-40. Cerrar [Medline] [Descargar cita] |
24. O'Brien C.. Anticraving medications for relapse prevention: a possible class of psychoactive medications. Am J Psychiatry. 2005;162:1423-31. Cerrar [Medline] [Descargar cita] |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
12. Caroll K.. Tratamientos combinados para la dependencia de sustancias. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
25. Rounsaville BJ, Carroll KM.. Individual psychotherapy for drug abusers. En: Lowinsohn JH, Ruiz P, Millman RB, editors. Comprehensive textbook of substance abuse. 3th ed. New York: Williams & Wilkins; 1997. p. 430-9. Cerrar |
26. Schuckit MA.. Recent developments in the pharmacotherapy of alcohol dependence. J Consult Clin Psicol. 1996;64:669-76. Cerrar |
28. Sol� J.. Tratamiento del consumo de coca�na integrando psicoterapia y farmacoterapia. Adicciones. 2001;13 Supl 2:209-25. Cerrar |
29. Washton A.. Cocaine Addiction Treatment. Recovery and Relapse Prevention. New York: Norton; 1989. Cerrar |
30. Bobes J, Carre�o J, Guti�rrez C.. Beneficios con el uso del topiramato para el tratamiento de las adicciones. Actas Esp Psiquiatr. 2005;32: 299-306. Cerrar |
31. San L.. Gabapentina en la dependencia a coca�na. En: Rubio G, Jim�nez J, Casas M, editores. Avances en el tratamiento de las adicciones, bases cl�nicas para el uso de la gabapentina. Madrid: Ed Entheos; 2004. Cerrar |
18. Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirth PW, Gawin FH.. One year follow-up of psychotherapy and pharmacotherapy for cocaine dependence: delayed emergence of psycotherapy effects. Arch Gen Psychiatry. 1994;51:989-98. Cerrar [Medline] [Descargar cita] |
32. Carroll K, Ziedonis D, O'Malley S.. Pharmacologic interventions for abusers of alcohol and cocaine: a pilot study of disulfiran versus naltrexone. Am J Addict. 1993;2:77-9. Cerrar |
33. Carroll K, Nich C, Ball S, McCance E, Rousanville B.. Treatment of cocaine and alcohol dependence with psychoterapy and disulfiran. Addiction. 1998;93:713-28. Cerrar [Medline] [Descargar cita] |
16. Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg F, Badger G.. Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry. 1993;150:763-9. Cerrar [Medline] [Descargar cita] |
20. Gruber K, Chutuape MA, Stitzer ML.. Reinforcement based intensive outpatient treatment for inner city opiate abusers: a short-tern evaluation. Drug Alcohol Depend. 2000;57:211-23. Cerrar [Medline] [Descargar cita] |
34. O'Brien CP.. Recent developments in the pharmacotherapy of sustance abuse. J Consult Clin Psychol. 1996;64:677-86. Cerrar [Medline] [Descargar cita] |
19. Jones HE, Haug NA, Stitzer ML, Svikis DS.. Improving treatment outcomes for pregnant drug dependent women using low magnitude woucher incentives. Addict Behav. 2000;7:285-90. Cerrar |
20. Gruber K, Chutuape MA, Stitzer ML.. Reinforcement based intensive outpatient treatment for inner city opiate abusers: a short-tern evaluation. Drug Alcohol Depend. 2000;57:211-23. Cerrar [Medline] [Descargar cita] |
35. Sung S, Conry J.. Role of buprenorphine in the management of heroin addiction. Ann Pharmacotherapy. 2006;24. En prensa. Cerrar |
36. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD.. Disulfiram treatment for alcoholism. A veterans administation cooperative study. JAMA. 1986;256:1449-55. Cerrar [Medline] [Descargar cita] |
37. Azrin NH.. Improvements in the community-reinforcement approach to alcoholism. Behav Res Methods. 1976;14:339-48. Cerrar |
38. Allen JP, Litten RZ.. Techniques to enhance compliance with disulfiram. Alcohol Clin Exp Res. 1992;16:1035-41. Cerrar [Medline] [Descargar cita] |
39. Volpicelli JR, O'Brien CP, Alterman AL.. Naltrexone and the treatment of alcohol dependence. En: Reid LD, editor. Opioids, bulimia, and alcohol abuse and alcoholism. New York: Springer-Verlag; 1990. Cerrar |
40. Volpicelli JR, Rhines JS, Volpicelli LA, Alterman AL, O'Brien CP.. Naltrexone and alcohol dependence: Role of subject compliance. Arch Gen Psychiatry. 1997;54:737-42. Cerrar [Medline] [Descargar cita] |
12. Caroll K.. Tratamientos combinados para la dependencia de sustancias. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
41. De Witte P, Littleton J, Parot P, Koob G.. Neoroprotecctive and abstinence promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs. 2005;19:517-37. Cerrar [Medline] [Descargar cita] |
42. WHO Europe.. The treatment of tobacco dependence. Draft evidenced based recommendations for health care systems in Europe. London: WHO; 1999. Cerrar |
43. CNPT.. Comit� Nacional para la Prevenci�n del Tabaquismo. Gu�a de procedimientos para ayudar a los fumadores a dejar de fumar. Adicciones. 2001;13:211-6. Cerrar |
44. AHRQ.. Agency for Healthcare Research and Quality. Treating tobacco abuse and dependence. Rockville: US Department of Health and Human Services; 2000. Cerrar |
45. Hooney M, Hatsukani D.. Tratamientos combinados para la superaci�n del tabaquismo. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
46. Herrrero F, Moreno J.. Tratamientos combinados del tabaquismo: psicol�gicos y farmacol�gicos. Adiciones: Monogr�fico Tabaco. 2004;16 Supl 2:287-301. Cerrar |
47. Fr�as M, Pascual J.. Psicolog�a cl�nica basada en pruebas: efecto del tratamiento. Papeles del Psic�logo. 2003;85:11-8. Cerrar |
48. Beutler L.. Empirically Based Decision Making in Clinical Practice. Prevention & Treatment. 2000;3:article 27. Cerrar |
49. Wolf S, Grol S, Htchinson A.. Potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999;318:527-30. Cerrar |
50. Shekelle PG, Woolf SH, Eccles M.. Grimshaw J. Developing guidelines. BMJ. 1999;318:593-8. Cerrar |
50. Shekelle PG, Woolf SH, Eccles M.. Grimshaw J. Developing guidelines. BMJ. 1999;318:593-8. Cerrar |
51. Nutting PA, Beasley JW, Werner JJ.. Practice-Based research networks answer primary care questions. JAMA. 1999;281:686-8. Cerrar |
52. S�nchez-Herv�s E, Morales E, Tom�s V, Sanoguera M, Bosch C.. Psicoterapia y farmacoterapia en la dependencia a drogas: un estudio de seguimiento de seis meses. P�ster presentado al I Congreso Europeo de Trastornos Adictivos. Alicante: marzo 2003. Cerrar |
53. Meredith J, Lambert M, Drozd J.. Evaluaci�n de resultados cl�nicos en la pr�ctica. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
54. Burlingame GM, Lambert MJ, Reisinger CW, Neff J, Mosier J.. Pragmatics of tracking mental health outcomes in a managed care setting. J Ment Health Adm. 1995;22:26-236. Cerrar |
55. Newman FL, Ciarlo JA.. Criteria for selecting psychological instruments for treatment outcome assessments. En: Maruish ME, editor. The use of psychological testing for treatment planning and outcome assessment. Hillsdale, NJ: Erlbaum; 1994. p. 98-110. Cerrar |
66. Carroll KM.. Integrating psychotheraphy and pharmacotherapy to improve drug abuse outcomes. J Addic Behav. 1997;22:233-45. Cerrar |
67. Sammons M, Schmidt N.. Hacia un modelo psicol�gico de provisi�n de servicios farmacol�gicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
27. Labrador J, Echeburua E, Beco�a E.. Gu�a para la elecci�n de tratamientos psicol�gicos efectivos. Madrid: Ed. Dykinson; 2000. Cerrar |
68. Carroll KM, Rounsaville BJ.. Implications of recent research on psychotherapy for drug abuse. En: Edwards G, Strang J, Jaffe J H, editors. Drugs, alcohol, and tabaco: Making the science and policy connections. New York: Oxford University Press; 1993. p. 211-21. Cerrar |
10. De Pablo J.. Psicofarmacolog�a y terapia de conducta. Madrid: Fundaci�n Universidad-Empresa; 1996. Cerrar |
27. Labrador J, Echeburua E, Beco�a E.. Gu�a para la elecci�n de tratamientos psicol�gicos efectivos. Madrid: Ed. Dykinson; 2000. Cerrar |
69. S�nchez-Herv�s E.. Tratamientos psicol�gicos en adicciones: eficacia, limitaciones y propuestas para mejorar su implantaci�n. Papeles del Psic�logo. 2004;87:34-44. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
70. Richards T.. Partnership with patients: Patients want more than simply information, they need involvement, too. BMJ. 1998;316:85-6. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
71. Redelmeier DA, Rozin P, Kahneman D.. Understanding patients decisions: Cognitive and emotional perspectives. JAMA. 1993;270:72-6. Cerrar |
67. Sammons M, Schmidt N.. Hacia un modelo psicol�gico de provisi�n de servicios farmacol�gicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
1. Echeburua E.. Modificaci�n de conducta y psicolog�a cl�nica. Bilbao: Servicio de Publicaciones del Pa�s Vasco; 1993. Cerrar |
2. NIDA.. Principles of Drug Addiction Treatment. A Research-Based Guide. National Institute of Drug Abuse. Disponible en: http://www.nida. nih.gov/PODAT/PODATTindex.htlm; 1999. Cerrar |
3. NIDA.. Developing effective addiction treatments. Special supplement. Nida Notes. 2004;19:1. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
5. S�nchez-Herv�s E.. Tratamientos psicol�gicos emp�ricamente validados en drogodependencias. Ponencia presentada en el XXXVII Congreso Nacional de Socidrogalcohol. Ciudad Real; febrero 2005. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
6. Jacobson NS, Hollon SD.. Cognitive behavior therapy versus pharmacotherapy: Now that the jury�s returned its verdict, it�s time to present the rest of the evidence. J Consult Clin Psychol. 1996;64:295-304. Cerrar [Medline] [Descargar cita] |
7. Seligman ME.. The effectiveness of psychotherapy: The Consumer Reports Study. Am Psychol. 1995;50:965-74. Cerrar [Medline] [Descargar cita] |
8. Roberts G, Ogborne A, Leigh G, Adam L.. Mejores pr�cticas: alcoholismo y toxicoman�as, tratamiento y rehabilitaci�n. Office of alcohol, drugs and dependency issues. Health Canada: Minister of Public Work and Government Services; 1999. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. & nbsp;Cerrar |
9. Telch M, Bandura A, Vincguerra P, Agras W, Stout A.. Social demand and the congruence between self-efficacy and performance. Behav Ther. 1982;13:694-701. Cerrar |
10. De Pablo J.. Psicofarmacolog�a y terapia de conducta. Madrid: Fundaci�n Universidad-Empresa; 1996. Cerrar |
11. Klerman GL.. Ideological conflicts in integrating pharmacotherapy and psychotherapy. En: Beitman BD, Klerman GL, editors. Inegrating pharmacotherapy and psychotherapy. Washington, DC: American Psychiatric Press; 1991. p. 3-19. Cerrar |
11. Klerman GL.. Ideological conflicts in integrating pharmacotherapy and psychotherapy. En: Beitman BD, Klerman GL, editors. Inegrating pharmacotherapy and psychotherapy. Washington, DC: American Psychiatric Press; 1991. p. 3-19. Cerrar |
12. Caroll K.. Tratamientos combinados para la dependencia de sustancias. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
13. Holder HD, Longabaugh R, Miller WR, Rubonis AV.. The cost effectiveness of treatment for alcoholism: a first approximation. J. Stud Alcohol. 1991;52:517-40. 14. Miller WR, Hester RK.. Inpatient treatment for alcoholism: Who benefits? Am Psychol. 1986;41:794-805. 15. Budney AJ, Higgins ST.. A Community Reinforcement Approach: Treating Cocaine Addiction. Rockville, MD: Institute of Drug Abuse; 1998. 16. Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg F, Badger G.. Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry. 1993;150:763-9. [Medline] [Descargar cita] 17. Carroll K, Rousanvilee B, Kleber D.. Relapse prevention strategies for the treatment of cocaine abuse. Am J Drug Alcohol Abuse. 1991;17: 249-65. [Medline] [Descargar cita] 18. Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirth PW, Gawin FH.. One year follow-up of psychotherapy and pharmacotherapy for cocaine dependence: delayed emergence of psycotherapy effects. Arch Gen Psychiatry. 1994;51:989-98. [Medline] [Descargar cita] 19. Jones HE, Haug NA, Stitzer ML, Svikis DS.. Improving treatment outcomes for pregnant drug dependent women using low magnitude woucher incentives. Addict Behav. 2000;7:285-90. 20. Gruber K, Chutuape MA, Stitzer ML.. Reinforcement based intensive outpatient treatment for inner city opiate abusers: a short-tern evaluation. Drug Alcohol Depend. 2000;57:211-23. [Medline] [Descargar cita] 21. Baker T, Fox B, Hasselbald V.. Treating tobacco use and dependence. Clinical practice guideline. Rockville: US Department of Health and Human Services, Public Health Service; 2000. 22. Carroll K, Onken L.. Behavioural therapies for drug abuse. Am J Psychiatry. 2005;162:1452-60. [Medline] [Descargar cita] Cerrar |
23. Vocci F, Acri J, Elkashef A.. Medication development for addictive disorders: the state of the science. Am J Psychiatry. 2005;162:1423-40. Cerrar [Medline] [Descargar cita] |
24. O'Brien C.. Anticraving medications for relapse prevention: a possible class of psychoactive medications. Am J Psychiatry. 2005;162:1423-31. Cerrar [Medline] [Descargar cita] |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
12. Caroll K.. Tratamientos combinados para la dependencia de sustancias. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
25. Rounsaville BJ, Carroll KM.. Individual psychotherapy for drug abusers. En: Lowinsohn JH, Ruiz P, Millman RB, editors. Comprehensive textbook of substance abuse. 3th ed. New York: Williams & Wilkins; 1997. p. 430-9. Cerrar |
26. Schuckit MA.. Recent developments in the pharmacotherapy of alcohol dependence. J Consult Clin Psicol. 1996;64:669-76. Cerrar |
28. Sol� J.. Tratamiento del consumo de coca�na integrando psicoterapia y farmacoterapia. Adicciones. 2001;13 Supl 2:209-25. Cerrar |
29. Washton A.. Cocaine Addiction Treatment. Recovery and Relapse Prevention. New York: Norton; 1989. Cerrar |
30. Bobes J, Carre�o J, Guti�rrez C.. Beneficios con el uso del topiramato para el tratamiento de las adicciones. Actas Esp Psiquiatr. 2005;32: 299-306. Cerrar |
31. San L.. Gabapentina en la dependencia a coca�na. En: Rubio G, Jim�nez J, Casas M, editores. Avances en el tratamiento de las adicciones, bases cl�nicas para el uso de la gabapentina. Madrid: Ed Entheos; 2004. Cerrar |
18. Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirth PW, Gawin FH.. One year follow-up of psychotherapy and pharmacotherapy for cocaine dependence: delayed emergence of psycotherapy effects. Arch Gen Psychiatry. 1994;51:989-98. Cerrar [Medline] [Descargar cita] |
32. Carroll K, Ziedonis D, O'Malley S.. Pharmacologic interventions for abusers of alcohol and cocaine: a pilot study of disulfiran versus naltrexone. Am J Addict. 1993;2:77-9. Cerrar |
33. Carroll K, Nich C, Ball S, McCance E, Rousanville B.. Treatment of cocaine and alcohol dependence with psychoterapy and disulfiran. Addiction. 1998;93:713-28. Cerrar [Medline] [Descargar cita] |
16. Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg F, Badger G.. Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry. 1993;150:763-9. Cerrar [Medline] [Descargar cita] |
20. Gruber K, Chutuape MA, Stitzer ML.. Reinforcement based intensive outpatient treatment for inner city opiate abusers: a short-tern evaluation. Drug Alcohol Depend. 2000;57:211-23. Cerrar [Medline] [Descargar cita] |
34. O'Brien CP.. Recent developments in the pharmacotherapy of sustance abuse. J Consult Clin Psychol. 1996;64:677-86. Cerrar [Medline]< /A> [Descargar cita] |
19. Jones HE, Haug NA, Stitzer ML, Svikis DS.. Improving treatment outcomes for pregnant drug dependent women using low magnitude woucher incentives. Addict Behav. 2000;7:285-90. Cerrar |
20. Gruber K, Chutuape MA, Stitzer ML.. Reinforcement based intensive outpatient treatment for inner city opiate abusers: a short-tern evaluation. Drug Alcohol Depend. 2000;57:211-23. Cerrar [Medline] [Descargar cita] |
35. Sung S, Conry J.. Role of buprenorphine in the management of heroin addiction. Ann Pharmacotherapy. 2006;24. En prensa. Cerrar |
36. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD.. Disulfiram treatment for alcoholism. A veterans administation cooperative study. JAMA. 1986;256:1449-55. Cerrar [Medline] [Descargar cita] |
37. Azrin NH.. Improvements in the community-reinforcement approach to alcoholism. Behav Res Methods. 1976;14:339-48. Cerrar |
38. Allen JP, Litten RZ.. Techniques to enhance compliance with disulfiram. Alcohol Clin Exp Res. 1992;16:1035-41. Cerrar [Medline] [Descargar cita] |
39. Volpicelli JR, O'Brien CP, Alterman AL.. Naltrexone and the treatment of alcohol dependence. En: Reid LD, editor. Opioids, bulimia, and alcohol abuse and alcoholism. New York: Springer-Verlag; 1990. Cerrar |
40. Volpicelli JR, Rhines JS, Volpicelli LA, Alterman AL, O'Brien CP.. Naltrexone and alcohol dependence: Role of subject compliance. Arch Gen Psychiatry. 1997;54:737-42. Cerrar [Medline] [Descargar cita] |
12. Caroll K.. Tratamientos combinados para la dependencia de sustancias. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
41. De Witte P, Littleton J, Parot P, Koob G.. Neoroprotecctive and abstinence promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs. 2005;19:517-37. Cerrar [Medline] [Descargar cita] |
42. WHO Europe.. The treatment of tobacco dependence. Draft evidenced based recommendations for health care systems in Europe. London: WHO; 1999. Cerrar |
43. CNPT.. Comit� Nacional para la Prevenci�n del Tabaquismo. Gu�a de procedimientos para ayudar a los fumadores a dejar de fumar. Adicciones. 2001;13:211-6. Cerrar |
44. AHRQ.. Agency for Healthcare Research and Quality. Treating tobacco abuse and dependence. Rockville: US Department of Health and Human Services; 2000. Cerrar |
45. Hooney M, Hatsukani D.. Tratamientos combinados para la superaci�n del tabaquismo. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
46. Herrrero F, Moreno J.. Tratamientos combinados del tabaquismo: psicol�gicos y farmacol�gicos. Adiciones: Monogr�fico Tabaco. 2004;16 Supl 2:287-301. Cerrar |
47. Fr�as M, Pascual J.. Psicolog�a cl�nica basada en pruebas: efecto del tratamiento. Papeles del Psic�logo. 2003;85:11-8. Cerrar |
48. Beutler L.. Empirically Based Decision Making in Clinical Practice. Prevention & Treatment. 2000;3:article 27. Cerrar |
49. Wolf S, Grol S, Htchinson A.. Potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999;318:527-30. Cerrar |
50. Shekelle PG, Woolf SH, Eccles M.. Grimshaw J. Developing guidelines. BMJ. 1999;318:593-8. Cerrar |
50. Shekelle PG, Woolf SH, Eccles M.. Grimshaw J. Developing guidelines. BMJ. 1999;318:593-8. Cerrar |
51. Nutting PA, Beasley JW, Werner JJ.. Practice-Based research networks answer primary care questions. JAMA. 1999;281:686-8. Cerrar |
52. S�nchez-Herv�s E, Morales E, Tom�s V, Sanoguera M, Bosch C.. Psicoterapia y farmacoterapia en la dependencia a drogas: un estudio de seguimiento de seis meses. P�ster presentado al I Congreso Europeo de Trastornos Adictivos. Alicante: marzo 2003. Cerrar |
53. Meredith J, Lambert M, Drozd J.. Evaluaci�n de resultados cl�nicos en la pr�ctica. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
54. Burlingame GM, Lambert MJ, Reisinger CW, Neff J, Mosier J.. Pragmatics of tracking mental health outcomes in a managed care setting. J Ment Health Adm. 1995;22:26-236. Cerrar |
55. Newman FL, Ciarlo JA.. Criteria for selecting psychological instruments for treatment outcome assessments. En: Maruish ME, editor. The use of psychological testing for treatment planning and outcome assessment. Hillsdale, NJ: Erlbaum; 1994. p. 98-110. Cerrar |
66. Carroll KM.. Integrating psychotheraphy and pharmacotherapy to improve drug abuse outcomes. J Addic Behav. 1997;22:233-45. Cerrar |
67. Sammons M, Schmidt N.. Hacia un modelo psicol�gico de provisi�n de servicios farmacol�gicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
27. Labrador J, Echeburua E, Beco�a E.. Gu�a para la elecci�n de tratamientos psicol�gicos efectivos. Madrid: Ed. Dykinson; 2000. Cerrar |
68. Carroll KM, Rounsaville BJ.. Implications of recent research on psychotherapy for drug abuse. En: Edwards G, Strang J, Jaffe J H, editors. Drugs, alcohol, and tabaco: Making the science and policy connections. New York: Oxford University Press; 1993. p. 211-21. Cerrar |
10. De Pablo J.. Psicofarmacolog�a y terapia de conducta. Madrid: Fundaci�n Universidad-Empresa; 1996. Cerrar |
27. Labrador J, Echeburua E, Beco�a E.. Gu�a para la elecci�n de tratamientos psicol�gicos efectivos. Madrid: Ed. Dykinson; 2000. Cerrar |
69. S�nchez-Herv�s E.. Tratamientos psicol�gicos en adicciones: eficacia, limitaciones y propuestas para mejorar su implantaci�n. Papeles del Psic�logo. 2004;87:34-44. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
70. Richards T.. Partnership with patients: Patients want more than simply information, they need involvement, too. BMJ. 1998;316:85-6. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
71. Redelmeier DA, Rozin P, Kahneman D.. Understanding patients decisions: Cognitive and emotional perspectives. JAMA. 1993;270:72-6. Cerrar |
67. Sammons M, Schmidt N.. Hacia un modelo psicol�gico de provisi�n de servicios farmacol�gicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
1. Echeburua E.. Modificaci�n de conducta y psicolog�a cl�nica. Bilbao: Servicio de Publicaciones del Pa�s Vasco; 1993. Cerrar |
2. NIDA.. Principles of Drug Addiction Treatment. A Research-Based Guide. National Institute of Drug Abuse. Disponible en: http://www.nida. nih.gov/PODAT/PODATTindex.htlm; 1999. Cerrar |
3. NIDA.. Developing effective addiction treatments. Special supplement. Nida Notes. 2004;19:1. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
5. S�nchez-Herv�s E.. Tratamientos psicol�gicos emp�ricamente validados en drogodependencias. Ponencia presentada en el XXXVII Congreso Nacional de Socidrogalcohol. Ciudad Real; febrero 2005. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
6. Jacobson NS, Hollon SD.. Cognitive behavior therapy versus pharmacotherapy: Now that the jury�s returned its verdict, it�s time to present the rest of the evidence. J Consult Clin Psychol. 1996;64:295-304. Cerrar [Medline] [Descargar cita] |
7. Seligman ME.. The effectiveness of psychotherapy: The Consumer Reports Study. Am Psychol. 1995;50:965-74. Cerrar [Medline] [Descargar cita] |
8. Roberts G, Ogborne A, Leigh G, Adam L.. Mejores pr�cticas: alcoholismo y toxicoman�as, tratamiento y rehabilitaci�n. Office of alcohol, drugs and dependency issues. Health Canada: Minister of Public Work and Government Services; 1999. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
9. Telch M, Bandura A, Vincguerra P, Agras W, Stout A.. Social demand and the congruence between self-efficacy and performance. Behav Ther. 1982;13:694-701. Cerrar |
10. De Pablo J.. Psicofarmacolog�a y terapia de conducta. Madrid: Fundaci�n Universidad-Empresa; 1996. Cerrar |
11. Klerman GL.. Ideological conflicts in integrating pharmacotherapy and psychotherapy. En: Beitman BD, Klerman GL, editors. Inegrating pharmacotherapy and psychotherapy. Washington, DC: American Psychiatric Press; 1991. p. 3-19. Cerrar |
11. Klerman GL.. Ideological conflicts in integrating pharmacotherapy and psychotherapy. En: Beitman BD, Klerman GL, editors. Inegrating pharmacotherapy and psychotherapy. Washington, DC: American Psychiatric Press; 1991. p. 3-19. Cerrar |
12. Caroll K.. Tratamientos combinados para la dependencia de sustancias. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
13. Holder HD, Longabaugh R, Miller WR, Rubonis AV.. The cost effectiveness of treatment for alcoholism: a first approximation. J. Stud Alcohol. 1991;52:517-40. 14. Miller WR, Hester RK.. Inpatient treatment for alcoholism: Who benefits? Am Psychol. 1986;41:794-805. 15. Budney AJ, Higgins ST.. A Community Reinforcement Approach: Treating Cocaine Addiction. Rockville, MD: Institute of Drug Abuse; 1998. 16. Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg F, Badger G.. Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry. 1993;150:763-9. [Medline] [Descargar cita] 17. Carroll K, Rousanvilee B, Kleber D.. Relapse prevention strategies for the treatment of cocaine abuse. Am J Drug Alcohol Abuse. 1991;17: 249-65. [Medline] [Descargar cita] 18. Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirth PW, Gawin FH.. One year follow-up of psychotherapy and pharmacotherapy for cocaine dependence: delayed emergence of psycotherapy effects. Arch Gen Psychiatry. 1994;51:989-98. [Medline] [Descargar cita] 19. Jones H E, Haug NA, Stitzer ML, Svikis DS.. Improving treatment outcomes for pregnant drug dependent women using low magnitude woucher incentives. Addict Behav. 2000;7:285-90. 20. Gruber K, Chutuape MA, Stitzer ML.. Reinforcement based intensive outpatient treatment for inner city opiate abusers: a short-tern evaluation. Drug Alcohol Depend. 2000;57:211-23. [Medline] [Descargar cita] 21. Baker T, Fox B, Hasselbald V.. Treating tobacco use and dependence. Clinical practice guideline. Rockville: US Department of Health and Human Services, Public Health Service; 2000. 22. Carroll K, Onken L.. Behavioural therapies for drug abuse. Am J Psychiatry. 2005;162:1452-60. [Medline] [Descargar cita] Cerrar |
23. Vocci F, Acri J, Elkashef A.. Medication development for addictive disorders: the state of the science. Am J Psychiatry. 2005;162:1423-40. Cerrar [Medline] [Descargar cita] |
24. O'Brien C.. Anticraving medications for relapse prevention: a possible class of psychoactive medications. Am J Psychiatry. 2005;162:1423-31. Cerrar [Medline] [Descargar cita] |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
12. Caroll K.. Tratamientos combinados para la dependencia de sustancias. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
25. Rounsaville BJ, Carroll KM.. Individual psychotherapy for drug abusers. En: Lowinsohn JH, Ruiz P, Millman RB, editors. Comprehensive textbook of substance abuse. 3th ed. New York: Williams & Wilkins; 1997. p. 430-9. Cerrar |
26. Schuckit MA.. Recent developments in the pharmacotherapy of alcohol dependence. J Consult Clin Psicol. 1996;64:669-76. Cerrar |
28. Sol� J.. Tratamiento del consumo de coca�na integrando psicoterapia y farmacoterapia. Adicciones. 2001;13 Supl 2:209-25. Cerrar |
29. Washton A.. Cocaine Addiction Treatment. Recovery and Relapse Prevention. New York: Norton; 1989. Cerrar |
30. Bobes J, Carre�o J, Guti�rrez C.. Beneficios con el uso del topiramato para el tratamiento de las adicciones. Actas Esp Psiquiatr. 2005;32: 299-306. Cerrar |
31. San L.. Gabapentina en la dependencia a coca�na. En: Rubio G, Jim�nez J, Casas M, editores. Avances en el tratamiento de las adicciones, bases cl�nicas para el uso de la gabapentina. Madrid: Ed Entheos; 2004. Cerrar |
18. Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirth PW, Gawin FH.. One year follow-up of psychotherapy and pharmacotherapy for cocaine dependence: delayed emergence of psycotherapy effects. Arch Gen Psychiatry. 1994;51:989-98. Cerrar [Medline] [Descargar cita] |
32. Carroll K, Ziedonis D, O'Malley S.. Pharmacologic interventions for abusers of alcohol and cocaine: a pilot study of disulfiran versus naltrexone. Am J Addict. 1993;2:77-9. Cerrar |
33. Carroll K, Nich C, Ball S, McCance E, Rousanville B.. Treatment of cocaine and alcohol dependence with psychoterapy and disulfiran. Addiction. 1998;93:713-28. Cerrar [Medline] [Descargar cita] |
16. Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg F, Badger G.. Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry. 1993;150:763-9. Cerrar [Medline] [Descargar cita] |
20. Gruber K, Chutuape MA, Stitzer ML.. Reinforcement based intensive outpatient treatment for inner city opiate abusers: a short-tern evaluation. Drug Alcohol Depend. 2000;57:211-23. Cerrar [Medline] [Descargar cita] |
34. O'Brien CP.. Recent developments in the pharmacotherapy of sustance abuse. J Consult Clin Psychol. 1996;64:677-86. Cerrar [Medline] [Descargar cita] |
19. Jones HE, Haug NA, Stitzer ML, Svikis DS.. Improving treatment outcomes for pregnant drug dependent women using low magnitude woucher incentives. Addict Behav. 2000;7:285-90. Cerrar |
20. Gruber K, Chutuape MA, Stitzer ML.. Reinforcement based intensive outpatient treatment for inner city opiate abusers: a short-tern evaluation. Drug Alcohol Depend. 2000;57:211-23. Cerrar [Medline] [Descargar cita] |
35. Sung S, Conry J.. Role of buprenorphine in the management of heroin addiction. Ann Pharmacotherapy. 2006;24. En prensa. Cerrar |
36. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD.. Disulfiram treatment for alcoholism. A veterans administation cooperative study. JAMA. 1986;256:1449-55. Cerrar [Medline] [Descargar cita] |
37. Azrin NH.. Improvements in the community-reinforcement approach to alcoholism. Behav Res Methods. 1976;14:339-48. Cerrar |
38. Allen JP, Litten RZ.. Techniques to enhance compliance with disulfiram. Alcohol Clin Exp Res. 1992;16:1035-41. Cerrar [Medline] [Descargar cita] |
39. Volpicelli JR, O'Brien CP, Alterman AL.. Naltrexone and the treatment of alcohol dependence. En: Reid LD, editor. Opioids, bulimia, and alcohol abuse and alcoholism. New York: Springer-Verlag; 1990. Cerrar |
40. Volpicelli JR, Rhines JS, Volpicelli LA, Alterman AL, O'Brien CP.. Naltrexone and alcohol dependence: Role of subject compliance. Arch Gen Psychiatry. 1997;54:737-42. Cerrar [Medline] [Descargar cita] |
12. Caroll K.. Tratamientos combinados para la dependencia de sustancias. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
41. De Witte P, Littleton J, Parot P, Koob G.. Neoroprotecctive and abstinence promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs. 2005;19:517-37. Cerrar [Medline] [Descargar cita] |
42. WHO Europe.. The treatment of tobacco dependence. Draft evidenced based recommendations for health care systems in Europe. London: WHO; 1999. Cerrar |
43. CNPT.. Comit� Nacional para la Prevenci�n del Tabaquismo. Gu�a de procedimientos para ayudar a los fumadores a dejar de fumar. Adicciones. 2001;13:211-6. Cerrar |
44. AHRQ.. Agency for Healthcare Research and Quality. Treating tobacco abuse and dependence. Rockville: US Department of Health and Human Services; 2000. Cerrar |
45. Hooney M, Hatsukani D.. Tratamientos combinados para la superaci�n del tabaquismo. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
46. Herrrero F, Moreno J.. Tratamientos combinados del tabaquismo: psicol�gicos y farmacol�gicos. Adiciones: Monogr�fico Tabaco. 2004;16 Supl 2:287-301. Cerrar |
47. Fr�as M, Pascual J.. Psicolog�a cl�nica basada en pruebas: efecto del tratamiento. Papeles del Psic�logo. 2003;85:11-8. Cerrar |
48. Beutler L.. Empirically Based Decision Making in Clinical Practice. Prevention & Treatment. 2000;3:article 27. Cerrar |
49. Wolf S, Grol S, Htchinson A.. Potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999;318:527-30. Cerrar |
50. Shekelle PG, Woolf SH, Eccles M.. Grimshaw J. Developing guidelines. BMJ. 1999;318:593-8. Cerrar |
50. Shekelle PG, Woolf SH, Eccles M.. Grimshaw J. Developing guidelines. BMJ. 1999;318:593-8. Cerrar |
51. Nutting PA, Beasley JW, Werner JJ.. Practice-Based research networks answer primary care questions. JAMA. 1999;281:686-8. Cerrar |
52. S�nchez-Herv�s E, Morales E, Tom�s V, Sanoguera M, Bosch C.. Psicoterapia y farmacoterapia en la dependencia a drogas: un estudio de seguimiento de seis meses. P�ster presentado al I Congreso Europeo de Trastornos Adictivos. Alicante: marzo 2003. Cerrar |
53. Meredith J, Lambert M, Drozd J.. Evaluaci�n de resultados cl�nicos en la pr�ctica. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
54. Burlingame GM, Lambert MJ, Reisinger CW, Neff J, Mosier J.. Pragmatics of tracking mental health outcomes in a managed care setting. J Ment Health Adm. 1995;22:26-236. Cerrar |
55. Newman FL, Ciarlo JA.. Criteria for selecting psychological instruments for treatment outcome assessments. En: Maruish ME, editor. The use of psychological testing for treatment planning and outcome assessment. Hillsdale, NJ: Erlbaum; 1994. p. 98-110. Cerrar |
66. Carroll KM.. Integrating psychotheraphy and pharmacotherapy to improve drug abuse outcomes. J Addic Behav. 1997;22:233-45. Cerrar |
67. Sammons M, Schmidt N.. Hacia un modelo psicol�gico de provisi�n de servicios farmacol�gicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
27. Labrador J, Echeburua E, Beco�a E.. Gu�a para la elecci�n de tratamientos psicol�gicos efectivos. Madrid: Ed. Dykinson; 2000. Cerrar |
68. Carroll KM, Rounsaville BJ.. Implications of recent research on psychotherapy for drug abuse. En: Edwards G, Strang J, Jaffe J H, editors. Drugs, alcohol, and tabaco: Making the science and policy connections. New York: Oxford University Press; 1993. p. 211-21. Cerrar |
10. De Pablo J.. Psicofarmacolog�a y terapia de conducta. Madrid: Fundaci�n Universidad-Empresa; 1996. Cerrar |
27. Labrador J, Echeburua E, Beco�a E.. Gu�a para la elecci�n de tratamientos psicol�gicos efectivos. Madrid: Ed. Dykinson; 2000. Cerrar |
69. S�nchez-Herv�s E.. Tratamientos psicol�gicos en adicciones: eficacia, limitaciones y propuestas para mejorar su implantaci�n. Papeles del Psic�logo. 2004;87:34-44. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
70. Richards T.. Partnership with patients: Patients want more than simply information, they need involvement, too. BMJ. 1998;316:85-6. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
71. Redelmeier DA, Rozin P, Kahneman D.. Understanding patients decisions: Cognitive and emotional perspectives. JAMA. 1993;270:72-6. Cerrar |
67. Sammons M, Schmidt N.. Hacia un modelo psicol�gico de provisi�n de servicios farmacol�gicos. En: Sammons M, Schmidt N, editores. Tratamien tos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
1. Echeburua E.. Modificaci�n de conducta y psicolog�a cl�nica. Bilbao: Servicio de Publicaciones del Pa�s Vasco; 1993. Cerrar |
2. NIDA.. Principles of Drug Addiction Treatment. A Research-Based Guide. National Institute of Drug Abuse. Disponible en: http://www.nida. nih.gov/PODAT/PODATTindex.htlm; 1999. Cerrar |
3. NIDA.. Developing effective addiction treatments. Special supplement. Nida Notes. 2004;19:1. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
5. S�nchez-Herv�s E.. Tratamientos psicol�gicos emp�ricamente validados en drogodependencias. Ponencia presentada en el XXXVII Congreso Nacional de Socidrogalcohol. Ciudad Real; febrero 2005. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
6. Jacobson NS, Hollon SD.. Cognitive behavior therapy versus pharmacotherapy: Now that the jury�s returned its verdict, it�s time to present the rest of the evidence. J Consult Clin Psychol. 1996;64:295-304. Cerrar [Medline] [Descargar cita] |
7. Seligman ME.. The effectiveness of psychotherapy: The Consumer Reports Study. Am Psychol. 1995;50:965-74. Cerrar [Medline] [Descargar cita] |
8. Roberts G, Ogborne A, Leigh G, Adam L.. Mejores pr�cticas: alcoholismo y toxicoman�as, tratamiento y rehabilitaci�n. Office of alcohol, drugs and dependency issues. Health Canada: Minister of Public Work and Government Services; 1999. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
9. Telch M, Bandura A, Vincguerra P, Agras W, Stout A.. Social demand and the congruence between self-efficacy and performance. Behav Ther. 1982;13:694-701. Cerrar |
10. De Pablo J.. Psicofarmacolog�a y terapia de conducta. Madrid: Fundaci�n Universidad-Empresa; 1996. Cerrar |
11. Klerman GL.. Ideological conflicts in integrating pharmacotherapy and psychotherapy. En: Beitman BD, Klerman GL, editors. Inegrating pharmacotherapy and psychotherapy. Washington, DC: American Psychiatric Press; 1991. p. 3-19. Cerrar |
11. Klerman GL.. Ideological conflicts in integrating pharmacotherapy and psychotherapy. En: Beitman BD, Klerman GL, editors. Inegrating pharmacotherapy and psychotherapy. Washington, DC: American Psychiatric Press; 1991. p. 3-19. Cerrar |
12. Caroll K.. Tratamientos combinados para la dependencia de sustancias. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
13. Holder HD, Longabaugh R, Miller WR, Rubonis AV.. The cost effectiveness of treatment for alcoholism: a first approximation. J. Stud Alcohol. 1991;52:517-40. 14. Miller WR, Hester RK.. Inpatient treatment for alcoholism: Who benefits? Am Psychol. 1986;41:794-805. 15. Budney AJ, Higgins ST.. A Community Reinforcement Approach: Treating Cocaine Addiction. Rockville, MD: Institute of Drug Abuse; 1998. 16. Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg F, Badger G.. Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry. 1993;150:763-9. [Medline] [Descargar cita] 17. Carroll K, Rousanvilee B, Kleber D.. Relapse prevention strategies for the treatment of cocaine abuse. Am J Drug Alcohol Abuse. 1991;17: 249-65. [Medline] [Descargar cita] 18. Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirth PW, Gawin FH.. One year follow-up of psychotherapy and pharmacotherapy for cocaine dependence: delayed emergence of psycotherapy effects. Arch Gen Psychiatry. 1994;51:989-98. [Medline] [Descargar cita] 19. Jones HE, Haug NA, Stitzer ML, Svikis DS.. Improving treatment outcomes for pregnant drug dependent women using low magnitude woucher incentives. Addict Behav. 2000;7:285-90. 20. Gruber K, Chutuape MA, Stitzer ML.. Reinforcement based intensive outpatient treatment for inner city opiate abusers: a short-tern evaluation. Drug Alcohol Depend. 2000;57:211-23. [Medline] [Descargar cita] 21. Baker T, Fox B, Hasselbald V.. Treating tobacco use and dependence. Clinical practice guideline. Rockville: US Department of Health and Human Services, Public Health Service; 2000. 22. Carroll K, Onken L.. Behavioural therapies for drug abuse. Am J Psychiatry. 2005;162:1452-60. [Medline] [Descargar cita] Cerrar |
23. Vocci F, Acri J, Elkashef A.. Medication development for addictive disorders: the state of the science. Am J Psychiatry. 2005;162:1423-40. Cerrar [Medline] [Descargar cita] |
24. O'Brien C.. Anticraving medications for relapse prevention: a possible class of psychoactive medications. Am J Psychiatry. 2005;162:1423-31. Cerrar [Medline] [Descargar cita] |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
12. Caroll K.. Tratamientos combinados para la dependencia de sustancias. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
25. Rounsaville BJ, Carroll KM.. Individual psychotherapy for drug abusers. En: Lowinsohn JH, Ruiz P, Millman RB, editors. Comprehensive textbook of substance abuse. 3th ed. New York: Williams & Wilkins; 1997. p. 430-9. Cerrar |
26. Schuckit MA.. Recent developments in the pharmacotherapy of alcohol dependence. J Consult Clin Psicol. 1996;64:669-76. Cerrar |
28. Sol� J.. Tratamiento del consumo de coca�na integrando psicoterapia y farmacoterapia. Adicciones. 2001;13 Supl 2:209-25. Cerrar |
29. Washton A.. Cocaine Addiction Treatment. Recovery and Relapse Prevention. New York: Norton; 1989. Cerrar |
30. Bobes J, Carre�o J, Guti�rrez C.. Beneficios con el uso del topiramato para el tratamiento de las adicciones. Actas Esp Psiquiatr. 2005;32: 299-306. Cerrar |
31. San L.. Gabapentina en la dependencia a coca�na. En: Rubio G, Jim�nez J, Casas M, editores. Avances en el tratamiento de las adicciones, bases cl�nicas para el uso de la gabapentina. Madrid: Ed Entheos; 2004. Cerrar |
18. Carroll KM, Rounsaville BJ, Nich C, Gordon LT, Wirth PW, Gawin FH.. One year follow-up of psychotherapy and pharmacotherapy for cocaine dependence: delayed emergence of psycotherapy effects. Arch Gen Psychiatry. 1994;51:989-98. Cerrar [Medline] [Descargar cita] |
32. Carroll K, Ziedonis D, O'Malley S.. Pharmacologic interventions for abusers of alcohol and cocaine: a pilot study of disulfiran versus naltrexone. Am J Addict. 1993;2:77-9. Cerrar |
33. Carroll K, Nich C, Ball S, McCance E, Rousanville B.. Treatment of cocaine and alcohol dependence with psychoterapy and disulfiran. Addiction. 1998;93:713-28. Cerrar [Medline] [Descargar cita] |
16. Higgins ST, Budney AJ, Bickel WK, Hughes JR, Foerg F, Badger G.. Achieving cocaine abstinence with a behavioral approach. Am J Psychiatry. 1993;150:763-9. Cerrar [Medline] [Descargar cita] |
20. Gruber K, Chutuape MA, Stitzer ML.. Reinforcement based intensive outpatient treatment for inner city opiate abusers: a short-tern evaluation. Drug Alcohol Depend. 2000;57:211-23. Cerrar [Medline] [Descargar cita] |
34. O'Brien CP.. Recent developments in the pharmacotherapy of sustance abuse. J Consult Clin Psychol. 1996;64:677-86. Cerrar [Medline] [Descargar cita] |
19. Jones HE, Haug NA, Stitzer ML, Svikis DS.. Improving treatment outcomes for pregnant drug dependent women using low magnitude woucher incentives. Addict Behav. 2000;7:285-90. Cerrar |
20. Gruber K, Chutuape MA, Stitzer ML.. Reinforcement based intensive outpatient treatment for inner city opiate abusers: a short-tern evaluation. Drug Alcohol Depend. 2000;57:211-23. Cerrar [Medline] [Descargar cita] |
35. Sung S, Conry J.. Role of buprenorphine in the management of heroin addiction. Ann Pharmacotherapy. 2006;24. En prensa. Cerrar |
36. Fuller RK, Branchey L, Brightwell DR, Derman RM, Emrick CD.. Disulfiram treatment for alcoholism. A veterans administation cooperative study. JAMA. 1986;256:1449-55. Cerrar [Medline] [Descargar cita] |
37. Azrin NH.. Improvements in the community-reinforcement approach to alcoholism. Behav Res Methods. 1976;14:339-48. Cerrar |
38. Allen JP, Litten RZ.. Techniques to enhance compliance with disulfiram. Alcohol Clin Exp Res. 1992;16:1035-41. Cerrar [Medline] [Descargar cita] |
39. Volpicelli JR, O'Brien CP, Alterman AL.. Naltrexone and the treatment of alcohol dependence. En: Reid LD, editor. Opioids, bulimia, and alcohol abuse and alcoholism. New York: Springer-Verlag; 1990. Cerrar |
40. Volpicelli JR, Rhines JS, Volpicelli LA, Alterman AL, O'Brien CP.. Naltrexone and alcohol dependence: Role of subject compliance. Arch Gen Psychiatry. 1997;54:737-42. Cerrar [Medline] [Descargar cita] |
12. Caroll K.. Tratamientos combinados para la dependencia de sustancias. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
41. De Witte P, Littleton J, Parot P, Koob G.. Neoroprotecctive and abstinence promoting effects of acamprosate: elucidating the mechanism of action. CNS Drugs. 2005;19:517-37. Cerrar [Medline] [Descargar cita] |
42. WHO Europe.. The treatment of tobacco dependence. Draft evidenced based recommendations for health care systems in Europe. London: WHO; 1999. Cerrar |
43. CNPT.. Comit� Nacional para la Prevenci�n del Tabaquismo. Gu�a de procedimientos para ayudar a los fumadores a dejar de fumar. Adicciones. 2001;13:211-6. Cerrar |
44. AHRQ.. Agency for Healthcare Research and Quality. Treating tobacco abuse and dependence. Rockville: US Department of Health and Human Services; 2000. Cerrar |
45. Hooney M, Hatsukani D.. Tratamientos combinados para la superaci�n del tabaquismo. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
46. Herrrero F, Moreno J.. Tratamientos combinados del tabaquismo: psicol�gicos y farmacol�gicos. Adiciones: Monogr�fico Tabaco. 2004;16 Supl 2:287-301. Cerrar |
47. Fr�as M, Pascual J.. Psicolog�a cl�nica basada en pruebas: efecto del tratamiento. Papeles del Psic�logo. 2003;85:11-8. Cerrar |
48. Beutler L.. Empirically Based Decision Making in Clinical Practice. Prevention & Treatment. 2000;3:article 27. Cerrar |
49. Wolf S, Grol S, Htchinson A.. Potential benefits, limitations, and harms of clinical guidelines. BMJ. 1999;318:527-30. Cerrar |
50. Shekelle PG, Woolf SH, Eccles M.. Grimshaw J. Developing guidelines. BMJ. 1999;318:593-8. Cerrar |
50. Shekelle PG, Woolf SH, Eccles M.. Grimshaw J. Developing guidelines. BMJ. 1999;318:593-8. Cerrar |
51. Nutting PA, Beasley JW, Werner JJ.. Practice-Based research networks answer primary care questions. JAMA. 1999;281:686-8. Cerrar |
52. S�nchez-Herv�s E, Morales E, Tom�s V, Sanoguera M, Bosch C.. Psicoterapia y farmacoterapia en la dependencia a drogas: un estudio de seguimiento de seis meses. P�ster presentado al I Congreso Europeo de Trastornos Adictivos. Alicante: marzo 2003. Cerrar |
53. Meredith J, Lambert M, Drozd J.. Evaluaci�n de resultados cl�nicos en la pr�ctica. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
54. Burlingame GM, Lambert MJ, Reisinger CW, Neff J, Mosier J.. Pragmatics of tracking mental health outcomes in a managed care setting. J Ment Health Adm. 1995;22:26-236. Cerrar |
55. Newman FL, Ciarlo JA.. Criteria for selecting psychological instruments for treatment outcome assessments. En: Maruish ME, editor. The use of psychological testing for treatment planning and outcome assessment. Hillsdale, NJ: Erlbaum; 1994. p. 98-110. Cerrar |
66. Carroll KM.. Integrating psychotheraphy and pharmacotherapy to improve drug abuse outcomes. J Addic Behav. 1997;22:233-45. Cerrar |
67. Sammons M, Schmidt N.. Hacia un modelo psicol�gico de provisi�n de servicios farmacol�gicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
27. Labrador J, Echeburua E, Beco�a E.. Gu�a para la elecci�n de tratamientos psicol�gicos efectivos. Madrid: Ed. Dykinson; 2000. Cerrar |
68. Carroll KM, Rounsaville BJ.. Implications of recent research on psychotherapy for drug abuse. En: Edwards G, Strang J, Jaffe J H, editors. Drugs, alcohol, and tabaco: Making the science and policy connections. New York: Oxford University Press; 1993. p. 211-21. Cerrar |
10. De Pablo J.. Psicofarmacolog�a y terapia de conducta. Madrid: Fundaci�n Universidad-Empresa; 1996. Cerrar |
27. Labrador J, Echeburua E, Beco�a E.. Gu�a para la elecci�n de tratamientos psicol�gicos efectivos. Madrid: Ed. Dykinson; 2000. Cerrar |
69. S�nchez-Herv�s E.. Tratamientos psicol�gicos en adicciones: eficacia, limitaciones y propuestas para mejorar su implantaci�n. Papeles del Psic�logo. 2004;87:34-44. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
70. Richards T.. Partnership with patients: Patients want more than simply information, they need involvement, too. BMJ. 1998;316:85-6. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
71. Redelmeier DA, Rozin P, Kahneman D.. Understanding patients decisions: Cognitive and emotional perspectives. JAMA. 1993;270:72-6. Cerrar |
67. Sammons M, Schmidt N.. Hacia un modelo psicol�gico de provisi�n de servicios farmacol�gicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
4. Sammons M.. Tratamientos combinados en los trastornos mentales: dilemas cl�nicos. En: Sammons M, Schmidt N, editores. Tratamientos combinados de los trastornos mentales: una gu�a de intervenciones psicol�gicas y farmacol�gicas. Bilbao: DDB; 2004. Cerrar |
1. Rosenthal NE, Sack DA, Gillin JC, Lewy AJ, Goodwin FK, Davenport Y, et al.. Seasonal affective disorder: a description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiat. 1984;41:72-80. [Medline] [Descargar cita] 2. Magnusson A.. An overview of epidemiological studies on seasonal affective disorder. Acta Psychiatrica Scandinavica. 2000;101:176-84. [Medline] [Descargar cita] 3. Ozaki N, Ono Y, Ito A, Rosenthal, NE.. Prevalence of seasonal dificulties in mood and behavior among Japanese civil servants. Am J Psychiatry. 1995;152:1225. [Medline] [Descargar cita] Cerrar |
4. Carskadon MA, Acebo C.. Parental reports of seasonal mood and behavior changes in children. J Am Acad Child Adolesc Psychiatry. 1993;32:264-9. [Medline] [Descargar cita] 5. Swedo SE, Pleeter JD, Richter DM, et al.. Rates of seasonal affective disorder in children and adolescents. Am J Psych. 1995;152: 1016-9. 6. Low K, Fleissner J.. Seasonal affective disorder in college students: prevalence and latitude. J Am Coll Health. 1998;47:135-7. [Medline] [Descargar cita] Cerrar |
2. Magnusson A.. An overview of epidemiological studies on seasonal affective disorder. Acta Psychiatrica Scandinavica. 2000;101:176-84. Cerrar [Medline] [Descargar cita] |
7. Mersch PP, Middendorp HM, Bouhuys AL, Beersma DG, Van den Hoofdakker RH.. The prevalence of seasonal affective disorder in the netherlands: a prospective and retrospective study of seasonal mood variation in the general population. Biol Psychiatry. 1999;45:1013-22. Cerrar [Medline] [Descargar cita] |
8. Sakamoto K, Nakadaira S, Kamo K, Kamo T, Takahashi K.. A longitudinal follow-up study of seasonal affective disorder. Am J Psychiatry. 1995;152:862-8. Cerrar [Medline] [Descargar cita] |
1. Rosenthal NE, Sack DA, Gillin JC, Lewy AJ, Goodwin FK, Davenport Y, et al.. Seasonal affective disorder: a description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiat. 1984;41:72-80. Cerrar [Medline] [Descargar cita] |
9. Krauchi K, Wirz-Justice A, Graw P.. High intake of sweets late in the day predicts a rapid and persistent response to light therapy in winter depression. Psychiatr Res. 1993;46:107-17. Cerrar |
10. Wirz-Justice A, Graw P, Kr�uchi K, Wacker HR.. Seasonality in affective disorders in Switzerland. Acta Psychiatrica Scandinavica. 2003;108 Suppl 418:92-5. Cerrar |
11. Allen JM, Lam RW, Remick RA, Sadovnick AD.. Depressive symptoms and family history in seasonal and nonseasonal mood disorders. Am J Psychiatry. 1993;150:443-8. Cerrar [Medline] [Descargar cita] |
11. Allen JM, Lam RW, Remick RA, Sadovnick AD.. Depressive symptoms and family history in seasonal and nonseasonal mood disorders. Am J Psychiatry. 1993;150:443-8. Cerrar [Medline] [Descargar cita] |
12. Thal�n BE, Kjellman BF, Morkrid L, Wetterbeg L.. Seasonal and non-seasonal depression: a comparison of clinical characteristics in Swedish patients. Eur Arch Psychiatry Clin Neurosci. 1995;245:101-8. Cerrar [Medline] [Descargar cita] |
13. Garvey MJ, Wesner R, Godes M.. Comparison of seasonal and nonseasonal affective disorders. Am J Psychiatry. 1988;145:100-2. Cerrar [Medline] [Descargar cita] |
14. Tam EM, Lam RW, Robertson HA, Stewart JN, Yatham LN, Zis AP.. Atypical depressive symptoms in seasonal and non-seasonal mood disorders. J Affect Dis. 1997;44:39-44. Cerrar [Medline] [Descargar cita] |
11. Allen JM, Lam RW, Remick RA, Sadovnick AD.. Depressive symptoms and family history in seasonal and nonseasonal mood disorders. Am J Psychiatry. 1993;150:443-8. Cerrar [Medline] [Descargar cita] |
15. Boyce P, Parker G.. Seasonal affective disorder in the southern hemisphere. Am J Psychiatry. 1988;145:96-9. Cerrar [Medline] [Descargar cita] |
16. Lingjaerde O, Reichborn-Kjennerud T.. Characteristics of winter depression in the Oslo area (60 degrees N). Acta Psychiatr Scand. 1993;88:111-20. Cerrar [Medline] [Descargar cita] |
17. Rosenthal NE, Carpenter CJ, James SP, Parry BL, Rogers SL, Wehr TA.. Seasonal affective disorder in children and adolescents. Am J Psychiatry. 1986;143:356-8. Cerrar [Medline] [Descargar cita] |
18. Thompson C, Isaacs G.. Seasonal affective disorder--a British sample symptomatology in relation to mode of referral and diagnostic subtype. J Affect Dis. 1988;14:1-12. Cerrar [Medline] [Descargar cita] |
19. Lam RW, Buchanan A, Remick RA.. Seasonal affective disorder�a Canadian sample. Ann Clin Psychiatry. 1989;1:241-5. Cerrar |
11. Allen JM, Lam RW, Remick RA, Sadovnick AD.. Depressive symptoms and family history in seasonal and nonseasonal mood disorders. Am J Psychiatry. 1993;150:443-8. Cerrar [Medline] [Descargar cita] |
20. White DM, Lewy AJ, Sack RL, Blood ML, Wesche DL.. Is winter depression a bipolar disorder? Compr Psychiatry. 1990;31:196-204. Cerrar |
20. White DM, Lewy AJ, Sack RL, Blood ML, Wesche DL.. Is winter depression a bipolar disorder? Compr Psychiatry. 1990;31:196-204. Cerrar |
21. Sasaki T, Sakamoto K, Akaho R, Nakajima T, Takahashi K.. Familial transmission of seasonal changes in sleep and eating function in the general population. Psychiatry Res. 1998;81:211-7. Cerrar [Medline] [Descargar cita] |
22. Stamenkovic M, Aschauer HN, Riederer F, Schindler SD, Leisch F, Resinger E, et al.. Study of family history in seasonal affective disorder. Neuropsychobiology. 2001;44:65-9. Cerrar [Medline] [Descargar cita] |
23. Lewy AJ, Wehr TA, Goodwin FK, Newsome DA, Markey SP.. Light suppresses melatonin secretion in humans. Science. 1980;210: 1267-9. Cerrar [Medline] [Descargar cita] |
24. Lewy AJ, Sack RL, Singer CM, White DM.. The phase shift hypothesis for bright light's therapeutic mechanism of action: theoretical considerations and experimental evidence. Psychopharmacol. 1987;23:349-53. Cerrar |
1. Rosenthal NE, Sack DA, Gillin JC, Lewy AJ, Goodwin FK, Davenport Y, et al.. Seasonal affective disorder: a description of the syndrome and preliminary findings with light therapy. Arch Gen Psychiat. 1984;41:72-80. Cerrar [Medline] [Descargar cita] |
25. Rosenthal NE, Sack DA, Carpenter CJ, Parry BL, Mendelson WB, Wehr TA.. Antidepressant effects of light in seasonal affective disorder. Amer J Psychiat. 1985;142:606. Cerrar [Medline] [Descargar cita] |
26. Wehr TA, Jacobsen FM, Sack DA, Arendt J, Tamarkin L, Rosenthal NE.. Phototherapy of seasonal affective disorder: time of day and suppression of melatonin are not critical for antidepressant effects. Arch Gen Psychiat. 1986;43:870-5. Cerrar [Medline] [Descargar cita] |
27. Jacobsen FM, Sack DA, Wehr TA, Rogers S, Rosenthal NE.. Neuroendocrine responses to 5-hydroxytryptophan in seasonal affective disorder. Arch Gen Psychiat. 1987;44:1086-91. Cerrar [Medline] [Descargar cita] |
28. Rosenthal NE, Sack DA, Jacobsen FM, James SP, Parry BL, Arendt J, et al.. Melatonin in seasonal affective disorder and phototherapy. J. Neural Trans. 1986;21 Suppl: 257-67. Cerrar |
29. Espiritu RC, Kripke DF, Ancoli-Israel S, Mowen MA, Mason WJ, Fell RL, et al.. Low illumination experienced by San Diego adults: association with atypical depressive symptoms. Biol Psychiatry. 1994;35:403-7. Cerrar [Medline] [Descargar cita] |
30. Kral A.. The role of pineal gland in circadian rhythms regulation. Bratisl Lek Listy. 1994;95:295-303. Cerrar [Medline] [Descargar cita] |
31. Cassone VM, Warren WS, Brooks DS, Lu J.. Melatonin, the pineal gland and circadian rhythms. J Biol Rhythms. 1993;8 Suppl:73-81. Cerrar |
32. Rosenthal NE, Jacobsen FM, Sack DA, Arendt J, James SP, Parry BL, et al.. Atenolol in seasonal affective disorder: a test of the melatonin hypothesis. Am J Psychiat. 1988;145:52-6. Cerrar [Medline] [Descargar cita] |
33. Lewy AJ, Sack RL, Millar LS, Hoban TM.. Antidepressant and circadian phase-shifting effects of light. Science. 1987;235:352-4. Cerrar [Medline] [Descargar cita] |
34. Benabarre A, Reinares M, Vieta E.. Fisiopatolog�a del viraje en los trastornos bipolares. Monogr Psiquiatr. 2000;12:5-13. Cerrar |
30. Kral A.. The role of pineal gland in circadian rhythms regulation. Bratisl Lek Listy. 1994;95:295-303. Cerrar [Medline] [Descargar cita] |
35. Aschoff J.. Handbook of behavioral neurobiology. Vol 4, Biological Rhythms. New York: Plenum; 1981. Cerrar |
36. Lacoste V, Wirz-Justice A.. Seasonal variation in normal subjects: an update of variables current in depression research. En: Rosenthal NE, Blear MC, editores. Seasonal affective disorders and phototherapy. New York: The Guildford Press; 1989. p. 167-229. Cerrar |
37. Carlsson A, Svennerholm L, Winblad B.. Seasonal and circadian monoamine variations in human brains examined post-mortem. Acta Psychiat Scand. 1980;61:75-85. Cerrar |
38. Jouvet M.. Biogenic amines and the states of the sleep. Science. 1969;163:32-41. [Medline] [Descargar cita] 39. Stunkard AJ.. Obesity. Philadelphia: WB Saunders; 1980. 40. Wurtman J, Wurtman R.. Human obesity. Ann N Y Acad Sci. 1987;499:343-8. Cerrar |
41. Fernstrom JD.. Food-induced changes in brain serotonin synthesis: Is there a relationship to appetite for specific macronutrients? Appetite. 1987;8:163-82. Cerrar |
42. Reichlin S.. Neuroendocrinology. En: Williams RH, editor. Texbook of endocrinology. Philadelphia: WB Saunders; 1981. p. 616-7. Cerrar |
43. Coiro V, Volpi R, Marchesi C, De Ferri A, Davoli C, Caffarra P, et al.. Abnormal serotonergic control of prolactin and cortisol secretion in patients with seasonal affective disorder. Psychoneuroendocrinology. 1993;18:551-6. Cerrar [Medline] [Descargar cita] |
44. Yatham LN, Michalon M.. Hormonal responses to d-fenfluramine challenge are not blunted in seasonal affective disorder. Psychoneuroendocrinology. 1995;20:433-8. Cerrar [Medline] [Descargar cita] |
45. Monteleone P, Bortolotti F, Orazzo C, Serino I, Maj M.. Differences between morning and afternoon hormonal responses to d-fenfluramine in healthy humans. Psychoneuroendocrinology. 1997;22:79-87. Cerrar [Medline] [Descargar cita] |
46. Jacobsen FM, Mueller EA, Sack DA, Rosenthal NE.. Subjective and psysiological responses of SAD patients and controls to intravenous m-CPP. Paper presented at the 42nd annual meeting of the Society of Biological Psychiatry; Chicago, 1987. Cerrar |
47. Joseph-Vanderpool JR, Jacobsen FM, Murphy DL, Hill JL, Rosenthal NE.. Seasonal variation in behavioral responses to m-CPP in patients with seasonal affective disorder and controls. Biol Psychiatry. 1993;33:496-504. Cerrar [Medline] [Descargar cita] |
48. O'Rourke DA, Wurtman JJ, Brzezinski A, Nader TA, Chef B.. Serotonin implicated in the etiology of seasonal affective disorder. Psychopharmacol Bull. 1987;23:358-9. Cerrar [Medline] [Descargar cita] |
49. Lam RW, Zis AP, Grewal A, Delgado PL, Charney DS, Cristal JH.. Effects of rapid tryptophan depletion in patients with seasonal affective disorder in remission after light therapy. Arch Gen Psychiatry. 1996;53:41-4. Cerrar [Medline] [Descargar cita] |
50. Sz�d�czky E, Falus A, Arat� M, N�meth A, Tesz�ri G, Moussong-K�v�cs E.. Phototherapy increases platelet 3Himipramine binding in patients with winter depression. J Affect Disord. 1989;16:121-5. Cerrar [Medline] [Descargar cita] |
51. Mellerup ET, Erebo I, Molin J, Plenge P, Dam H.. Platelet paroxetine binding and light therapy in winter depression. J Affect Dis. 1993;29:11-5. Cerrar [Medline] [Descargar cita] |
51. Mellerup ET, Erebo I, Molin J, Plenge P, Dam H.. Platelet paroxetine binding and light therapy in winter depression. J Affect Dis. 1993;29:11-5. Cerrar [Medline] [Descargar cita] |
52. Ruhrmann S, Kasper S, Rao ML, M�ller HJ.. 3-himipramine binding and light therapy in seasonal affective disorder. Biol Psychiatry. 1991;29. Abstracts 5th World Congress Biol Psychiatry; 204S. Cerrar |
27. Jacobsen FM, Sack DA, Wehr TA, Rogers S, Rosenthal NE.. Neuroendocrine responses to 5-hydroxytryptophan in seasonal affective disorder. Arch Gen Psychiat. 1987;44:1086-91. Cerrar [Medline] [Descargar cita] |
34. Benabarre A, Reinares M, Vieta E.. Fisiopatolog�a del viraje en los trastornos bipolares. Monogr Psiquiatr. 2000;12:5-13. Cerrar |
53. Rudorfer MV, Skwerer RG, Rosenthal NE.. Biogenic amines in seasonal affective disorder: effects of light therapy. Psychiatry Res. 1993;46:19-28. Cerrar [Medline] [Descargar cita] |
53. Rudorfer MV, Skwerer RG, Rosenthal NE.. Biogenic amines in seasonal affective disorder: effects of light therapy. Psychiatry Res. 1993;46:19-28. Cerrar [Medline] [Descargar cita] |
54. Golden RN, Markey SP, Risby ED, Rudorfer MV, Cowdry RW, Potter WZ.. Antidepressants reduce whole-body norepinephrine turnover while enhacing 6-hydroxymelatonin output. Arch Gen Psychiatry. 1988;45:150-4. Cerrar [Medline] [Descargar cita] |
55. Linnoila M, Karoum F, Calil HM, Kopin IJ, Potter WZ.. Alteration of norepinephrine metabolism with desipramine and zimelidine in depressed patients. Arch Gen Psychiatry. 1982;39:1025-8. Cerrar [Medline] [Descargar cita] |
56. Anderson JL, Vasile RG, Mooney JJ, Bloomingdale KL, Samson JA, Schildkraut JJ.. Changes in norepinephrine output following light therapy for fall/winter seasonal depression. Biol Psychiatry. 1992;32:700-4. Cerrar [Medline] [Descargar cita] |
57. Jimerson DC, Post RM.. Psychomotor stimulants and dopamine agonists in depression. En: Post RM, Ballenger JC, editores. Neurobiology of mood disorders. Baltimore: Williams & Wilkins; 1984. p. 619-20. Cerrar |
58. Depue RA, Arbisi P, Spoont MR, Leon A, Ainsworth B.. Dopamine functioning in the behavioral facilitation system and seasonal variation in behavior: normal population and clinical studies. En: Rosenthal NE, Blehar MC, editores. Seasonal affective disorders & phototherapy. New York: The Guildford Press; 1989. Cerrar |
46. Jacobsen FM, Mueller EA, Sack DA, Rosenthal NE.. Subjective and psysiological responses of SAD patients and controls to intravenous m-CPP. Paper presented at the 42nd annual meeting of the Society of Biological Psychiatry; Chicago, 1987. Cerrar |
59. Oren DA, Levendosky AA, Kasper S, Duncan CC, Rosenthal NE.. Circadian profiles of cortisol, prolactin, and thyrotropin in seasonal affective disorder. Biol Psychiatry. 1996;39:157-70. Cerrar [Medline] [Descargar cita] |
60. Neumeister A, Willeit M, Praschak-Rieder N, Asenbaum S, Stastny J, Hilger E, et al. Dopamine transporter availability in symptomatic depressed patients with seasonal affective disorder and healthy controls. Psychol Med. 2001;31:1467-73. Cerrar [Medline] [Descargar cita] |
61. Skwerer RG, Jacobsen FM, Duncan CC, Nelly DA, Sack DA, Tamarkin L, et al.. Neurobiology of seasonal affective disorder and phototherapy. En: Rosenthal NE, Blehar MC, editores. Seasonal affective disorders & phototherapy. New York: The Guildford Press; 1989. Cerrar |
34. Benabarre A, Reinares M, Vieta E.. Fisiopatolog�a del viraje en los trastornos bipolares. Monogr Psiquiatr. 2000;12:5-13. Cerrar |
62. Bunney W, Kopanda R, Murphy D.. Sleep and behavioral changes possibly reflecting central receptor hypersensitivity following catecholamine synthesis inhibition in man. Acta Psychiatr Scand. 1977;56:189-203. Cerrar [Medline] [Descargar cita] |
63. Gold PW, Kling MA, Khan I, Cal�brese JR, Kalogresas K, Post RM, et al.. Corticotropin releasing hormone: relevance to normal physiology and the pathophysiology and differential diagnosis of hypercortisolism and adrenal insufficiency. En: Nerozzi D, Goodwin FK, Costa E, editores. Hypothalamic disfunction in neuropsychiatric disorders. New York: Raven Press; 1987. p. 183-200. Cerrar |
63. Gold PW, Kling MA, Khan I, Cal�brese JR, Kalogresas K, Post RM, et al.. Corticotropin releasing hormone: relevance to normal physiology and the pathophysiology and differential diagnosis of hypercortisolism and adrenal insufficiency. En: Nerozzi D, Goodwin FK, Costa E, editores. Hypothalamic disfunction in neuropsychiatric disorders. New York: Raven Press; 1987. p. 183-200. Cerrar |
64. James SP, Wehr TA, Sack DA, Parry BL, Rosenthal NE.. Evening light treatment of seasonal affective disorder. Br J Psychiat. 1985;147:424-8. Cerrar |
59. Oren DA, Levendosky AA, Kasper S, Duncan CC, Rosenthal NE.. Circadian profiles of cortisol, prolactin, and thyrotropin in seasonal affective disorder. Biol Psychiatry. 1996;39:157-70. Cerrar [Medline] [Descargar cita] |
65. Vieta E, Gast� C, Mart�nez de Osaba MJ, Nieto E, Cant� TJ, Otero A, et al.. Prediction of depressive relapse in remitted bipolar patients using corticotrophin-releasing hormone challenge test. Acta Psychiatr Scand. 1997;95:205-11. Cerrar [Medline] [Descargar cita] |
36. Lacoste V, Wirz-Justice A.. Seasonal variation in normal subjects: an update of variables current in depression research. En: Rosenthal NE, Blear MC, editores. Seasonal affective disorders and phototherapy. New York: The Guildford Press; 1989. p. 167-229. Cerrar |
61. Skwerer RG, Jacobsen FM, Duncan CC, Nelly DA, Sack DA, Tamarkin L, et al.. Neurobiology of seasonal affective disorder and phototherapy. En: Rosenthal NE, Blehar MC, editores. Seasonal affective disorders & phototherapy. New York: The Guildford Press; 1989. Cerrar |
66. Coiro V, Volpi R, Marchesi C, De Ferri A, D'Amato L, Gaffari G, et al.. Lack of seasonal variation in abnormal TSH secretion in patients with seasonal affective disorder. Biol Psychiatry. 1994;35:36-41. Cerrar [Medline] [Descargar cita] |
59. Oren DA, Levendosky AA, Kasper S, Duncan CC, Rosenthal NE.. Circadian profiles of cortisol, prolactin, and thyrotropin in seasonal affective disorder. Biol Psychiatry. 1996;39:157-70. Cerrar [Medline] [Descargar cita] |
67. Rosenthal NE, Genhart M, Jacobsen FM, Skwerer RG, Wehr TA.. Disturbances of appetite and weight regulation in seasonal affective disorder. Ann N Y Acad Sci. 1987;499:216-30. Cerrar [Medline] [Descargar cita] |
61. Skwerer RG, Jacobsen FM, Duncan CC, Nelly DA, Sack DA, Tamarkin L, et al.. Neurobiology of seasonal affective disorder and phototherapy. En: Rosenthal NE, Blehar MC, editores. Seasonal affective disorders & phototherapy. New York: The Guildford Press; 1989. Cerrar |
68. Gillin JC, Sitaram N, Wehr TA, Duncan W, Post R, Murphy DL, et al.. Sleep and affective illness. En: Post RM, Ballenger JC, editores. Neurobiology of mood disorders. Baltimore: Williams & Wilkins; 1984. p. 175-80. Cerrar |
69. Jacobsen FM, Dreizzen A, Rosenthal NE, Wehr TA.. Diurnal variation in seasonal affective disorder. Presented at the 140th annual meeting of the American Psychiatric Association. Chicago; 1987. Cerrar |
56. Anderson JL, Vasile RG, Mooney JJ, Bloomingdale KL, Samson JA, Schildkraut JJ.. Changes in norepinephrine output following light therapy for fall/winter seasonal depression. Biol Psychiatry. 1992;32:700-4. Cerrar [Medline] [Descargar cita] |
61. Skwerer RG, Jacobsen FM, Duncan CC, Nelly DA, Sack DA, Tamarkin L, et al.. Neurobiology of seasonal affective disorder and phototherapy. En: Rosenthal NE, Blehar MC, editores. Seasonal affective disorders & phototherapy. New York: The Guildford Press; 1989. Cerrar |
70. Ozaki N, Rosenthal NE, Myers F, Schwartz PJ, Oren DA.. Effects of season on electro-oculographic ratio in winter seasonal affective disorder. Psychiatry Res. 1995;59:151-5. Cerrar [Medline] [Descargar cita] |
71. Kronfol Z, Silva J, Greden J, Demginski S, Gardner R, Carroll BJ.. Impaired lymphyocyte function in depressive illness. Life Sci. 1983;33:241. [Medline] [Descargar cita] 72. Schleifer SJ, Seller SE, Meyerson AT, Raskin MJ, Davis KL, Stein M.. Lymphocyte function in major depressive disorder. Arch Gen Psychiat. 1984;41:484. [Medline] [Descargar cita] 73. Calabrese JR, Skwerer RG, Barna B, Gulledge AD, Valenzuela R, Butkus A, et al.. Depression, immunocompetence and prostaglandins of the E series. Psychiat Res. 1985;7:41. Cerrar |
74. Albretch JJ, Helderman JH, Schlesser MA, Rush AJ.. A controlled study of cellular immune function in affective disorders before and during somatic therapy. Psychiat Res. 1985;15:185. Cerrar |
75. Agency for Health Care Policy and Research Clinical Practice Guidelines.. Depression in primary care. Rockville: US Department of Health and Human Services; 1993. Cerrar |
75. Agency for Health Care Policy and Research Clinical Practice Guidelines.. Depression in primary care. Rockville: US Department of Health and Human Services; 1993. Cerrar |
76. Eastman CI, Young MA, Fogg LF, Liu L, Meaden PM.. Bright light treatment of winter depression: a placebo-controlled trial. Arch Gen Psychiatry. 1998;55:883-9. Cerrar [Medline] [Descargar cita] |
77. Terman M, Terman JS, Ross DC.. A controlled trial of timed bright light and negative air ionization for treatment of winter depression. Arch Gen Psychiatry. 1998;55:875-82. Cerrar [Medline] [Descargar cita] |
78. Lee TM, Chan CC.. Dose-response relationship of phototherapy for seasonal affective disorder: a meta-analysis. Acta Psychiat Scand. 1999;99:315-23. Cerrar [Medline] [Descargar cita] |
79. Thompson C.. Light therapy in the treatment of seasonal and non-seasonal affective disorders: a meta-analysi s of randomised controlled trials. J Affect Disord. 2002;68:89. Cerrar |
80. Kogan AO, Guilford PM.. Side effects of short-term 10,000-lux light therapy. Am J Psychiatry. 1998;155:293-4. Cerrar [Medline] [Descargar cita] |
81. Terman M, Schlager D, Fairhurst S, Perlman B.. Dawn and dusk simulation as a therapeutic intervention. Biol Psychiatry. 1989;25:966-70. Cerrar [Medline] [Descargar cita] |
82. Lingjaerde O, Foreland AR, Dankertsen J.. Dawn simulation vs. lightbox treatment in winter depression: a comparative study. Acta Psychiat Scand. 1998;98:73-80. Cerrar [Medline] [Descargar cita] |
83. Avery DH, Eder DN, Bolte MA, Hellekson CJ, Dunner DL, Vitiello MV, et al.. Dawn simulation and bright light in the treatment of SAD: a controlled study. Biol Psychiatry. 2001;50:205-16. Cerrar [Medline] [Descargar cita] |
84. Lam RW, Levitt AJ.. Clinical guidelines for the treatment of seasonal affective disorder. Vancouver: Clinical & Academic Publishing; 1999. Cerrar |
85. Lam RW, Gorman CP, Michalon M, Steiner M, Levitt AJ, Corral MR, et al.. Multicenter, placebo-controlled study of fluoxetine in seasonal affective disorder. Am J Psychiatry. 1995;152:1765-70. Cerrar [Medline] [Descargar cita] |
86. Ruhrmann S, Kasper S, Hawellek B, Martinez B, Hoflich G, Nickelsen T, et al.. Effects of fluoxetine versus bright light in the treatment of seasonal affective disorder. Psychol Med. 1998;28:923-33. Cerrar [Medline] [Descargar cita] |
87. Moscovitch A, Blashko CA, Eagles JM, Darcourt G, Thompson C, Kasper S, et al.. A placebo-controlled study of sertraline in the treatment of outpatients with seasonal affective disorder. Psychopharmacology (Berl). 2004;171:390-7. Cerrar [Medline] [Descargar cita] |
88. Martiny K, Lunde M, Simonsen C, Clemmensen L, Poulsen DL, Solstad K, et al.. Relapse prevention by citalopram in SAD patients responding to 1 week of light therapy. A placebo-controlled study. Acta Psychiatr Scand. 2004;109:230-4. Cerrar [Medline] [Descargar cita] |
77. Terman M, Terman JS, Ross DC.. A controlled trial of timed bright light and negative air ionization for treatment of winter depression. Arch Gen Psychiatry. 1998;55:875-82. Cerrar [Medline] [Descargar cita] |
89. Pinchasov BB, Shurgaja AM, Grischin OV, Putilov AA.. Mood and energy regulation in seasonal and non-seasonal depression before and after midday treatment with physical exercise or bright light. Psychiatry Res. 2000;94:29-42. Cerrar [Medline] [Descargar cita] |
90. Schlager DS.. Early-morning administration of short-acting beta blockers for treatment of winter depression. Am J Psychiatry. 1994;151:1383-5. Cerrar [Medline] [Descargar cita] |
91. Lewy AJ, Bauer VK, Cutler NL, Sack RL.. Melatonin treatment of winter depression: a pilot study. Psychiatry Res. 1998;77:57-61. Cerrar [Medline] [Descargar cita] |
92. Lam RW.. Tratamiento. En: Trastorno afectivo estacional. Bibliotecas Aula M�dica. 2004;6:111-26. Cerrar |
1. Furst P.. Flesh of the Gods. The Ritual Use of Hallucinogens. New York: Praeger Publications; 1972. 2. Furst P.. Alucin�genos y Cultura. M�xico: Fondo de Cultura Econ�mica; 1980. 3. Harner M, editor.. Alucin�genos y chamanismo. Madrid: Labor; 1976. 4. Ott J.. Pharmacoteon. Drogas ente�genas, sus fuentes vegetales y su historia. Barcelona: Los Libros de la Liebre de Marzo; 1996. 5. Schultes RE, Hofmann A.. Plantas de los Dioses. Or�genes del uso de los alucin�genos. M�xico: Fondo de Cultura Econ�mica; 1982. Cerrar |
6. Brau JL.. Historia de las drogas, Barcelona: Bruguera; 1974. Cerrar |
7. Escohotado A.. Historia general de las drogas incluyendo el ap�ndice fenomenolog�a de las drogas. Madrid: Espasa Calpe; 1998. Cerrar |
8. Merlin MD.. On the Trail of the Ancient Opium Poppy. London and Toronto: Associated University Presses; 1984. Cerrar |
9. Krikorian AD.. Were the Opium Poppy and Opium Known in the Ancient Near East? J Hist Biol. 1975;8:95-114. Cerrar |
10. Gabra S.. Papaver Species and Opium through the Ages. Bulletin de l'Institut d�Egypte. 1956; XXXVII (I) Session 1954-1955:39-56. Cerrar |
11. Benet S.. Early Diffusion and Folk Uses of Hemp. En Rubin V, editor. Cannabis and Culture. The Hague: Mouton; 1975. p. 39-50. Cerrar |
12. Guerra Doce E.. Las drogas en la Prehistoria. Evidencias arqueol�gicas de los or�genes del consumo de sustancias psicoactivas en Europa. Barcelona: Bellaterra; 2005. Cerrar |
7. Escohotado A.. Historia general de las drogas incluyendo el ap�ndice fenomenolog�a de las drogas. Madrid: Espasa Calpe; 1998. Cerrar |
13. Kritikos PG, Papadaki SP.. The history of the poppy and of opium and their expansion in Antiquity in the Eastern Mediterranean Area. Bulletin on Narcotics. 1967; XIX(3):17-38;XIX(4):5-10. Cerrar |
15. Marinatos S.. Ai Minoikai Theai tou Gadsi. Archaoilogike Ephemeris; 1937. p. 278-91. Cerrar |
16. G�ngora y Mart�nez M.. Antig�edades Prehist�ricas de Andaluc�a, monumentos, inscripciones, armas, utensilios y otros importantes objetos pertenecientes a los tiempos m�s remotos de su poblaci�n. Madrid; 1868. Cerrar |
17. Cacho Quesada C, Pap� Rodes C, S�nchez-Barriga Fern�ndez A, Alonso Mathias F.. La cester�a decorada de la cueva de los Murci�lagos (Albu�ol, Granada). Homenaje al Profesor Manuel Fern�ndez-Miranda. Complutum Extra. 1996;6(I):105-22. Cerrar |
12. Guerra Doce E.. Las drogas en la Prehistoria. Evidencias arqueol�gicas de los or�genes del consumo de sustancias psicoactivas en Europa. Barcelona: Bellaterra; 2005. Cerrar |
18. Juan-Tresserras J.. La Arqueolog�a de las drogas en la Pen�nsula Ib�rica. Una s�ntesis de las recientes investigaciones arqueobot�nicas. Complutum. 2000;11:261-74. Cerrar |
19. Merlin MD.. Archaeological evidence of the Tradition of Psychoactive Plant Use in the Old World. Economic Botany. 2003;57:295-323. Cerrar |
20. Rudenko SI.. Frozen Tombs of Siberia. The Pazyryk Burials of Iron Age Horsemen. London: Dent; 1970. Cerrar |
13. Kritikos PG, Papadaki SP.. The history of the poppy and of opium and their expansion in Antiquity in the Eastern Mediterranean Area. Bulletin on Narcotics. 1967; XIX(3):17-38;XIX(4):5-10. Cerrar |
21. Evans A.. �The Ring of Nestor�: A Glimpse into the Minoan After-World and a Sepulcral Treasure of Gold Signet-Rings and Bead Seals from Thisbe, Boeotia. Journal of Hellenic Studies. 1925;45(I):1-75. Cerrar |
13. Kritikos PG, Papadaki SP.. The history of the poppy and of opium and their expansion in Antiquity in the Eastern Mediterranean Area. Bulletin on Narcotics. 1967; XIX(3):17-38;XIX(4):5-10. Cerrar |
21. Evans A.. �The Ring of Nestor�: A Glimpse into the Minoan After-World and a Sepulcral Treasure of Gold Signet-Rings and Bead Seals from Thisbe, Boeotia. Journal of Hellenic Studies. 1925;45(I):1-75. Cerrar |
22. Cartmell LW, Aufderheide AC, Springfield A, Weems C, Arriaza B.. The Frequency and Antiquity of Prehistoric Coca-Leaf Chewing Practices in Northern Chile: Radioimmunoassay of a Cocaine Metabolite in Human-Mummy Hair. Latin American Antiquity. 1991;2:260-8. Cerrar |
23. Cartmell LW, Aufderheide AC, Springfield A, Buikstra J, Arriaza B, Weems C.. Radioimmunoassay for Cocaine in Mummy Hair to determine Antiquity and Demography of Coca Leaf Chewing Practices in Southern Peru and Northern Chile. Eres. 1994;5:83-95. Cerrar |
24. Balanova S, Pirsig W, Parsche F, Schneider E.. Cocaine, Xanthine Derivatives and Nicotine in Cranial Hair of a Pre-Columbian Peruvian Mummy. Actas del I Congreso Internacional de Estudios sobre Momias, II. Tenerife: Museo Arqueol�gico y Etnogr�fico. 1992; p. 465-70. Cerrar |
25. Rafferty SM.. Identification of Nicotine by Gas Chromatography/Mass Spectroscopy Analysis of Smoking Pipe Residue. Journal of Archaeological Science. 2002;29:897-907. Cerrar |
26. Balanova S, Wie B, Kr�mer M.. First detection of nicotine in ancient population of Southern China. Homo. 1995;46:68-75. Cerrar |
27. Oxenham MF, Locher C, Cuong NL, Thuy NK.. Identification of Areca catechu (Betel nut) Residues on the Dentitions of Bronze Age Inhabitants of Nui Nap, Northern Vietnam. Journal of Archaeological Science. 2002;29:909-17. Cerrar |
18. Juan-Tresserras J.. La Arqueolog�a de las drogas en la Pen�nsula Ib�rica. Una s�ntesis de las recientes investigaciones arqueobot�nicas. Complutum. 2000;11:261-74. Cerrar |
28. Van der Merwe NJ.. Cannabis Smoking in 13th-14th Century Ethiopia: Chemical Evidence. En: Rubin V, editor. Cannabis and Culture. The Hague: Mouton; 1975. p. 77-80. Cerrar |
29. Balanova S, Parsche F, Pirsig W.. First identification of Drugs in Egyptian Mummies, Naturwissenschaften. 1992;79:358. Cerrar |
30. Parsche F, Balanova S, Pirsig W.. Drugs in ancient populations. Lancet. 1993;341:503. Cerrar |
31. Hobmeier U, Parsche F.. Drugs in Egyptian and Peruvian mummies. Homo 1994;45 Suppl:59. Cerrar |
32. Nerlich AG, Parsche F, Wiest I, Schramel P, L�hrs U.. Extensive pulmonary haemorrhage in an Egyptian mummy. Virchows Archiv. 1995;427:423-9. Cerrar [Medline] [Descargar cita] |
33. Parsche F, Nerlich A.. Presence of drugs in different tissues of an Egyptian mummy. Fresenius J Anal Chem. 1995;352:380-4. Cerrar |
34. Buckland PC, Panagiotakopulu E.. Remeses and the tobacco beetle. Antiquity. 2001;75:549-56. Cerrar |
35. Balanova S, Schultz M.. Investigation of nicotine concentrations in prehistoric human skeletons found in early Neolithic populations (Late PPNB) from the Near East (Turkey and Jordan). Homo. 1994;45 Suppl:14. Cerrar |
30. Parsche F, Balanova S, Pirsig W.. Drugs in ancient populations. Lancet. 1993;341:503. Cerrar |
36. Balanova S, Teschler-Nicola M.. Was nicotine used as a medicinal agent in ancient populations? Homo. 1994;45 Suppl:15. Cerrar |
37. F�bregas Valcarce R.. Los petroglifos y su contexto: un ejemplo de la Galicia meridional. Vigo: Instituto de Estudios Vigueses; 2001. Cerrar |
38. Guerra Doce E.. Sobre la funci�n y el significado de la cer�mica campaniforme a la luz de los an�lisis de contenidos. Trabajos de Prehistoria e.p.; 63(1). Cerrar |
39. Sanz M�nguez C, Velasco V�zquez J, editores.. Pintia. Un oppidum en los confines orientales de la regi�n vaccea. Investigaciones Arqueol�gicas Vacceas, Romanas y Visigodas (1999-2003). Valladolid: Universidad de Valladolid; 2003. Cerrar |
12. Guerra Doce E.. Las drogas en la Prehistoria. Evidencias arqueol�gicas de los or�genes del consumo de sustancias psicoactivas en Europa. Barcelona: Bellaterra; 2005. Cerrar |
37. F�bregas Valcarce R.. Los petroglifos y su contexto: un ejemplo de la Galicia meridional. Vigo: Instituto de Estudios Vigueses; 2001. Cerrar |
40. Matamala JC, Juan-Tresserras J.. Consumo de alcohol y substancias ente�genas en el Neol�tico Peninsular: un estado de la cuesti�n. Comunicaci�n presentada en el III Congreso del Neol�tico en la Pen�nsula Ib�rica. Santander: octubre 2003. Cerrar |
41. Juan-Tresserras J, Villalba MJ.. Consumo de adormidera (Papaver somniferum L.) en el Neol�tico Peninsular: el enterramiento M28 del complejo minero de Can Tintorer. Actes del II Congr�s del Neol�tic a la Pen�nsula Ib�rica. Saguntum-PLAV. 1999; Extra-2:397-404. Cerrar |
42. Juan-Tresserras J.. Fuente �lamo (Almer�a): An�lisis de contenidos de recipientes cer�micos, sedimentos y colorantes procedentes de tumbas arg�ricas. Madrider Mitteilungen. 2004;45:132-9. Cerrar |
43. Merrillees RS.. Opium Trade in Bronze Age Levant. Antiquity. 1962;XXXVI:287-92. Cerrar |
44. Merrillees RS.. The Cypriote Bronze Age Pottery found in Egypt. Studies in Mediterranean Archaeology 18. Lund: Paul �str�ms; 1968. Cerrar |
45. Bisset NG, Bruhn JG, Curto S, Holmstedt B, Nyman U, Zenk MH.. Was opium known in 18th dynasty ancient Egypt? An examination of materials from the tom of the chief royal architect Kha. J Ethnopharmacol. 1994;41:99-114. Cerrar [Medline] [Descargar cita] |
46. Schiaparelli E.. La tomba intatta dell'architetto Cha nella necropoli di Tebe. Torino: Museo de Antichit�; 1927. Cerrar |
45. Bisset NG, Bruhn JG, Curto S, Holmstedt B, Nyman U, Zenk MH.. Was opium known in 18th dynasty ancient Egypt? An examination of materials from the tom of the chief royal architect Kha. J Ethnopharmacol. 1994;41:99-114. Cerrar [Medline] [Descargar cita] |
47. Rudgley R.. Enciclopedia de las substancias psicoactivas. Barcelona: Paid�s; 1999. Cerrar |
48. Sherratt AG.. Sacred and Profane Substances: The Ritual Use of Narcotics in Later Neolithic Europe. En: Garwood P, Jennings D, Skeates R, Toms J, editors. Sacred and Profane: Proceedings of a Conference on Archaeology, Ritual and Religion. Oxford 1989. Oxford: Oxford University Committee for Archaeology. Monographs 32; 1991. p. 50-64. Cerrar |
49. Sherratt AG.. Alcohol and its alternatives: symbol and substance in pre-industrial cultures. En: Goodman J, Lovejoy PE, Sherratt A, editors. Consuming Habits: Drugs in History and Anthropology. London and New York: Routledge; 1995. p. 11-46. Cerrar |
50. Guerra Doce E.. Sobre el papel de la adormidera como posible vi�tico en el ritual funerario de la Prehistoria Reciente peninsular. Bolet�n del Seminario de Estudios de Arte y Arqueolog�a. 2002;LXVIII:49-75. Cerrar |
1. Furst P.. Flesh of the Gods. The Ritual Use of Hallucinogens. New York: Praeger Publications; 1972. 2. Furst P.. Alucin�genos y Cultura. M�xico: Fondo de Cultura Econ�mica; 1980. 3. Harner M, editor.. Alucin�genos y chamanismo. Madrid: Labor; 1976. 4. Ott J.. Pharmacoteon. Drogas ente�genas, sus fuentes vegetales y su historia. Barcelona: Los Libros de la Liebre de Marzo; 1996. 5. Schultes RE, Hofmann A.. Plantas de los Dioses. Or�genes del uso de los alucin�genos. M�xico: Fondo de Cultura Econ�mica; 1982. Cerrar |
6. Brau JL.. Historia de las drogas, Barcelona: Bruguera; 1974. Cerrar |
7. Escohotado A.. Historia general de las drogas incluyendo el ap�ndice fenomenolog�a de las drogas. Madrid: Espasa Calpe; 1998. Cerrar |
8. Merlin MD.. On the Trail of the Ancient Opium Poppy. London and Toronto: Associated University Presses; 1984. Cerrar |
9. Krikorian AD.. Were the Opium Poppy and Opium Known in the Ancient Near East? J Hist Biol. 1975;8:95-114. Cerrar |
10. Gabra S.. Papaver Species and Opium through the Ages. Bulletin de l'Institut d�Egypte. 1956; XXXVII (I) Session 1954-1955:39-56. Cerrar |
11. Benet S.. Early Diffusion and Folk Uses of Hemp. En Rubin V, editor. Cannabis and Culture. The Hague: Mouton; 1975. p. 39-50. Cerrar |
12. Guerra Doce E.. Las drogas en la Prehistoria. Evidencias arqueol�gicas de los or�genes del consumo de sustancias psicoactivas en Europa. Barcelona: Bellaterra; 2005. Cerrar |
7. Escohotado A.. Historia general de las drogas incluyendo el ap�ndice fenomenolog�a de las drogas. Madrid: Espasa Calpe; 1998. Cerrar |
13. Kritikos PG, Papadaki SP.. The history of the poppy and of opium and their expansion in Antiquity in the Eastern Mediterranean Area. Bulletin on Narcotics. 1967; XIX(3):17-38;XIX(4):5-10. Cerrar |
14. Majno G.. The Healing Hand. Man and Wound in the Ancient World. Cambridge: Harvard University Press; 1975. Cerrar |
15. Marinatos S.. Ai Minoikai Theai tou Gadsi. Archaoilogike Ephemeris; 1937. p. 278-91. Cerrar |
16. G�ngora y Mart�nez M.. Antig�edades Prehist�ricas de Andaluc�a, monumentos, inscripciones, armas, utensilios y otros importantes objetos pertenecientes a los tiempos m�s remotos de su poblaci�n. Madrid; 1868. Cerrar |
17. Cacho Quesada C, Pap� Rodes C, S�nchez-Barriga Fern�ndez A, Alonso Mathias F.. La cester�a decorada de la cueva de los Murci�lagos (Albu�ol, Granada). Homenaje al Profesor Manuel Fern�ndez-Miranda. Complutum Extra. 1996;6(I):105-22. Cerrar |
12. Guerra Doce E.. Las drogas en la Prehistoria. Evidencias arqueol�gicas de los or�genes del consumo de sustancias psicoactivas en Europa. Barcelona: Bellaterra; 2005. Cerrar |
18. Juan-Tresserras J.. La Arqueolog�a de las drogas en la Pen�nsula Ib�rica. Una s�ntesis de las recientes investigaciones arqueobot�nicas. Complutum. 2000;11:261-74. Cerrar |
19. Merlin MD.. Archaeological evidence of the Tradition of Psychoactive Plant Use in the Old World. Economic Botany. 2003;57:295-323. Cerrar |
20. Rudenko SI.. Frozen Tombs of Siberia. The Pazyryk Burials of Iron Age Horsemen. London: Dent; 1970. Cerrar |
13. Kritikos PG, Papadaki SP.. The history of the poppy and of opium and their expansion in Antiquity in the Eastern Mediterranean Area. Bulletin on Narcotics. 1967; XIX(3):17-38;XIX(4):5-10. Cerrar |
21. Evans A.. �The Ring of Nestor�: A Glimpse into the Minoan After-World and a Sepulcral Treasure of Gold Signet-Rings and Bead Seals from Thisbe, Boeotia. Journal of Hellenic Studies. 1925;45(I):1-75. Cerrar |
13. Kritikos PG, Papadaki SP.. The history of the poppy and of opium and their expansion in Antiquity in the Eastern Mediterranean Area. Bulletin on Narcotics. 1967; XIX(3):17-38;XIX(4):5-10. Cerrar |
21. Evans A.. �The Ring of Nestor�: A Glimpse into the Minoan After-World and a Sepulcral Treasure of Gold Signet-Rings and Bead Seals from Thisbe, Boeotia. Journal of Hellenic Studies. 1925;45(I):1-75. Cerrar |
22. Cartmell LW, Aufderheide AC, Springfield A, Weems C, Arriaza B.. The Frequency and Antiquity of Prehistoric Coca-Leaf Chewing Practices in Northern Chile: Radioimmunoassay of a Cocaine Metabolite in Human-Mummy Hair. Latin American Antiquity. 1991;2:260-8. Cerrar |
23. Cartmell LW, Aufderheide AC, Springfield A, Buikstra J, Arriaza B, Weems C.. Radioimmunoassay for Cocaine in Mummy Hair to determine Antiquity and Demography of Coca Leaf Chewing Practices in Southern Peru and Northern Chile. Eres. 1994;5:83-95. Cerrar |
24. Balanova S, Pirsig W, Parsche F, Schneider E.. Cocaine, Xanthine Derivatives and Nicotine in Cranial Hair of a Pre-Columbian Peruvian Mummy. Actas del I Congreso Internacional de Estudios sobre Momias, II. Tenerife: Museo Arqueol�gico y Etnogr�fico. 1992; p. 465-70. Cerrar |
25. Rafferty SM.. Identification of Nicotine by Gas Chromatography/Mass Spectroscopy Analysis of Smoking Pipe Residue. Journal of Archaeological Science. 2002;29:897-907. Cerrar |
26. Balanova S, Wie B, Kr�mer M.. First detection of nicotine in ancient population of Southern China. Homo. 1995;46:68-75. Cerrar |
27. Oxenham MF, Locher C, Cuong NL, Thuy NK.. Identification of Areca catechu (Betel nut) Residues on the Dentitions of Bronze Age Inhabitants of Nui Nap, Northern Vietnam. Journal of Archaeological Science. 2002;29:909-17. Cerrar |
18. Juan-Tresserras J.. La Arqueolog�a de las drogas en la Pen�nsula Ib�rica. Una s�ntesis de las recientes investigaciones arqueobot�nicas. Complutum. 2000;11:261-74. Cerrar |
28. Van der Merwe NJ.. Cannabis Smoking in 13th-14th Century Ethiopia: Chemical Evidence. En: Rubin V, editor. Cannabis and Culture. The Hague: Mouton; 1975. p. 77-80. Cerrar |
29. Balanova S, Parsche F, Pirsig W.. First identification of Drugs in Egyptian Mummies, Naturwissenschaften. 1992;79:358. Cerrar |
30. Parsche F, Balanova S, Pirsig W.. Drugs in ancient populations. Lancet. 1993;341:503. Cerrar |
31. Hobmeier U, Parsche F.. Drugs in Egyptian and Peruvian mummies. Homo 1994;45 Suppl:59. Cerrar |
32. Nerlich AG, Parsche F, Wiest I, Schramel P, L�hrs U.. Extensive pulmonary haemorrhage in an Egyptian mummy. Virchows Archiv. 1995;427:423-9. Cerrar [Medline] [Descargar cita] |
33. Parsche F, Nerlich A.. Presence of drugs in different tissues of an Egyptian mummy. Fresenius J Anal Chem. 1995;352:380-4. Cerrar |
34. Buckland PC, Panagiotakopulu E.. Remeses and the tobacco beetle. Antiquity. 2001;75:549-56. Cerrar |
35. Balanova S, Schultz M.. Investigation of nicotine concentrations in prehistoric human skeletons found in early Neolithic populations (Late PPNB) from the Near East (Turkey and Jordan). Homo. 1994;45 Suppl:14. Cerrar |
30. Parsche F, Balanova S, Pirsig W.. Drugs in ancient populations. Lancet. 1993;341:503. Cerrar |
36. Balanova S, Teschler-Nicola M.. Was nicotine used as a medicinal agent in ancient populations? Homo. 1994;45 Suppl:15. Cerrar |
37. F�bregas Valcarce R.. Los petroglifos y su contexto: un ejemplo de la Galicia meridional. Vigo: Instituto de Estudios Vigueses; 2001. Cerrar |
38. Guerra Doce E.. Sobre la funci�n y el significado de la cer�mica campaniforme a la luz de los an�lisis de contenidos. Trabajos de Prehistoria e.p.; 63(1). Cerrar |
39. Sanz M�nguez C, Velasco V�zquez J, editores.. Pintia. Un oppidum en los confines orientales de la regi�n vaccea. Investigaciones Arqueol�gicas Vacceas, Romanas y Visigodas (1999-2003). Valladolid: Universidad de Valladolid; 2003. Cerrar |
12. Guerra Doce E.. Las drogas en la Prehistoria. Evidencias arqueol�gicas de los or�genes del consumo de sustancias psicoactivas en Europa. Barcelona: Bellaterra; 2005. Cerrar |
37. F�bregas Valcarce R.. Los petroglifos y su contexto: un ejemplo de la Galicia meridional. Vigo: Instituto de Estudios Vigueses ; 2001. Cerrar |
40. Matamala JC, Juan-Tresserras J.. Consumo de alcohol y substancias ente�genas en el Neol�tico Peninsular: un estado de la cuesti�n. Comunicaci�n presentada en el III Congreso del Neol�tico en la Pen�nsula Ib�rica. Santander: octubre 2003. Cerrar |
41. Juan-Tresserras J, Villalba MJ.. Consumo de adormidera (Papaver somniferum L.) en el Neol�tico Peninsular: el enterramiento M28 del complejo minero de Can Tintorer. Actes del II Congr�s del Neol�tic a la Pen�nsula Ib�rica. Saguntum-PLAV. 1999; Extra-2:397-404. Cerrar |
42. Juan-Tresserras J.. Fuente �lamo (Almer�a): An�lisis de contenidos de recipientes cer�micos, sedimentos y colorantes procedentes de tumbas arg�ricas. Madrider Mitteilungen. 2004;45:132-9. Cerrar |
43. Merrillees RS.. Opium Trade in Bronze Age Levant. Antiquity. 1962;XXXVI:287-92. Cerrar |
44. Merrillees RS.. The Cypriote Bronze Age Pottery found in Egypt. Studies in Mediterranean Archaeology 18. Lund: Paul �str�ms; 1968. Cerrar |
45. Bisset NG, Bruhn JG, Curto S, Holmstedt B, Nyman U, Zenk MH.. Was opium known in 18th dynasty ancient Egypt? An examination of materials from the tom of the chief royal architect Kha. J Ethnopharmacol. 1994;41:99-114. Cerrar [Medline] [Descargar cita] |
46. Schiaparelli E.. La tomba intatta dell'architetto Cha nella necropoli di Tebe. Torino: Museo de Antichit�; 1927. Cerrar |
45. Bisset NG, Bruhn JG, Curto S, Holmstedt B, Nyman U, Zenk MH.. Was opium known in 18th dynasty ancient Egypt? An examination of materials from the tom of the chief royal architect Kha. J Ethnopharmacol. 1994;41:99-114. Cerrar [Medline] [Descargar cita] |
47. Rudgley R.. Enciclopedia de las substancias psicoactivas. Barcelona: Paid�s; 1999. Cerrar |
48. Sherratt AG.. Sacred and Profane Substances: The Ritual Use of Narcotics in Later Neolithic Europe. En: Garwood P, Jennings D, Skeates R, Toms J, editors. Sacred and Profane: Proceedings of a Conference on Archaeology, Ritual and Religion. Oxford 1989. Oxford: Oxford University Committee for Archaeology. Monographs 32; 1991. p. 50-64. Cerrar |
49. Sherratt AG.. Alcohol and its alternatives: symbol and substance in pre-industrial cultures. En: Goodman J, Lovejoy PE, Sherratt A, editors. Consuming Habits: Drugs in History and Anthropology. London and New York: Routledge; 1995. p. 11-46. Cerrar |
50. Guerra Doce E.. Sobre el papel de la adormidera como posible vi�tico en el ritual funerario de la Prehistoria Reciente peninsular. Bolet�n del Seminario de Estudios de Arte y Arqueolog�a. 2002;LXVIII:49-75. Cerrar |